Development, Characterization and Application of a Novel Mouse Line Humanized for the Intestinal Peptide Transporter PepT1. by Hu, Yongjun
 
 
DEVELOPMENT, CHARACTERIZATION AND 
APPLICATION OF A NOVEL MOUSE LINE HUMANIZED 
FOR THE INTESTINAL PEPTIDE TRANSPORTER PEPT1 
 
 
 
by 
 
 
 
 
Yongjun Hu 
 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy 
(Pharmaceutical Sciences) 
in The University of Michigan 
2015 
 
 
 
 
Doctoral Committee: 
 
Professor David E. Smith, Chair 
Professor Gordon L. Amidon 
Professor Richard F. Keep 
Professor Duxin Sun
 
 
 
 
 
 
 
 
 
 
 
 
 
©  Yongjun Hu 
  2015 
  
ii  
 
 
 
 
DEDICATION 
 
 
 
 
TO  
 
 
My Beloved Wife: Xia Jiang 
Daughter: Vivian Yuanyuan Hu 
Son: Jason Yuanheng Hu 
and  
My Dearest Parents: Ertong Hu and Ruizhen Deng 
  
iii  
 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
First of all, I would like to thank my advisor, Professor David E. Smith, for his 
comprehensive support during the entire course of my Ph.D. program. As a mentor, he 
inspired me to recognize the spirit of science and rigorous scholarship; as a friend, he 
has done many favors to help me stand up when I was in difficult situations of daily life; 
as a colleague, he taught me numerous strategies to tackle the hardships of my 
professional career. Without Dr. Smith’s interminable encouragement and substantial 
support, it would be impossible for me to achieve the success in my Ph.D. program and 
scientific career. 
I also want to thank the other committee members of my Ph.D. program, 
Professor Gordon L. Amidon, Professor Richard F. Keep and Professor Duxin Sun, for 
their service on my committee and for their helpful advice on my research project. Their 
thoughtful comments and insightful suggestions were extremely valuable for the 
successful completion of my doctoral degree.  
I would like to thank all my past and current colleagues: Scott M. Hynes, Hong 
Shen, Jianming Xiang, Zeng Lu, Jun Chen, Jie Shen, Huidi Jiang, Mohamed A. Kamal, 
Ke Ma, Dilara Jappar, Shupei Wu, Naoki Nishio, Bei Yang, Maria M. Posada, Yeamin 
Huh, Yehua Xie, Yuqing Wang, Xiaomei Chen, Xiaoxing Wang and Daniel Epling for 
iv  
their whole-hearted support and assistance in my studies.  I truly enjoyed working with 
them and appreciate their collaboration. 
I also would like to acknowledge the Department of Pharmaceutical Sciences, 
College of Pharmacy and the University of Michigan for their generous financial aid, 
great facilities and wonderful faculty and staff whose supports make it feasible for me to 
pursue my Ph.D. degree. I am indebted to the National Institutes of Health (GM035498) 
for supporting my research project.   
Most importantly, no words can completely express my gratitude to my beloved 
family and my dearest parents, brothers and sisters. Their sacrifice and limitless 
encouragement always motivated me to realize my dream. In particular, I want to say 
sorry and thanks to my wife, Xia, for her patience and for standing by me (shoulder to 
shoulder) during the past years, especially during difficult times. I also want to say 
thanks to my daughter Vivian and my son Jason. I am so proud of you both for your 
endeavors and achievements at your age. My life is filled fully with enjoyment, 
happiness and hope because of all of you. I have to acknowledge I have owed my 
family and parents too much in my lifetime. Whatever I have is yours … yesterday, 
today and tomorrow.   
Last but not least, I also want to thank all of the friends and relatives in my life. I 
wish everyone a wonderful time, every day.  
May God Bless! 
 
  
v  
 
 
 
 
TABLE OF CONTENTS 
 
DEDICATION .................................................................................................................. ii 
ACKNOWLEDGMENTS ................................................................................................ iii 
LIST OF TABLES ........................................................................................................... x 
LIST OF FIGURES ...................................................................................................... xiii 
LIST OF APPENICES .................................................................................................. xxi 
ABSTRACT ............................................................................................................... xxiii 
CHAPTER I ............................................................................................................................ 1 
RESEARCH OBJECTIVES ...................................................................................... 1 
CHAPTER II ........................................................................................................................... 5 
BACKGROUND ....................................................................................................... 5 
2.1  Biological Structure Of Small Intestine ............................................................ 5 
2.2  Proton-Coupled Oligopeptide Transporters (POTs) ......................................... 7 
2.2.1 Structure And Function Of PepT1 ............................................................... 9 
2.2.2   Substrate Specificity Of PepT1 ................................................................ 11 
2.2.3  Mechanism For Di-/Tri-Peptide Transport ................................................ 12 
2.2.4  Localization-Expression And Regulation Of PepT1 .................................. 14 
2.2.5  Single Nucleotide Polymorphisms Of PepT1 ........................................... 16 
vi  
2.2.6  Homology Of PepT1 In Mammalian Species............................................ 18 
2.2.7  Prodrug Design Targeting Intestinal PepT1 ............................................. 19 
2.3  Humanized Mouse Model .............................................................................. 21 
2.3.1  Rationale For Development Of Humanized Mouse Model ....................... 21 
2.3.2  Application Of Humanized Mouse Model In Drug Studies ........................ 23 
2.3.4   Strategy In Generating A Humanized Mouse Model ................................ 25 
2.3.5   Bacterial Artificial Chromosomes ............................................................. 27 
2.4   Predicting Pharmacokinetic Parameters ....................................................... 28 
2.4.1   Species Differences ................................................................................. 28 
2.4.2   Glycylsarcosine (GlySar) ......................................................................... 30 
2.4.3  Cefadroxil (CEF) ...................................................................................... 31 
REFERENCE ......................................................................................................... 47 
CHAPTER III .........................................................................................................................75 
DEVELOPMENT AND CHARACTERIZATION OF HUMANIZED huPEPT1 MOUSE 
MODEL USING MICROINJECTION TRANSGENIC METHOLOGY ...................... 75 
ABSTRACT ............................................................................................................ 75 
INTRODUCTION .................................................................................................... 78 
MATERIALS AND METHODS ............................................................................... 80 
Chemicals ........................................................................................................... 80 
Animals   ........................................................................................................... 81 
The Sensitivity of Genotyping PCR .................................................................... 81 
Generation of hPepT1 Humanized Mouse Line and Initial Characterization ...... 82 
Gene Copy Measurement of Human hPepT1 in Humanized Mice ..................... 83 
Real-time PCR and Immunoblot Analyses ......................................................... 83 
vii  
Cryosectioning and In situ Fluorescence Immunoblot Analyses ......................... 85 
H&E Staining for Frozen Tissue Sections ........................................................... 86 
Data analysis ...................................................................................................... 87 
RESULTS .............................................................................................................. 87 
The Sensitivity of Genotyping PCR .................................................................... 87 
Identification of Humanized Transgenic Mice ..................................................... 88 
Initial Phenotypic and Physiological-Chemical Analysis ..................................... 89 
Stable Expression of hPepT1 Transporter in Intestine of Humanized Mice ........ 89 
Tissue Expression Profile of Selected Relevant Transporters ............................ 91 
Localization of hPepT1 Transporters in Humanized Mouse Small Intestine ....... 91 
DISCUSSION ......................................................................................................... 92 
REFERENCE ....................................................................................................... 114 
CHAPTER IV ...................................................................................................................... 123 
FUNCTIONAL VALIDATION OF hPEPT1 PROTEIN IN HUMANIZED huPEPT1 
MICE USING THE MODEL DIPEPTIDE GLYCYLSARCOSINE .......................... 123 
ABSTRACT .......................................................................................................... 123 
INTRODUCTION .................................................................................................. 126 
MATERIALS AND METHODS ............................................................................. 128 
Chemicals ......................................................................................................... 128 
Animals  ......................................................................................................... 128 
In Situ Single-Pass Intestinal Perfusion Studies ............................................... 129 
In Vivo Oral Pharmacokinetic Studies .............................................................. 130 
Data Analysis .................................................................................................... 131 
RESULTS ............................................................................................................ 134 
viii  
In Situ Regional Perfusion Studies of GlySar in Humanized huPepT1 Mice 
Compared to Wildtype and mPepT1 Knockout Mice ........................ 134 
Concentration-Dependent Transport Kinetics of GlySar in Humanized and 
Wildtype mice ................................................................................... 135 
In Vivo Oral Pharmacokinetic Studies of GlySar in Humanized Mice Compared to 
Wildtype and mPepT1 Knockout Mice .............................................. 135 
DISCUSSION ....................................................................................................... 136 
REFERENCE ....................................................................................................... 145 
CHAPTER V ....................................................................................................................... 149 
APPLICATION OF HUMANIZED huPEPT1 MOUSE MODEL TO EVALUATE THE 
ABSORPTION AND DISPOSITION KINETICS OF CEFADROXIL ...................... 149 
ABSTRACT ...................................................................................................... 149 
INTRODUCTION .................................................................................................. 152 
MATERIALS AND METHODS ............................................................................. 155 
Chemicals ......................................................................................................... 155 
Animals  ......................................................................................................... 155 
In Situ Single-Pass Intestinal Perfusion Studies ............................................... 156 
In Vivo Intravenous Pharmacokinetic Studies................................................... 157 
In Vivo Oral Pharmacokinetic Studies .............................................................. 158 
Urinary Recovery of Cefadroxil ......................................................................... 159 
Data Analysis .................................................................................................... 160 
RESULTS ............................................................................................................ 163 
Concentration-Dependent In Situ Transport Kinetics of Cefadroxil in Jejunum of 
Humanized huPepT1 and Wildtype Mice .......................................... 163 
ix  
In Situ Transport Kinetics of Cefadroxil in Regional Intestinal Segments of 
Humanized huPepT1 and Wildtype Mice .......................................... 164 
Substrate Specificity of hPepT1 in Humanized Mouse Jejunum by In Situ 
Perfusion Studies ............................................................................. 164 
In Vivo Pharmacokinetic Studies Following Intravenous Bolus Doses of 
Cefadroxil ......................................................................................... 165 
In Vivo Pharmacokinetic Studies Following Oral Dose Escalation Dose of 
Cefadroxil ......................................................................................... 165 
Bioavailability of Cefadroxil in Humanized and Wildtype Mice .......................... 166 
Evaluation of Partial AUC versus Time or Dose for Comparison of Cefadroxil 
Absorption Kinetics between Humanized and Wildtype Mice ........... 166 
DISCUSSION ....................................................................................................... 167 
REFERENCE ....................................................................................................... 196 
APPENDICES ...................................................................................................... 205 
x  
     
LIST OF TABLES  
 
Table 2.1 Molecular and functional features of POT transporters ................................. 35 
Table 2.2 Species-dependent affinity of glycylsarcosine for PepT1 (Hu, et al. 2012) .... 36 
Table 3.1 Serum clinical chemistry of wildtype (WT), mPepT1 knockout (KO) and 
humanized huPepT1 (HU) micea ................................................................ 98 
Table 3.2 Primers used in quantitative real time PCR of select genes ....................... 99 
Table 3.3 Primers used in quantitative real time PCR of gene copy number ............ 100 
Table 4.1  The effective permeability of GlySar in mouse intestinal segments during in 
situ perfusions (pH 6.5) ............................................................................ 140 
Table 4.2  Non-compartmental analysis of the pharmacokinetics of [14C]GlySar 
following a 5.0 nmol/g oral dose ............................................................... 141 
Table 5.1 Non-compartmental pharmacokinetics of cefadroxil after intravenous bolus 
dosing in wildtype and humanized huPepT1 micea .................................. 177 
Table 5.2 Non-compartmental analysis of disposition parameters of [3H]cefadroxil 
following oral dose escalation in wildtype and humanized micea .............. 178 
Table 5.3 Slopes of partial cumulative area under the plasma concentration-time curve 
(AUC) of [3H]cefadroxil vs. time (5-30 min) after oral dose escalation in 
wildtype and humanized huPepT1 micea .................................................. 179 
xi  
Table 5.4 Regression parameters of partial cumulative area under the plasma 
concentration-time curve (AUC) of [3H]cefadroxil vs. dose after oral dose 
escalation in wildtype and humanized huPepT1 micea ............................. 180 
Table 5.5 Regression parameters of area under the plasma concentration-time curve 
from 0-120 min (AUC0-120) of [3H]cefadroxil vs. dose after oral dose 
escalation in wildtype and humanized huPepT1 mice, and in human 
subjectsa ................................................................................................... 181 
Table 5.6 Regression parameters of Cmax of [3H]cefadroxil vs. dose after oral dose 
escalation in wildtype and humanized huPepT1 mice, and in human 
subjectsa ................................................................................................... 182 
Table 5.7  Bioavailability of cefadroxil, as assessed by mass balance, in wildtype and 
humanized huPepT1 mice after oral dosesa ............................................. 183 
Table 5.8 Bioavailability of cefadroxil, as assessed by plasma, in wildtype and 
humanized huPepT1 mice after oral dosesa ............................................. 184 
Table A.3.3 mRNA transcripts of hPepT1 in funder of humanized huPepT1 mice ...... 205 
Table A.3.4 Gene copy number of BAC DNA in huPepT1 mice .................................. 205 
Table A.3.6 Real-time PCR analysis of PepT1 gene in WT, KO and huPepT1 ........... 206 
Table A.3.7 Real-time PCR analysis of POT gene in WT, KO and huPepT1 .............. 209 
Table A.3.8 Real-time PCR analysis of relevant gene in WT, KO and HU .................. 213 
Table B.4.1 In Situ Perfusion studies with GlySar in intestinal segments .................... 218 
Table B.4.2 Concentration-dependent flux of GlySar by in situ jejunal Perfusion studies 
in huPepT1 and Wildtype mice ................................................................. 219 
Table B.4.3 Plasma concentration of GlySar after oral administration (µM) ................ 220 
xii  
Table C.5.1 Concentration dependent flux of cefadroxil in jejunal perfusions 
(nmol/cm2/sec) .......................................................................................... 221 
Table C.5.2 Effective permeability of cefadroxil in intestinal perfusions ( x10-4,cm/sec)
 ................................................................................................................. 222 
Table C.5.3 Substrate specificity of cefadroxil in jejunal perfusions ( x10-4,cm/sec).... 222 
Table C.5.4 Plasma concentration of cefadroxil after IV single dose (µM) .................. 223 
Table C.5.6 Plasma concentration of cefadroxil after oral escalation doses (µM) ....... 225 
 
 
xiii  
      
LIST OF FIGURES 
  
Figure 2.1. Biological structure of the small intestine and its microscopic architecture, 
including the structure of villi, microvilli and epithelial cells. (Adopted from 
http://medicalterms.info/anatomy/Small-Intestine/) .................................... 37 
Figure 2.2. Mechanisms of transport through the intestinal epithelium.  (A) Paracellular 
transport; (B) Passive diffusion; (C) Endocytosis; (D) Carrier-mediated 
transport; (E) Carrier-mediated uptake; (F) Carrier-mediated efflux 
(Oostendorp, et al. 2009) .......................................................................... 38 
Figure 2.3. Membrane topology of peptide transporter 1 (PepT1). The protein contains 
12 transmembrane domains (TMDs), with N-terminal and C-terminal ends 
in the cytoplasm (Rubio-Aliaga, et al. 2002). ............................................. 39 
Figure 2.4   Model of peptide transport in epithelial cells. Di-/tri-peptides digested from 
ingested protein, were transported by the proton-coupled transporter 
PepT1 from intestinal lumen into epithelial cells, then hydrolyzed in the 
cytosol and effluxed into blood through various transporters located at the 
basolateral membrane. The driving force for uptake is dependent upon an 
electrochemical proton gradient across the membrane, partly produced by 
xiv  
the apical Na+-H+ exchanger, in which the Na+ gradient was established by 
Na+/K+ ATPase. (Rubio-Aliaga, et al. 2002) .............................................. 40 
Figure 2.5.  Model of the substrate/proton-coupled structural transition between the 
inward-open and partially occluded states for GsPOT transporter. The 
symport cycle was illustrated as half of transition including the inward-open 
and occluded forms. Black arrows represent the physiological symport 
cycle, and gray arrows represent other transitions (Doki et al., 2013). ...... 41 
Figure 2.6.  Cross-species protein sequence alignment between human, mouse and rat 
PepT1 transporters using the Cluster W 2.1 program.  The transmembrane 
domains are colored in grey, and conserved amino acid residues are 
highlighted in the blue box. ....................................................................... 42 
Figure 2.7   Key molecular structural features in compounds determining recognition as 
a substrate of PepT1. Critical structural properties that are essential for 
affinity are presented on the backbone of a tripeptide model (Zhang, et al. 
2013). ........................................................................................................ 43 
Figure 2.8.  Humanized mouse model by additive transgenesis. The targeted human 
gene, either cDNA or genomic DNA, was injected into a fertilized mouse 
egg, and the egg was then transferred to a pseudopregnant foster mother 
for development. After the pups were delivered, genotyping PCR was 
applied to screen out the positive founders, which were then cross-mated 
with knockout mice to produce the desired humanized mice (Devoy, et al. 
2012). ........................................................................................................ 44 
xv  
Figure 2.9.  Humanized mouse model by specific knock-in strategy. The mouse 
endogenous genome locus was replaced by a human genome BAC vector 
through homologous recombination in ESCs (Embryonic Stem Cells), such 
that the endogenous mouse locus was replaced by an equivalent human 
sequence. After positive colonies were screen out, the selection marker 
was removed by SSR (Site Specific Recombinase). Then transgenic ESCs 
were injected into blastocysts for producing humanized mice that can 
inherit the human gene by germline transmission (Ahn et al., 2010, Devoy, 
et al. 2012). ............................................................................................... 45 
Figure 2.10. The molecular structures of GlySar (top) and cefadroxil (bottom). Both 
compounds are substrates of PepT1 and PepT2. ..................................... 46 
Figure 3.1  Schematic of breeding strategy to maintain the colony of humanized mice. 
Humanized mice (hPepT1+/-/mPepT1-/-) were cross-mated with mPepT1 
knockout mice (hPepT1-/-/mPepT1-/-) to produce hemizygous humanized 
mice (hPepT1+/-/mPepT1-/-), which were then used for subsequent 
experiments............................................................................................. 101 
Figure 3.2 Sensitivity of genotyping PCR for identifying the hPepT1 gene. Two pairs of 
primers were designed and showed similarly high confidence in screening 
the one copy of gene integrated into the entire mouse genome. Lane 1: 10 
copies/200 ng DNA; Lane 2: 1 copy/200 ng DNA; Lane 3: 0.1 copy/200 ng 
DNA; Lane 4: 0.01 copy/200 ng DNA; Lane 5: 0.001 copy/200 ng DNA; 
Lane 6: positive control for BAC; Lane 7: Negative control for blank; Lane 
8: 100 bp ladder DNA marker. ................................................................. 102 
xvi  
Figure 3.3  Genotyping results for the identification of humanized huPepT1 mice. 
Genomic DNA was extracted from mouse tail biopsies and genotyped by 
PCR using specific primers, as described in the text. The DNA ladder, 
consisting of 100 bp repeats, was used to determine the size of PCR 
products. mPepT1-/-/hPepT1+/- represents the positive screen for 
humanized PepT1 (huPepT1) mice, mPepT1-/-/hPepT1-/- the negative 
screen for humanized PepT1 mice, mPepT1+/+ the wildtype mice, mPepT1-
/- the PepT1 knockout mice, and RP11-782G13 the purified BAC DNA 
(used to inject fertilized eggs in generating huPepT1), which served as a 
positive control. ....................................................................................... 103 
Figure 3.4  Expression of hPepT1 transcripts in humanized mouse founder lines (n=2), 
as determined by real-time qPCR. Total RNA was isolated from five mouse 
colonies (HU #1 to HU #6), wildtype and mPepT1 knockout mouse 
jejunum. Caco-2 cells served as a positive control, and wildtype and 
mPepT1 knockout mice served as negative controls. HU represents the 
humanized PepT1 mice. ......................................................................... 104 
Figure 3.5  Gene copy number of transgenic BAC DNA in humanized huPepT1 mice. 
Only one copy of BAC integration was detected using real-time PCR. HU 
represents humanized mice. ................................................................... 105 
Figure 3.6  H & E staining of the small intestine for wildtype (WT), humanized hPepT1 
(HU) and mouse mPepT1 knockout (KO) mice (magnification set at 20x). ...  
  ............................................................................................................... 106 
xvii  
Figure 3.7 H & E staining of the colon for wildtype (WT), humanized hPepT1 (HU) and 
mouse mPepT1 knockout (KO) mice (magnification set at 20x). ............. 107 
Figure 3.8 H & E staining of the kidney for wildtype (WT), humanized hPepT1 (HU) 
and mouse mPepT1 knockout (KO) mice (magnification set at 20x). ...... 108 
Figure 3.10  Immunoblots of hPepT1 protein in the small intestine, large intestine, and 
kidney of wildtype (WT), mPepT1 knockout (KO), and humanized hPepT1 
(HU) mice (A), and mouse mPepT1 protein in the jejunum of the same 
genotypes (B). Protein samples were separated by 10% SDS-PAGE, 
transferred onto PVDF membranes, and incubated for 1.5 hr with rabbit 
anti-human hPepT1 antiserum (1:3000) (A) or anti-mouse mPepT1 
antiserum (1:5000) (B), and a mouse monoclonal antibody for β-actin 
(1:1000). The membranes were washed three times with TBST and then 
incubated for 1 hr with an appropriate secondary antibody of IgG 
conjugated to HRP (1:3000). Caco-2 cells served as positive and negative 
controls, respectively, for hPepT1 and mPepT1. Duo represents the 
duodenum, Jej the jejunum, Ile the ileum, PC the proximal colon, DC the 
distal colon, and Kid the kidney. .............................................................. 110 
Figure 3.13 Immunofluorescence localization of hPepT1 protein in the jejunum of 
humanized huPepT1 mice.  The hPepT1 protein is clearly observed at the 
apical side of epithelial cells (highlighted square box was magnified 10x). ...  
  .............................................................................................................. 113 
xviii  
Figure 4.1. In situ perfusion studies of 10 µM GlySar in intestinal segments of wildtype 
(WT), mPepT1 knockout (KO) and humanized hPepT1 (HU) mice. Data are 
expressed as mean ± SE (n=4-6). ***P<0.001 as compared to WT. ....... 142 
Figure 4.2 Concentration-dependent flux of [3H]GlySar (0.01-50 mM) during jejunal 
perfusions of wildtype (WT) and humanized huPepT1 (HU) mice. Cin is the 
inlet concentration of GlySar in perfusate in which J*max = 3.75 ± 0.11 
nmol/cm2/sec and K*m = 13.2 ± 1.0 mM for WT mice (r2 = 0.988); J*max = 
0.50 ± 0.04 nmol/cm2/sec and K*m = 3.3 ± 0.9 mM for HU mice (r2 = 0.838) 
(top panel). Cw is the estimated concentration of GlySar at the membrane 
wall in which Jmax = 3.24 ± 0.13 nmol/cm2/sec and Km = 5.5 ± 0.7 mM for 
WT mice (r2 = 0.993); Jmax = 0.49 ± 0.03 nmol/ cm2/sec and Km = 2.7 ± 0.6 
mM for HU mice (r2 = 0.973) (bottom panel). All studies were performed in 
pH 6.5 buffer. Data are expressed as mean ± SE (n = 4−6). .................. 143 
Figure 4.3. In vivo pharmacokinetics of 5.0 nmol/g [14C]GlySar after oral gavage in 
wildtype (WT), mPepT1 knockout (KO) and humanized hPepT1 (HU) mice. 
Data are expressed as mean ± SE (n=3). ............................................... 144 
Figure 5.1 Concentration-dependent flux of [3H]cefadroxil (0.01 to 25.0 mM) during 
jejunal perfusion studies in wildtype (WT) and humanized huPepT1 (HU) 
mice (n=4). Cin is the inlet concentration of drug, where J*max=0.380±0.001 
nmol/cm2/sec and K*m=6.01±0.46 mM for WT (r2=0.982); 
J*max=0.057±0.006 nmol/cm2/sec and K*m=2.69±0.928 mM for HU mice 
(r2=0.658) (A). Cw is the estimated concentration of drug at the membrane 
wall where Jmax =0.392±0.010 nmol/cm2/sec and Km=4.80±1.0 mM for WT 
xix  
(r2=0.996); Jmax=0.0557±0.009 nmol/cm2/sec and Km=2.37±1.21 mM for HU 
(r2=0.728) (B). ......................................................................................... 185 
Figure 5.2  Effective permeability of 10 µM [3H]cefadroxil in different regions of small 
and large intestines in wildtype (WT), humanized huPepT1 (HU) and 
mPepT1 knockout (KO) mice (n=4). Different letters represent significant 
differences between the treatment groups, as evaluated by 
ANOVA/Tukey’s test. .............................................................................. 186 
Figure 5.3 Specificity studies on the jejunal permeability of 10 µM [3H]cefadroxil, +/- 10 
mM of potential inhibitors (0.1 mM for DMA) in humanized huPept1 mice 
(n=3). ***P<0.001, as evaluated by ANOVA/Dunnett’s test in which HU 
without inhibitor was set as the control group. PAH, p-aminohippuric acid, 
TEA, tetraethylammonium; NMN,  N1-methylnicotinamide; DMA, dimethy-
lamiloride. ................................................................................................ 187 
Figure 5.4 Plasma concentration-time profiles of [3H]cefadroxil in wildtype (WT) and 
humanized huPepT1 (HU) mice following intravenous bolus injections 
(n=4-5) in which the y-axis is displayed on a linear scale (left panel) and on 
a logarithmic scale (right panel). ............................................................. 188 
Figure 5.5 Tissue distribution and plasma-normalized tissue distribution profiles of 
[3H]cefadroxil in wildtype (WT) and humanized huPepT1 (HU) mice 
following intravenous bolus dosing. Tissues were collected 120 min after 
dosing (n=4-5). No significant differences were observed between the two 
genotypes, as evaluated by unpaired t-test. ............................................ 189 
xx  
Figure 5.6 Plasma concentration-time profiles of [3H]cefadroxil in wildtype (WT) and 
humanized huPepT1 (HU) mice following oral dose escalation (n=6-7) in 
which the y-axis is displayed on a linear scale (left panel) and on a 
logarithmic scale (right panel). ................................................................ 190 
Figure 5.6 Continued (see previous page for description) ........................................ 191 
Figure 5.7 Partial cumulative area under the plasma concentration-time curve (AUC) 
of [3H]cefadroxil as a function of time in wildtype (WT) and humanized 
huPepT1 (HU) mice. Data are expressed as mean ± SE (n=6-7). .......... 192 
Figure 5.8 Partial cumulative area under the plasma concentration-time curve (AUC) 
of [3H]cefadroxil vs. dose in wildtype (WT) and humanized huPepT1 (HU) 
mice following oral dose escalation. A proportional increase of AUC vs. 
dose was observed in WT  mice, whereas this relationship was nonlinear in 
HU mice.  Data are expressed as mean ± SE (n=6-7). ........................... 193 
Figure 5.9 Area under the plasma concentration-time curve from 0-120 min (AUC0-120) 
of [3H]cefadroxil vs. Dose in wildtype (WT), humanized huPepT1 (HU) and 
clinical data (humans) obtained from (Garrigues, et al. 1991) ................. 194 
Figure 5.10 Cmax vs. Dose of [3H]cefadroxil in wildtype (WT) mice, humanized huPepT1 
(HU) mice, and clinical data (humans) obtained from (Garrigues, et al. 
1991) (n=3) ............................................................................................. 195 
 
  
xxi  
 
 
 
LIST OF APPENICES  
 
Appendix A: Individual data from Chapter III .................................................... 205 
Appendix B: Individual data from Chapter IV .................................................... 218 
Appendix C: Individual data from Chapter V ..................................................... 221 
Appendix D: Species-dependent uptake of glycylsarcosine but not oseltamivir in 
Pichia Pastoris expressing rat, mouse, and human intestinal 
peptide transporter PepT1 ......................................................... 231 
Appendix E: Divergent developmental expression and function of the proton-
coupled oligopeptide transporters PepT2 and PhT1 in regional 
brain slices of mouse and rat. .................................................... 232 
Appendix F:  Development and characterization of a novel mouse line humanized 
for the intestinal peptide transporter PepT1 ............................... 233 
Appendix G: Impact of peptide transporter 1 on the intestinal absorption and 
pharmacokinetics of valacyclovir after oral dose escalation in wild-
type and PepT1 knockout mice .................................................. 234 
Appendix H: Corticosterone mediates stree-related increased intestinal 
permeability in a region-specific manner ................................... 235 
xxii  
Appendix I: Functional and Molecular Expression of the Proton-Coupled 
Oligopeptide Transporters in Spleen and Macrophages from 
Mouse and Human .................................................................... 236 
Appendix J: Expression and regulation of the proton-coupled oligopeptide 
transporter PhT2 by LPS in macrophages and mouse spleen ... 237 
Appendix K: Abbreviations ............................................................................... 238 
 
 
 
xxiii  
 
 
 
 
 
 
Development, Characterization And Application Of A Novel Mouse Line 
Humanized For The Intestinal Peptide Transporter PepT1 
 
 
ABSTRACT 
 
The proton-coupled oligopeptide transporter PepT1 is abundantly expressed on 
the apical side of small intestinal enterocytes and has major responsibility for the 
intestinal absorption of nutritional nitrogen, peptides and peptide-like drugs. However, 
there is growing evidence that a significant species difference exists in the affinity and 
capacity of substrates for PepT1. Therefore, a humanized PepT1 mouse model 
(huPepT1) was established by introducing hPepT1 genomic DNA into animals 
previously nulled for mouse PepT1. The mRNA and protein expression profiles 
indicated that huPepT1 mice had substantial but lower levels than wildtype animals in 
their expression of PepT1 in small intestine. However, colonic expression of PepT1 was 
greater in huPepT1 mice than wildtype mice, where the expression of PepT1 was quite 
low. In situ intestinal perfusion studies revealed that the permeability of glycylsarcosine 
(GlySar) and cefadroxil were similar, but lower, in the small intestine of huPepT1 mice 
as compared to wildtype animals. However, in colon, the permeability was greater in 
huPepT1 mice. Specificity studies, performed in the presence of potential inhibitors, 
xxiv  
demonstrated that GlySar and cefadroxil permeability was largely, if not solely, 
dependent upon PepT1 function in wildtype and humanized mice. However, a species 
difference was observed in the jejunal flux kinetics of GlySar and cefadroxil, where their 
Km values for PepT1 were 2-fold lower in humanized than wildtype mice. The in vivo 
studies indicated that the functional activity of intestinal PepT1 was fully restored for 
GlySar since nearly identical plasma concentration-time profiles and pharmacokinetic 
parameters were found following oral doses of GlySar in humanized and wildtype mice. 
After intravenous bolus doses of cefadroxil, virtually superimposable plasma 
concentration-time profiles were observed between wildtype and huPepT1 mice, and no 
differences were noted in clearance (CL), volume of distribution steady-state (Vss), and 
terminal half-life (T1/2) between these two genotypes. However, the Cmax, Tmax and AUC 
of humanized mice were 2-fold smaller than wildtype animals following oral dose 
escalation; T1/2 was unchanged. The slopes of partial cumulative AUC vs. time plots 
demonstrated that the absorption rate of cefadroxil was 2-fold greater in wildtype mice, 
and the AUC was dose-proportional in these animals. In contrast, a less than 
proportional increase was observed in AUC with increasing oral doses of cefadroxil in 
humanized mice. Finally, the AUC0-120 or Cmax of cefadroxil vs. dose profiles showed 
that humanized huPepT1 mice and humans (results obtained from the literature) were 
more similar visually than that of wildtype mice and humans. In concluding, this 
dissertation presents for the first time the generation and characterization of a mouse 
model humanized for the intestinal peptide transporter huPepT1.  This animal model 
should provide a valuable tool in probing the role, relevance and regulation of PepT1, 
xxv  
and in predicting the transport kinetics in humans. huPepT1 mice should also prove 
useful during the drug discovery process. 
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CHAPTER I   
RESEARCH OBJECTIVES 
 
 
 
Understanding the mechanisms of drug absorption, distribution, 
metabolism, excretion and transport (ADMET) is essential for improving the 
safety and efficacy of new chemical entities and therapeutic agents currently on 
the market. Using molecular biology techniques to clarify the role of proteins, 
particularly enzymes and transporters, in drug absorption and disposition is a 
priority of the pharmaceutical sciences. The first observation for active transport 
of the dipeptide glycylsarcosine (GlySar) in hamster jejunum (in vitro) lead to a 
new era of investigation for the cloning and functional characterization of 
transporters, and their relevance in drug kinetics and dynamics.   
Among these well-defined transport proteins, peptide transporter 1 
(PepT1), an integral membrane protein with 12 transmembrane domains, was 
brought to the forefront as a tempting delivery target for oral drugs and prodrugs. 
PepT1 transporter (SLC15A1) is one of four mammalian members in the solute 
carrier family 15 (SLC15). PepT1 protein is predominantly expressed on the 
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apical side of microvilli cells in small intestine, along with potential expression in 
colon (more controversial). The PepT1 transporter is well studied and 
responsible for facilitating the uptake of di-/tri-peptides and peptide-like drugs 
across the cell membrane from intestinal lumen.  
Following the cloning of PepT1 from a rabbit intestinal cDNA library, 
orthologues of this transporter were soon identified, cloned and then evaluated 
from different species, including human, mouse and rat. Numerous studies have 
indicated that these cross-species PepT1 transporters shared broad-spectrum 
biological properties, such as low affinity and high capacity, ion dependence and 
proton coupling in transporting substrates across cellular membranes. However, 
one group recently reported that PepT1 transporters showed a species difference 
in yeast cells expressing the human, rat and mouse cDNA in which GlySar 
exhibited a saturable uptake in all three species, with 3- to 5-fold differences in 
the Km values of mouse (0.30 mM), rat (0.16 mM) and human (0.86 mM). 
Furthermore, other studies reported a species difference for the PepT1 
transporter using mPepT1 knockout and wildtype mice, as compared to human 
subjects. In particular, while investigating the PepT1-mediated intestinal 
absorption and pharmacokinetics of cefadroxil and valacyclovir after oral dose 
escalation, the AUC vs. Dose was linear in mice, as opposed to non-proportional 
increases in AUC vs. Dose being observed in humans.   
In order to investigate in vivo species differences in the PepT1-mediated 
transport of peptides and peptide-like drugs, and to clarify the role and relevance 
of PepT1 in drug absorption and disposition in humans, a humanized huPepT1 
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mouse line was proposed as one of the best approaches to address 
pharmacokinetic discrepancies across species. Humanized huPepT1 mice would 
be generated using transgenic methodology, where the entire genomic hPepT1 
DNA would be introduced into mPepT1 knockout mice. It was hypothesized that 
the humanized huPepT1 mice would restore the functional activities of PepT1 
protein in these knockout mice to the level of wildtype animals. The humanized 
huPepT1 mouse line would be of special value because the human PepT1 gene 
would be controlled and regulated by its own regulatory elements, given that 
other mammalian systemic elements were conserved. Therefore, the protein 
expression levels, post-translational modifications, tissue distribution and PepT1 
functional activity in humanized mice might be similar to that in human subjects.   
With this in mind, the following specific aims were addressed in my 
dissertation:  
 
Aim 1:  To develop and validate a humanized huPepT1 mouse model, and 
characterize the mRNA and protein expression of hPepT1 in small and 
large intestines, and kidney as compared to that of wildtype mice 
Aim 2:  To define the in situ permeability of peptides (i.e., GlySar) or peptide-
like drugs (i.e., cefadroxil) in humanized huPepT1 mice, and compare 
the results to wildtype and mPepT1 knockout mice 
Aim 3:  To investigate the in vivo oral absorption kinetics of peptides (i.e., 
GlySar) or peptide-like drugs (i.e., cefadroxil) in humanized huPepT1 
mice, and compare the results to wildtype mice and human subjects  
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To achieve the proposed aims, various techniques in molecular biology, 
cell biology, animal sciences, pharmacology and pharmacokinetic-computational 
skills were applied during in vitro, in situ, in vivo and in silico studies. The 
derivative data from these studies in humanized huPepT1 and wildtype mice may 
provide valuable insight into understanding species differences in PepT1-
mediated absorption and disposition kinetics of relevant substrates. Collectively, 
these humanized huPepT1 mice may offer a novel animal model to prospectively 
translate the pharmacokinetics of peptides/mimetics and peptide-like drugs from 
mice to humans during drug development.      
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CHAPTER II 
 
BACKGROUND 
 
2.1  Biological Structure Of Small Intestine  
The small intestine in an adult human is approximately 3.5 meters in 
length (Gondolesi et al., 2012), along with a mean value of 2.5-3.0 centimeter in 
diameter. It is the longest part of the gastrointestinal tract and the principle site of 
absorption for any ingested compound and most oral medicines. Normally, the 
small intestine is divided into three segments differing at the microscopic 
structures: the duodenum, jejunum and ileum that comprise 5%, 50% and 45% of 
the length, respectively. The surface of the small intestine wall commonly 
contains: 1) circular folds that have a crescent shape, 2) small projections called 
villi, 3) tiny projections called microvilli. Villi are microscopic structures that have 
a hair-like shape and measures around 0.5-1.6 mm in height depending on the 
intestinal segment (Smith et al., 2010).  Consequently, villi increase the internal 
surface area of the intestinal walls, which is useful for absorption of nutrients and 
drugs. Each villus contains a capillary network and a lymph vessel so that the 
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circulating blood can carry these nutrients away. Microvilli are microscopic 
cellular membrane protrusions on the apical (luminal) side of the intestinal 
epithelial cells, also called enterocytes, where highly differentiated microvilli of 
these cells increase its surface area substantially and are involved in a wide 
variety of functions, including absorption, secretion, cellular adhesion and 
mechanic transduction (Figure 2.1). Therefore, the inner surface of the small 
intestine is extremely scaled-up by villi and microvilli, and it is claimed that the 
average surface area of the small intestinal mucosa in an adult human is 30 
square meters (Helander et al., 2014), which tremendously enhances the 
efficiency of absorption. 
Under normal conditions, most of the absorption of electrolytes, nutrients, 
water and drugs occurs in the proximal segment of the small intestine, which is 
facilitated by its vast surface area. In the small intestine, absorption can be 
divided into two major categories, paracellular permeation and transcellular 
transport (Pade et al., 1997). Paracellular permeation occurs between the cells 
and is only possible for small molecules (Figure 2.2). Still, absorption through 
paracellular permeation is very low since the tight junctions restrict the passive 
transepithelial movement. Transcellular transport occurs across the cells and 
includes passive diffusion, endocytosis and carrier-mediated transport. 
Transcellular transport from lumen to blood requires uptake across the apical 
membrane, followed by movement through the cytosol, and then exit across the 
basolateral membrane and into the blood circulation (Figure 2.2). Carrier-
mediated transport is facilitated or active for the influx and efflux of hydrophilic 
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drugs, toxins and metabolites. Numerous transporters have been extensively 
described in intestinal tissues, and most of them belong to two major transporter 
super-families, the ATP-binding cassette (ABC) and solute carrier (SLC) family 
(Oostendorp et al., 2009). Drug absorption relevant SLC families in the small 
intestine commonly locate on the apical side of epithelial cells, and includes the 
organic anion-transporting polypeptide (OATP) sub-family, the organic cation 
transporter (OCT) sub-family, and the proton-coupled oligopeptide transporter 
(POT; gene SLC15A) sub-family (Englund et al., 2006).  
 
2.2  Proton-Coupled Oligopeptide Transporters (POTs)  
Proton-coupled oligopeptide transporters (POTs), also known as peptide 
transporters (PTRs), are members of the solute carrier membrane proteins 
(SLC15A subfamilies) that mediate the cellular uptake of di-/tri-peptides in 
addition to a variety of peptide-like drugs.  The mechanism by which peptide 
transport occurs across cellular membranes is an important topic in membrane 
carrier research, along with their impact on drug absorption, disposition, 
pharmacologic response and pathophysiology such as inflammatory bowel 
disease (Charrier et al., 2006, Merlin et al., 2001, Shi et al., 2006, Teuscher et 
al., 2004, Vavricka et al., 2006, Zucchelli et al., 2009). In mammals, four 
transporter members in SLC15 family have been identified with similar topology. 
They are denoted peptide transporter 1 (PepT1, SLC15A1), peptide transporter 2 
(PepT2, SLC15A2), peptide/histidine transporter 1 (PhT1, SLC15A4) and 
peptide/histidine transporter 2 (PhT2, SLC15A3). In 1994, Hediger and 
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coworkers (Fei et al., 1994) first isolated the SLC15A1 gene encoding the PepT1 
transporter from a rabbit intestinal cDNA library and evaluated its function. Using 
a similar approach (i.e., expression cloning), the same SCL15A1 gene and 
functional characteristics of rabbit PepT1 were subsequently confirmed by Boll 
and coworkers (Boll et al., 1994). In 1995, another peptide transporter PepT2 
was cloned from human kidney (Liu et al., 1995). Three years later, the PhT1 
transporter was cloned from rat brain and its functional activity characterized 
(Yamashita et al., 1997).  Four years later, the PhT2 transporter was identified 
(Sakata et al., 2001). At present, the high-capacity low-affinity transporter PepT1 
and the low-capacity high-affinity transporter PepT2 have been extensively 
studied, including their structure, localization, function, substrate specificity and 
regulation (Wang et al., 2010). However, much less is known about the cellular 
localization, function and regulation of the PhT1 and PhT2 transporters even 
though they have been discovered for more than 15 years. Still, it is known that 
PhT1 and PhT2 can translocate histidine in addition to some di/tri-peptides 
(Rubio-Aliaga et al., 2008). Recently, PhT1 was shown to have abundant 
expression in adult, but not neonatal, mouse brain in which expression levels 
steadily increased with age in rats, a finding believed to impact histamine 
homeostasis in the brain (Hu et al., 2014a). Furthermore, PhT1 protein was 
localized in cellular endosomes to regulate toll-like receptors, such as TLR9 and 
NOD1, thereby affecting the innate immune system and promoting colitis in mice 
(Baccala et al., 2013, Blasius et al., 2010, Blasius et al., 2012, Dosenovic et al., 
2015, Nakamura et al., 2014, Sasawatari et al., 2011). However, the functional 
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role of PhT2 is still unclear although it is believed to be involved in inflammatory 
regulation (Wang et al., 2014).  A comprehensive description of the four POT 
transporters is summarized in Table 2.1.  
2.2.1 Structure And Function Of PepT1  
 The PepT1 gene is located on different chromosomes depending on 
species, where human PepT1 is on chromosome 13 (Liang et al., 1995, 
Ramamoorthy et al., 1995) and mouse PepT1 is on chromosome 14 (Rubio-
Aliaga et al., 2000). Mouse PepT1 protein is composed of 709 amino acid 
residues, human PepT1 708 amino acid residues, and rat PepT1 710 amino acid 
resides. PepT1 transporter is an integral membrane protein, with a predicted 
molecular weight of 78 kDa and a high degree of glycosylation (Herrera-Ruiz et 
al., 2003, Wuensch et al., 2013a). Based on hydropathic analysis of amino acid 
sequences, PepT1 transporter has twelve putative transmembrane domains 
(TMDs) with a large extracellular loop between the 9th and 10th TMDs, and both 
the N-terminus and C-terminus being oriented toward the cytoplasmic side 
(Knutter et al., 2004) (Figure 2.3). Since 1990’s, various approaches have been 
used to investigate the membrane topology of human PepT1 and the relationship 
between functional domains and its corresponding function. Studies with several 
constructed chimeras, consisting of different regions of PepT1 and PepT2, have 
shown that TMDs 1-4 and 7-9 are composed of protein domains that determine, 
or at least contribute, to substrate binding affinity (Doring et al., 1996). Several 
investigators have reported that TMDs 7-9 (Fei et al., 1998) and TMDs 1-6 
determines the functional characteristics (Terada et al., 2000) of PepT1, and that 
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even small regions of N-terminal PepT1 is very important for affinity and function 
(Doring et al., 2002). Recently, the first high-resolution crystal structure of a 
prokaryotic POT transporter, PepTso (From bacterial Shewanella oniedensis), 
provided new insight in our structural understanding of peptide transport within a 
proton-coupled oligopeptide transporter (Newstead et al., 2011). The structure of 
PepTso revealed a novel asymmetrical occluded conformation, suggesting that 
while the N-terminal helix bundle should be less dynamic and more involved in 
peptide binding, the C-terminal helix bundle contains mobile gates, possibly 
driven by proton gradient. Furthermore, the 3.3Å resolution crystal structure of 
PepTst (From Bacterial Streptococcus thermophilus) confirmed that H1-H6 
forming the N-terminal bundle connects to H7-H12 forming the C-terminal bundle 
(Solcan et al., 2012) by two additional semi-helices, HA and HB, to form a “V-
shaped” structure that defines two hydrophilic cavities with a functional role. 
Based on the crystal structure of PepTSo, a possible mechanism of peptide 
transport was proposed, in which translocation occurred via the transitions 
among three states: 1) outward-facing, 2) occluded, and 3) inward-facing 
(Newstead, et al. 2011).  A similar model was also proposed by Doki et al (Doki 
et al., 2013) using X-ray crystallography to assay the GkPOT protein (Figure 2.5).   
However, many questions remain unsolved regarding the mechanism of 
coupling, substrate recognition and structural transition. Further efforts are still 
needed to identify the structure of mammalian peptide transporters and to better 
understand its structural requirements and transport mechanism.  
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2.2.2   Substrate Specificity Of PepT1  
The proton-coupled oligopeptide transporter PepT1 has a broad substrate 
spectrum, covering di/tri-peptides and a variety of peptide analogs and drugs. 
With a few exceptions, peptide transporters are able to recognize and transport 
up to 400 di-peptides and 8000 tri-peptides formed from 20 standard amino 
acids, plus numerous β-lactam antibiotics, selected angiotensin-converting 
enzyme (ACE) inhibitors, and other peptidomimetics (Brandsch et al., 2008, 
Rubio-Aliaga et al., 2002). Peptides consisting of L-amino acids are preferred 
over those containing individual D-amino acid residues, while those consisting 
solely of D-stereoisomers are not transported (Daniel et al., 1992). Most 
substrate specificity studies are based on the relationship between substrate 
transport and corresponding inhibition on substrate transporter activity. For 
example, the minimal structural requirements for a PepT1 substrate is that two 
opposite charged groups (NH2 and COOH for di-peptide) be separated by an 
intra-molecular distance of 500-630 nm (Doring et al., 1998). Common essential 
structural features of PepT1 substrates are considered the following: a) with 
respect to stereospecificity, L-amino acids are preferred; b) a trans-conformation 
of the peptide bond, however, it can be replaced by a ketomethylene or thioxo 
group; c) hydrophobic side chains are preferred for high-affinity interactions, 
especially a positively charged N-terminus; d) for tripeptides, neutral amino acids 
are preferred as the third residue; e) a second peptide bond is not essential, and 
can be modified as well as methylated; f) a carboxylic group is not required at the 
C-terminus, but should contain a high electrogenic density region, such as an 
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aryl or phosphoric group; and g) a weakly basic group in the α-position of the N-
terminus (Figure 2.7) (Brandsch, et al. 2008, Daniel et al., 2004, Rubio-Aliaga, et 
al. 2002, Rubio-Aliaga, et al. 2008, Zhang et al., 2013). 
2.2.3  Mechanism For Di-/Tri-Peptide Transport  
POT members are symporters that use a downhill proton gradient to co-
transport di-/tri-peptides from the luminal side (pH≈5.5-6.0) into cells (pH≈7.0-
7.2), against the peptide/drug concentration gradient (Kurtin et al., 1984, Lucas et 
al., 1975). Many PepT1 transport studies using cell cultures, Xenopus laevis 
oocytes, and yeast Pichia pastoris expression systems have confirmed that 
substrate uptake strongly depends on extracellular pH and membrane potential 
(Amasheh et al., 1997, Doring et al., 1997, Ganapathy et al., 1983, Margheritis et 
al., 2013, Zhu et al., 2000). It is generally believed that the proton gradient is 
generated and maintained by the activity of a Na+/H+ exchanger located on the 
apical side of the enterocyte (Thwaites et al., 1999). A typical model proposed for 
tertiary-active peptide uptake at the intestinal epithelial cells is illustrated in 
Figure 2.4.  Dipeptides, tripeptides, β-lactams, ACE inhibitors, and prodrugs are 
transported by PepT1 into cells against a concentration gradient, where these 
activities are coupled to the movement of protons down an electrochemical 
proton gradient.  The Na+/H+ exchanger (NHE) creates and maintains this proton 
gradient by pumping H+ out of cells and Na+ into cells. The intracellular Na+ is 
then removed by Na+-K+-ATPase at the basolateral membrane. Once naturally 
occurring di-/tri-peptides enter the cell, they are hydrolyzed rapidly to their 
constituent amino acids and then enter the blood compartment through a large 
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group of basolateral-located amino acid transporters. In contrast, non-
hydrolysable peptides and peptide-like drugs are transported by basolateral 
peptide transporter(s) into blood. The nature of this transport process is unclear 
at present since the responsible protein has not been cloned and characterized. 
The dynamic mechanism by which PepT1 translocates di-/tri-peptides and 
peptide-like drugs was unclear until Doki and coworkers (Doki, et al. 2013) 
proposed a model to reveal the symport mechanism of proton-coupled 
oligopeptide transport (Figure 2.5). To understand the molecular mechanism of 
H+-driven oligopeptide symport by POTs, a crystal structure of full length GkPOT, 
which is similar PepTso and PepTst, was defined.  In this model, Arg43 and 
Glu310 played pivotal roles in substrate/H+ coupling. Glu310 is first protonated 
and substrates bind to Arg43 and Glu310. The de-protonation of Glu310 and salt 
bridge formation between Arg43 and Glu310 then induces a structural transition 
between the inward-open and occluded states, and the subsequent release of 
peptide to the intracellular side. It should be appreciated that the structural 
transition cannot take place when o`nly proton is bound to transporter because 
the weak interaction between protonated Glu310 and Arg43 is of insufficient 
driving force to bring the N-terminal and C-terminal bundles close together.  
Likewise, the peptide substrate cannot bind to the peptide-binding pocket in the 
Glu310-deprotonated form because of the electrostatic repulsion observed 
between the carboxylate group of the peptide and the negative charge on the 
deprotonated Glu310 in the binding site.  
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The above mechanism is similar to the coupling model proposed for a 
fungal high-affinity phosphate transporter (Pedersen et al., 2013). However, 
although this model may explain the half-cycle of symport for PepT1, it does not 
explain the transition mechanism between the outward-facing and occluded 
forms. Notwithstanding this uncertainty, the authors (Doki, et al. 2013) 
hypothesized that the highly conserved Glu32 on helix H1 may play a role in the 
transition between outward-open and occluded states since the mutation of 
Glu32 to Gln32 abolished both the substrate uptake and counterflow activities. 
Even though great progress has been made from recent 3D structural studies of 
the POT membrane proteins, many aspects of transporter structural biology 
remain enigmatic.   
2.2.4  Localization-Expression And Regulation Of PepT1  
The expression levels and functional activities of peptide transporters are 
affected by various factors, such as developmental stage, physiological status, 
pathological conditions, hormones, and drugs (Rubio-Aliaga, et al. 2008), 
especially in regard to intestine, kidney and brain. In the small intestine, PepT1 
protein is predominantly expressed at the apical membrane of enterocytes in 
mouse, rat and human duodenum, jejunum and ileum. For example, it was 
reported that PepT1 protein occupied 50% of the total amount of major 
membrane transporters present in the human jejunum (Drozdzik et al., 2014).  It 
was also reported that along with species differences in protein density (Jappar 
et al., 2010, Tanaka et al., 1998), the expression of PepT1 protein in colon is still 
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controversial (Drozdzik, et al. 2014, Hu et al., 2014b, Jappar, et al. 2010, 
Wuensch et al., 2013b). 
The expression of PepT1 is variable and a function of development and 
age. After birth, the expression level of PepT1 was found to increase markedly 
over 3-5 days to a maximal level in the small intestine. It then declined rapidly, 
reaching steady-state levels, close to that of adult, after 28 days. In the kidney, 
PepT1 expression levels were low in the adult rat (Hu, et al. 2014a, Shen et al., 
1999).  
Numerous studies have shown that diet can have a significant effect on 
the expression and activity of PepT1 in intestine. During a high protein diet, an 
increase in PepT1 mRNA was observed along with an increase in the intestinal 
transport of a model dipeptide in rats (Erickson et al., 1995, Shiraga et al., 1999). 
However, an increase was also observed in PepT1 expression in the small 
intestine of fasted rats (Ogihara et al., 1999) and mice (Ma et al., 2012). In 
addition, a diurnal rhythm was observed for PepT1 expression in rat small 
intestine, which was later speculated to be the result of diurnal food intake (Pan 
et al., 2004).  
The expression of peptide transporters may be affected by some 
pathological conditions. PepT1 in the small intestine will be upregulated during 
inflammation, which also elicits an aberrant expression in colon where normally 
no PepT1 is expressed in healthy adult rats. A similar observation of colonic 
PepT1 upregulation was confirmed in patients with inflammatory bowel disease, 
including both ulcerative colitis and Crohn’s disease (Coon et al., 2015, Merlin, et 
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al. 2001, Merlin et al., 1998).  Contrary to these findings, PepT1 down regulation 
was observed by Wuensch et al (Wuensch et al., 2014).  
Some hormones such as thyroid hormone, leptin, insulin and EGF, and 
drugs such as pentazocine, 5-fluorouracil, Ca2+-channel blockers and 
cyclosporine A have been reported to affect the expression of peptide 
transporters (Daniel et al., 2003, Rubio-Aliaga, et al. 2008). For example, calcium 
channel blockers can indirectly stimulate the sodium-proton antiporter in 
intestine, thereby increasing the proton electromotive force and PepT1 activity 
(Wenzel et al., 2002).   
2.2.5  Single Nucleotide Polymorphisms Of PepT1  
Single nucleotide polymorphisms (SNPs) are defined as single base pair 
positions in genomic DNA that differ from normal alleles in the population with a 
frequency of 1% or greater (Brookes 1999). However, the term SNP is typically 
used more loosely, and may refer to single base variants in genomic DNA. 
Consequently, SNPs data-sets also contain SNP variants of less than 1% allele 
frequency.  
Modern genetic techniques, particularly the advance of high-throughput 
DNA sequencing, provide powerful tools to screen for the abundance of SNPs 
that are present in enzymes and transporters during pharmacogenomic and 
pharmacogenetic studies. Genetic variants of peptide transporters could not only 
have an impact on nutritional absorption but could also contribute to the variable 
absorption and disposition of peptide-like drugs. An overview on the SNPs of 
transporter proteins was summarized by Gerloff (Gerloff 2004). Several studies 
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have reported the SNPs of POT transporters, especially for human PepT1 and 
PepT2 (Sobin et al., 2009, Zhang et al., 2004b).  
Regarding the SNPs of human PepT1, Leabman and coworkers 
(Leabman et al., 2003) were the first to report the existence of several genetic 
variants, however, they did not offer corresponding functional data. 
Subsequently, Zhang et al (Zhang, et al. 2004b) found nine non-synonymous 
hPepT1 SNPs from a panel of 44 ethnically diverse individuals. The authors 
observed that only a Pro586Leu variant demonstrated a significantly reduced 
uptake of GlySar in transfected HELA cells, a result that might be explained by a 
post-translational reduction in protein expression. In a study reported by Anderle 
et al (Anderle et al., 2006), a low frequency PepT1-Phe28Tyr variant displayed a 
significantly reduced uptake of GlySar in HEK293 cells, an increased km for 
cephalexin in CHO and Cos7 cells, and a change in pH dependency. Other 
variants included Val2Ile in exon 1, Ser117Asn and Ser122Met in exon 5, 
Gly419Argin exon 16, Val450Ile, Thr451Asn and Arg459Cys in exon 17, 
Pro537Ser and many synonymous SNPs that did not show any significant 
change of peptide uptake (Anderle, et al. 2006, Zhang, et al. 2004b). One 
interesting “flip-flop” function of hPepT1-SNPs was observed by Zucchelli et al 
(Zucchelli, et al. 2009) when investigating a functional hPepT1-SNP. They 
reported a correlation of Ser117Asn with Crohn’s disease susceptibility in two 
cohorts of Swedish and Finnish patients, where the hPepT1-SNP showed a 
protective role in Finnish but increasing risk in Swedish subjects.  
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There is little information regarding the clinical relevance of genetic 
polymorphisms on oral drug bioavailability. Valacyclovir, a substrate of PepT1, 
was used to investigate the impact of hPepT1 polymorphisms on a 
pharmacokinetic study in 16 healthy volunteers (Phan et al., 2003).  The authors 
reported that inter-individual differences in bioavailability were not related to 
genetic differences, suggesting that hPepT1 variants were, unlikely so far, to 
have clinical impact on drug absorption.   
2.2.6  Homology Of PepT1 In Mammalian Species  
Encoded by SLC15A1 genes, the human PepT1 protein has 708 residues, 
whereas mouse PepT1 has 709 amino acids and rat PepT1 has 710 amino 
acids. Cross-species protein sequence alignment using the Cluster W 2.1 
program has shown that the amino acid identity is about 85.0%, 83.6% and 
93.4% between hPepT1-mPepT1, hPepT1-rPepT1 and mPepT1-rPepT1, 
respectively (Figure 2.6). All important residues were conserved between 
species, including the Tyr12, His57, Tyr64, Tyr167, Trp294, Phe297 and Glu595 
residues, which are crucial for forming the peptide-binding cavity of transporters 
and are important for peptide uptake. These residues are located within highly 
conserved transmembrane domains H1, H2, H5, H7 and H10, which match well 
with the findings from site-directed mutagenesis studies described in section 
2.2.5. This is not surprising because, in general, residue mutations within a 
critical transmembrane domain might be fatal and, therefore, have less 
evolutionary pressure to change. On the other hand, mutations in non-critical 
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regions, such as the large extracellular loop between H9 and H10, may have 
more mutations since their impact is less drastic.   
2.2.7  Prodrug Design Targeting Intestinal PepT1  
Since the PepT1 transporter was predominantly expressed on the apical 
side of enterocytes, and assumes major responsibility for the uptake of di-/tri-
peptide and mimetics from intestinal lumen, this transport protein has become an 
important target for enhancing the bioavailability of some poorly absorbed drugs. 
The PepT1-targeted approach for oral drug design has several advantages. First, 
PepT1 has a wide spectrum of substrate specificity including 400 dipeptides and 
8000 tripeptides, and many peptide-like drugs such as bestatin, β-lactam 
antibiotics, angiotensin-converting enzyme (ACE) inhibitors and the prodrug 
valacyclovir (Meredith 2009, Yang et al., 2013a, Yang et al., 2013b). Second, 
PepT1 is a low-affinity (i.e., Km ranges from 0.3-10 mM) and high-capacity 
transporter, therefore, it is not easily saturated following the typical doses of 
orally administered drugs (Hu et al., 2012). It is also possible that innovative 
design changes in chemical structure of a drug or prodrug might improve its 
chemical/metabolic stability in the intestines, as well as attenuates or nullifies the 
influence of efflux transporters. In particular, targeting of the intestinal transporter 
PepT1 is emerging as a promising strategy to improve the permeability-limited 
absorption of oral drugs, particularly those in the BCS III and IV categories. 
According to the structure-transport requirements of PepT1, summarized 
in Figure 2.7 (Bailey et al., 2000, Daniel, et al. 2004, Meredith et al., 2000, 
Zhang, et al. 2013), rational prodrug design might include modifying parent drug 
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by adding amino acid or dipeptide-like moieties, or by adding an intermediate 
linker if necessary. As a result of covalent conjugation, prodrugs can be 
recognized as PepT1 substrates and, consequently, be effectively transported 
across cell membrane. However, inadequate bioconversion of prodrug (once 
absorbed) to the pharmacologically active species could impair its expected 
efficacy by remaining in the inactive prodrug form with potentially fatal side 
effects not usually observed in patients.   
Successful synthetic approaches in designing prodrugs include the 
following categories (Zhang, et al. 2013): 1) amide-type prodrug – developed by 
attaching a carboxyl group of the pro-moiety (i.e., amino acid or small dipeptide) 
directly onto a free amino group of the parent drug, thus forming an amide bond, 
generally results in a prodrug with moderate affinity for PepT1. Typical prodrugs 
in this group include the anti-cancer drugs Pro-Phe-pamidronate and Pro-Phe-
alendronate which have 3.8x higher bioavailability than their parent drug (Ezra et 
al., 2000), the prodrug LY544344 (developed for the anti-anxiety BCS III parent 
drug LY354740) which has a 10x higher intestinal permeability (Eriksson et al., 
2010, Varma et al., 2009), and the hypotension drug midodrine (a derivative of 1-
(2,5-dimethoxyphenyl)-2-aminoethanol) which has an improvement in 
bioavailability of 50% to 93% (Mackenzie et al., 1996, Tsuda et al., 2006); 2) 
ester-type prodrug - developed by conjugating an amino acid ester or dipeptide 
ester to the hydroxyl group of parent drug. The best example in this group is 
valacyclovir, the prodrug of active parent drug acyclovir, which belongs to BCS III 
and possesses activity against human herpes viruses, but with limited 
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bioavailability of 10-20%. In contrast, the prodrug valacyclovir has been reported 
to increase the oral bioavailability of acyclovir by 3- to 5-fold in humans (Weller et 
al., 1993).  Another prodrug successfully approved by the FDA was Val-Val-
saquinavir, a human immune-virus-1 (HIV-1) protease inhibitor which was 
modified from saquinavir in order to target both the PepT1 transporter as well as 
escape P-gp-mediated efflux to enhance oral bioavailability (Jain et al., 2007); 3) 
prodrug with intermediate linkers - developed by conjugating ketone-containing 
drugs with an appropriate intermediate linker, such as PEG. A typical prodrug, 
nabumeton (Foley et al., 2009), was reported to be a thio-dipeptide carrier 
prodrug and substrate of PepT1, which improved its transmembrane transport 
with enhanced resistance to hydrolysis.   
Oral dosing is the preferred route of drug administration due to its 
convenience and patient compliance, and the trending importance of developing 
more hydrophilic compounds in the pharmaceutical industry.  Thus, PepT1-
targeted prodrug strategies have become an essential method to enhance the 
oral bioavailability of BCS III and IV class drugs.  
 
2.3  Humanized Mouse Model  
2.3.1  Rationale For Development Of Humanized Mouse Model  
Animal models have become a valuable tool in understanding the 
absorption and disposition of drugs during normal physiology and during disease. 
Mouse models are especially useful since these animals have a well-known 
genetic background, are easy to breed, and have low maintenance costs. During 
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the past few decades, scientists have produced many genetically modified 
mouse strains in which a specific gene was removed or replaced by transgenic 
engineering technologies. These transgenic mouse models have proven to be 
powerful tools for identifying and validating target genes of interest, and in 
understanding their molecular mechanisms of activity. These engineered mouse 
models can generally be divided into three categories: additive transgenic, 
knockout and knock-in (Devoy et al., 2012).   
Most humanized mouse models have focused on changing the coding 
region of the genome before recent progress in genomic analyses have identified 
the importance of non-coding regions of the genome (both transcribed and non-
transcribed). Typically, a humanized mouse model can be generated by 
pronuclear injection or by gene targeting in embryonic stem cells, thus, creating 
gene knock-in mice.  Since a protein encoded by human DNA can have different 
biochemical properties from their mouse orthologues, transgenic mice have often 
been made with human cDNAs encoding human protein, or by substituting the 
mouse loci with the entire human genomic loci (including coding and non-coding 
regions) into the mouse genome. The latter method is achieved by the addition of 
human genomic sequences or by replacing regions of the mouse genome with 
equivalent human genomic sequences contained in yeast artificial chromosomes 
(YACs) or bacterial artificial chromosomes (BACs) (Devoy, et al. 2012). 
Why does one want to create a humanized mouse model?  First, few 
proteins are conserved 100% between humans and mice (Gregory et al., 2002, 
Mouse Genome Sequencing et al., 2002), and differences in orthologous 
 23 
sequences can lead to functional differences. For example, mouse serum 
amyloid P (SAP) binds to amyloid fibrils with only ~3% of the avidity of the human 
protein, even though mouse and human SAP are ~70% conserved (Hawkins et 
al., 1988). Second, a small number (<200) of human protein-coding genes do not 
have orthologues in mice (Stahl et al., 2009) and, as a result, it is necessary to 
introduce these human genes into mice for biological assessments. Third, the 
importance of non-coding regions would make it necessary to generate 
“genomic” humanized mice in order to investigate species-specific splicing 
patterns or to determine the function of “non-sense” sequences. For example, a 
long non-coding RNA of HOTAIR demonstrated different effects in humans as 
compared to its orthologue in mice, indicating that this RNA has a function in 
humans not easily determined from non-genomic humanized mice (Schorderet et 
al., 2011). Therefore, the non-coding genome must also be taken into account in 
studying gene function and genomic humanization will be essential to create an 
optimal set of models for human genes.   
A key question about transgenic humanized mice concerns the extent to 
which a human DNA sequence is correctly and efficiently read by mouse 
transcriptional machinery. Little information is available in this area and it is 
generally assumed that the mammalian system is conserved between humans 
and mice.  
2.3.2  Application Of Humanized Mouse Model In Drug Studies  
As the time, cost and regulatory hurdles for testing new drug candidates in 
human subjects have increased, a greater emphasis has been placed in 
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developing preclinical models that can provide more predictive information about 
drug pharmacokinetic and pharmacodynamic profiles. The results obtained from 
in vitro systems and from in vivo animal testing have not always accurately 
predicted human-specific drug metabolic pathways (Anderson et al., 2009, 
Walker et al., 2009). Genetic modification of mouse models has proven one of 
the best ways in drug discovery to overcome potential species differences in the 
efficacy, pharmacokinetics and toxicological properties of compounds. Species 
differences in drug discovery were proposed by Caldwell et al (Caldwell 1981) by 
studying the species’ inability to carry out a specific metabolism reaction (e.g., N-
hydroxylation of aliphatic amines in rats). It was recognized that rodents 
metabolize xenobiotics differently from humans due to differences in the 
expression and catalytic activities of the P450s.  For example, the murine Cyp2d 
genes do not have the same enzymatic activity as that in humans (Bogaards et 
al., 2000). To overcome species difference in P450s, and xenobiotic receptor 
expression and regulation machinery between rodents and humans, transgenic 
humanized mouse models were developed and these P450 humanized mice 
were evaluated for human toxicity risk and safety in drug discovery. In another 
example, humanized hCYP1A2 mice were shown to express CYP1A2 protein in 
a similar manner to that in humans. Compared with wild-type mice, a preferential 
N2-hydroxylation of PhiP was demonstrated in humanized hCYP1A2 mice, a 
pathway for PhiP metabolism that in vitro studies revealed was predominant with 
the human orthologue (Cheung et al., 2008). Currently available humanized 
mouse models containing drug-metabolizing enzymes and xenobiotic receptors 
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were summarized by Scheer et al (Scheer et al., 2013) and Jiang et al (Jiang et 
al., 2011).  
Recently, several organic anion-transporting polypeptide transporters 
(OATPs) were humanized in mice (van de Steeg et al., 2013) in which 
humanized OATP1B1, OATP1B3, and OATP1A2 transgenic mice showed partial 
or complete rescue of transporter function as compared to wildtype and knockout 
mice. A humanized multidrug resistance associated protein 2 (MRP2) mouse 
model versus mMRP2 null mice also demonstrated expression of the human 
transporter in the organs and cell types where MRP2 is normally expressed 
(Scheer et al., 2012). Still, further research is needed to address their species 
differences in drug pharmacokinetic studies.   
2.3.4   Strategy In Generating A Humanized Mouse Model  
Humanized mouse models can be generated with several technologies 
including additive transgenic and knock-in, as summarized by Devoy et al 
(Devoy, et al. 2012). The additive strategy for making humanized mouse models 
has often used human cDNAs, (e.g., MRP2 humanized mouse model (Scheer, et 
al. 2012) or bacterial artificial chromosome (BAC) DNA containing the complete 
human gene (e.g., CYP2D6 humanized mouse model by (Corchero et al., 2001)).  
Commonly, the cDNA construct comprises only the coding region, while the BAC 
construct consists of all the exons, introns, and 5’ and 3’-regulatory elements that 
are critical for genetic and epigenetic regulation of the transgene under 
physiological or pharmacological conditions. The construct is microinjected into 
fertilized zygotes followed by implantation of the eggs into pseudo-pregnant 
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females. Founders that carry the human gene can be crossed with a null 
background mouse to abolish endogenous gene effects, such that the 
humanized locus is only version expressed for the gene of interest (Figure 2.8). 
The advantage of this strategy is that the construct is easily prepared, the 
transgene has high expression of protein, and the humanized mouse model can 
be generated within a short period of time (<6 months). However, other 
endogenous genes can sometimes be interrupted, resulting in a loss of function 
because of random integration of the transgene. As a result, it is recommended 
that the transgenic mice be maintained as hemizygous rather than homozygous 
animals.  In addition, it is impossible to regulate exactly how many copies of the 
transgene will be introduced and how many genes will join in a row by head to 
end as a concatemer (Bishop et al., 1989).  
The second common strategy for making humanized mouse models is to 
integrate the transgene at specific and ubiquitously expressed chromosomal loci 
by homologous recombination or by site-specific recombination in embryonic 
stem cells (ESCs) (Figure 2.9) (Heaney et al., 2004, Prosser et al., 2008). The 
human gene is targeted and accurately integrated into an equivalent region of the 
mouse genome in ESCs, thus enabling a single copy of the human gene to 
residue at its natural site for expression while simultaneously replacing the gene 
at its corresponding mouse locus. This approach avoids the problems of deletion 
and concatemerization that may occur during random integration by non-
homologous recombination. However, in contrast to the pronuclear 
microinjection, this approach requires a skilled manipulation of gene construct 
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and cell cultures, and is time consuming (~2 years). Still, it can achieve a more 
representative expression profile for the gene of interest and avoid the impact of 
complicating endogenous genes.   
2.3.5   Bacterial Artificial Chromosomes   
Bacterial artificial chromosomes (BACs) are circular plasmid DNA 
molecules that are hosted in E.coli.  BACs, derived from the F factor of E. coli, 
can accommodate genomic inserts of DNA up to 300 kb (Shizuya et al., 1992). 
BAC vectors, such as pBeloBAC11, carry all the sequences needed for 
autonomous replication, copy-number control and partitioning of the plasmid 
(Hunter et al., 1999).  BACs are maintained as low-copy replicons and 
correspondingly yield lower quantities of DNA, but propagate large DNA inserts 
with high stability and a low frequency (<5%) of chimeras (Monaco et al., 1994).  
The use of BACs in transgenic experiments was first reported in 1997 
(Yang et al., 1997). Since then, BACs have been applied widely for studies 
including molecular complementation of mutations, in vivo studies of gene 
function, analysis of gene dosage, and identification and analysis of regulatory 
sequences (Giraldo et al., 2001). BACs have been microinjected in three different 
forms: circular supercoiled plasmid, linearized DNA and purified insert. BAC 
transgenic mice mostly carry a limited number of integrated transgene copies 
(<5) but up to 13 copies (Nielsen et al., 1997). However, there are not many 
studies addressing copy number-related expression of BAC transgenic mice.  
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2.4   Predicting Pharmacokinetic Parameters   
2.4.1   Species Differences  
Accurately and efficiently predicting the pharmacokinetic profiles of drugs 
in humans from preclinical data remains a problem in drug development.  In 
general, the approach for predicting drug pharmacokinetics in humans can be 
broadly divided into two categories: physiologically-based pharmacokinetic 
modeling and allometric scaling.  The application of allometric scaling in humans 
is widely accepted because of its simplicity (Obach et al., 1997). Predictions of 
human pharmacokinetics using interspecies allometric scaling was summarized 
by Kang et al (Kang et al., 2011). 
Interspecies allometric scaling methods are highly empirical and may be 
unreliable in predicting ADME because of differential expression patterns and 
functional characteristics of the proteins involved in differing animal species. For 
example, Takahashi et al. (Takahashi et al., 2009) concluded that the low 
bioavailability of several drugs (e.g., verapamil, methotrexate) in cynomolgus 
monkeys could be attributed not only to hepatic first-class metabolism but to 
intestinal absorption differences caused by divergent P450 enzyme activities 
between humans and monkeys. One impressive case involved a comparison of 
the permeability coefficients of 10 compounds between rat and human jejunum, 
as reported by Fagerholm et al (Fagerholm et al., 1996). The Peff coefficients 
were investigated with in situ single-pass perfusions of rat jejunum and compared 
to corresponding human values in vivo. The results indicated that, for passively 
absorbed drugs, Peff values were 3.6 times higher in human than rat and 
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significant deviations from linearity occurred for compounds that were actively 
transported. In 2006, Cao et al. compared the oral bioavailability of rats and 
humans for a variety of compounds with different absorption mechanisms, 
including passive diffusion and active transport. No correlation was found in oral 
drug bioavailability between these two species (r2=0.29), a finding agreed to by a 
previous report (Chiou et al., 2002), even though some transcripts shared 
similarly high expression levels of mRNA in the small intestine (r2>0.56). 
Furthermore, conflicting results were obtained by another group (Kim et al., 
2007), who compared mRNA expression profiles of intestinal transporters in 
mice, rats and humans. In analyzing a total of 86 transporter genes in mice, 50 
transporter genes in rats and 61 transporter genes in humans, they found the 
PepT1 gene to exhibit significant differences between species (i.e. about 2-fold 
between mice and humans, and about 6-fold between rats and humans). Overall, 
the results indicated that rodents and humans exhibit disparate levels of 
transcriptional proteins.  
A tragedy during the first Phase I clinical trial of TGN1412 made a good 
point of illustrating the difficulty of prediction from animal models to humans 
(Suntharalingam et al., 2006). It was observed that all six healthy subjects 
suffered an unexpected severe cytokine storm that resulted in multiple organ 
failure shortly after TGN1412 administration, even though preclinical animal 
models, including mice and monkeys, had shown that this monoclonal antibody 
was safe.  Recent data suggested that the CD28 receptor for binding TGN1412 
was not expressed in the CD4+ effecter memory T cells of preclinical animals that 
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were used for safety testing (Eastwood et al., 2010). The unexpected  'cytokine 
storm' occurred in humans even though the amino acid sequences of receptor 
CD28 were identical between species as was the affinity for binding with 
TGN1412. 
With the increasing number of species differences being discovered in 
drug development, further effort is necessary to improve the reliability in 
translating animal pharmacokinetics, response and toxicity to humans.   
2.4.2   Glycylsarcosine (GlySar)   
Peptide transporters (POTs) predominantly absorb di-/tri-peptides and 
peptide-like drugs from the intestinal lumen via uptake across the apical 
membrane. Glycylsarcosine (GlySar, MW=146) is currently used as a model 
dipeptide substrate for evaluating the functional activity of peptide transporters 
(Figure 2.10 top) because it is resistant to hydrolysis by peptidases, not 
metabolized, and commercially available in radioactive form (Hu, et al. 2012, 
Jappar, et al. 2010, Ocheltree et al., 2005). Since GlySar is a synthetic chemical, 
with no medical indications in human patients, there are no any data available 
from clinical studies.    
However, when GlySar was compared in wildtype and PepT1 knockout 
mice, its partial AUC was proportional to dose in both genotypes, along with a 
60% reduction in GlySar absorption in PepT1 knockout mice compared with 
wildtype animals (Jappar et al., 2011). Furthermore, our group recently reported 
that PepT1 transporters showed a species difference in yeast cells expressing 
the human, rat and mouse PepT1 cDNA, in which GlySar uptake exhibited 
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saturable kinetics in all three species, with 3- to 5-fold differences in Km values 
for mouse (0.30 mM), rat (0.16 mM) and human (0.86 mM) (Table 2.2).   
 
2.4.3  Cefadroxil (CEF)  
Cefadroxil (Figure 2.10 bottom), the para-hydroxy derivative of cephalexin, 
belongs to the first generation of β-lactam antibiotics that are usually 
administrated orally to patients for the treatment of mild to moderate susceptible 
infections, such as pneumonia caused by Streprococcus pyogenes and urinary 
tract infections caused by E. coli and P.mirabilis (Tanrisever et al., 1986). Among 
the aminocephalosporin drugs, cefadroxil has broad-spectrum activity, is more 
effective agent than either cephalexin or cephradine because of its slow rate of 
excretion into urine and slightly slower rate of absorption from the gastrointestinal 
tract. This drug is also a good oral candidate to substitute for penicillins because 
of concerns over allergic reactions to penicillins during outpatient therapy 
(Campagna et al., 2012).   
Cefadroxil (6R,7R)-7-[D-2-amino-2-(4-hydroxyphenyl) acetyl]amino]-3-
methyl-8-oxo-5-thia-l-anabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, has a zwitter-
ionic structure with an α-amino group in the side chain at position 7 and a free 
carboxylate group at position 4, in which the free α-amino group is generally 
believed to be essential for affinity to the peptide transporters (Tamai et al., 
1995). However, recent studies indicated that beta-lactam antibiotics without an 
α-amino group are transported by a carrier-mediated mechanism that is common 
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to dipeptides (Muranushi et al., 1989, Tsuji et al., 1987a, Tsuji et al., 1993, Tsuji 
et al., 1987b, Yoshikawa et al., 1989). 
Cefadroxil is believed to be a substrate for proton-coupled oligopeptide 
transporters (POT) because of the presence of an α-amino group, carboxylic 
group and peptide bond (Taylor et al., 1995), which are similar to physiological 
occurring peptides. Soon after cloning the PepT1 gene, which is predominantly 
expressed on the apical side of enterocytes, cefadroxil was confirmed as a 
substrate of PepT1 (Boll, et al. 1994). In addition, the intestinal transport of 
cefadroxil was saturable and shown to follow Michaelis-Menten kinetics (Garcia-
Carbonell et al., 1993, Garrigues et al., 1991, Sanchez-Pico et al., 1989, Sinko et 
al., 1988, Wenzel et al., 1996).  Still, other transporters have been found to 
transport cefadroxil. For example, the PepT2 transporter, which is located on the 
apical side of epithelial cells in choroid plexus and renal proximal tubule cells, is 
responsible for cefadroxil uptake from CSF and reabsorbed from urine (Ocheltree 
et al., 2004, Shen et al., 2005, Shen et al., 2007). However, it is still unclear how 
cefadroxil crosses the basolateral membrane of renal epithelial cells to reach the 
blood. However, transporters (active and facilitative) present at the basolateral 
membrane of epithelial cells in small intestine and kidney tubule cells are thought 
to be responsible for the cellular efflux of negatively charged endogenous and 
exogenous compounds, including cefadroxil. Transport experiments with plasma 
membrane vesicles indicated that cefadroxil was transported, in part, by ABCC3 
(MRP3) and ABCC4 (MRP4), which localize on the basolateral membrane of 
small intestine (de Waart et al., 2012). In the kidney, vectorial secretion of 
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cefadroxil is achieved via cellular uptake at the renal basolateral membrane by 
OAT1 (SLC22A6) and OAT3 (SLC22A8), coupled to cellular efflux at the renal 
apical membrane by ABCC4 (MRP4) (Granero et al., 1994, Khamdang et al., 
2003, Russel et al., 2008).  In addition, the OATP2 transporter was shown to 
transport cefadroxil using a Xenopus laevis oocyte expressing system 
(Nakakariya et al., 2008a, Nakakariya et al., 2008b).   
In metabolism and pharmacokinetic studies, cefadroxil is stable both in 
vitro and in vivo. It is neither hydrolyzed in the acidic environment of the stomach 
nor degraded by intra-/extra-cellular enzymes. As a substrate of PepT1, 
cefadroxil has a high bioavailability despite its anionic charge in the intestine and 
poor lipophilicity (Ginsburg et al., 1980, Oliveira et al., 2000, Otoom et al., 2004, 
Santella et al., 1982). The oral bioavailability of cefadroxil is not influenced by 
food and >90% of the drug is excreted unchanged in the urine within 24 hours 
because of free glomerular filtration, due to low serum binding of less than 20% 
(Bergan 1984), and active tubular secretion (Bins et al., 1988). Cefadroxil is also 
a substrate of PepT2 and, because of extensive renal reabsorption, the drug has 
a relatively longer half-life (~1.5 hrs.) than cephalexin, which is prolonged in 
patients with renal impairment (Brisson et al., 1982, Hampel et al., 1982, La Rosa 
et al., 1982, Marino et al., 1982, Olin 1980, Pfeffer et al., 1977, Prenna et al., 
1980, Santella, et al. 1982, Tanrisever, et al. 1986). To complicate matters, 
cefadroxil has been reported to have non-linear oral absorption and disposition 
kinetics within the usual dosage range of 250 - 2000 mg in healthy subjects, 
presumably because of capacity-limited PepT1 intestinal absorption, OAT renal 
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secretion, and PepT2 renal reabsorption (Arvidsson et al., 1979, Garcia-
Carbonell, et al. 1993, Garrigues, et al. 1991, La Rosa, et al. 1982). However, 
cefadroxil was found to have linear absorption and disposition kinetics in wildtype 
mice during oral escalation studies, where its partial AUC0-120 and Cmax was 
proportionally increased with increasing dose (Posada et al., 2013).   
Overall, PepT1, located at the apical membrane of small intestine, is a 
high-capacity low-affinity POT family member that is solely responsible for the 
uptake of nutrient di/tri-peptides and peptide-like drugs from the intestinal lumen. 
However, cross-species differences in pharmacokinetics make it difficult to 
translate animal studies in mice to that in humans. Therefore, the development 
and validation of a humanized huPepT1 mouse model might provide a valuable 
approach for clarifying the mechanism of species difference in drug absorption, 
and further aid drug design and discovery in a more rational way.   
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Table 2.1 Molecular and functional features of POT transporters  
Feature PepT1 PepT2 PhT1 PhT2 
Human Gene Name SLC15A1 SLC15A2 SLC15A4 SLC15A3 
Mammalian Species Rat, rabbit, human, mouse 
Rat, rabbit, human, 
mouse Rat Rat 
Amino Acids 707-710 729 572 582 
Human Gene Locus 13q33-q34 3q13.3-q21 12q24.32 11q12.1 
Sequence Accession ID NM-005073 NM-021082 NM-145648 NM-016582 
Splice Variants hPEPT1-RF  A, A', B and hPTR4 Multiple 
Transmembrane Domains 12 12 12 12 
Protein Kinase A Sites 0-1 0-3 0 2 
Protein Kinase C Sites 1-2 2-5 11  4  
Glycosylation Sites 4-7 2-5 4 3 
Amino Acid Identity 
~80-90% (species) ~80-90% (species) < 20% (PEPT1/2) <20% (PEPT1/2) 
 ~50% (PEPT1)  ~50% (PHT1) 
Transport Type/Coupling Cotransporter/H+   Cotransporter/H+   Cotransporter/H+   Cotransporter/H+   
Amino Acids in Substrate 2-3 2-3 2-3 2 
L-Histidine Transport No No Yes Yes 
Stereoselectivity L>D L>D --- --- 
Substrate Affinity Low High High --- 
Km Values mM uM uM --- 
Stoichiometry 1:1 (proton:substrate) 
2:1 
(proton:substrate) --- --- 
Information was obtained Hong Shen’s Dissertation(Hong 2006). 
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Table 2.2 Species-dependent affinity of glycylsarcosine for PepT1 (Hu, et al. 
2012)  
Animal Species GlySar Km (mM) Experimental Conditions for Uptake Reference 
Rabbit 1.9 cRNA-injected XLO, pH5.5 (Fei, et al. 1994) 
Human 0.29 cDNA-transfected HeLa Cells, ph6.0 (Liang, et al. 1995) 
Rat 0.24 cRNA-injected XLO, pH6.0 (Zhu, et al. 2000) 
Mouse 0.75 cRNA-injected XLO, pH5.5 (Fei et al., 2000) 
Sheep 0.61 cRNA-injected XLO, pH5.5 (Pan et al., 2001) 
Chicken 0.47 cRNA-injected XLO, pH6.0 (Chen et al., 2002) 
 2.6 cDNA-transfected CHO Cells, ph6.0  
Monkey 0.35 cDNA-transfected HeLa Cells, ph6.0 (Zhang et al., 2004a) 
Pig 0.94 cDNA-transfected CHO Cells, ph6.0 (Klang et al., 2005) 
Salmon 0.5 cRNA-injected XLO, pH6.5 (Ronnestad et al., 2010) 
Rat 0.16 cDNA-Yeast Cells, pH 6.5 (Hu, et al. 2012) 
Mouse 0.30 cDNA-Yeast Cells, pH 6.5 (Hu, et al. 2012) 
Human 0.86 cDNA-Yeast Cells, pH 6.5 (Hu, et al. 2012) 
* XLO: Xenopus lavis oocytes 
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Figure 2.1. Biological structure of the small intestine and its microscopic 
architecture, including the structure of villi, microvilli and epithelial 
cells. (Adopted from http://medicalterms.info/anatomy/Small-
Intestine/) 
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Figure 2.2. Mechanisms of transport through the intestinal epithelium.  (A) 
Paracellular transport; (B) Passive diffusion; (C) Endocytosis; (D) 
Carrier-mediated transport; (E) Carrier-mediated uptake; (F) Carrier-
mediated efflux (Oostendorp, et al. 2009) 
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Figure 2.3. Membrane topology of peptide transporter 1 (PepT1). The protein 
contains 12 transmembrane domains (TMDs), with N-terminal and C-
terminal ends in the cytoplasm (Rubio-Aliaga, et al. 2002). 
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Figure 2.4  Model of peptide transport in epithelial cells. Di-/tri-peptides 
digested from ingested protein, were transported by the proton-
coupled transporter PepT1 from intestinal lumen into epithelial 
cells, then hydrolyzed in the cytosol and effluxed into blood through 
various transporters located at the basolateral membrane. The 
driving force for uptake is dependent upon an electrochemical 
proton gradient across the membrane, partly produced by the 
apical Na+-H+ exchanger, in which the Na+ gradient was 
established by Na+/K+ ATPase. (Rubio-Aliaga, et al. 2002)   
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Figure 2.5.  Model of the substrate/proton-coupled structural transition between 
the inward-open and partially occluded states for GsPOT 
transporter. The symport cycle was illustrated as half of transition 
including the inward-open and occluded forms. Black arrows 
represent the physiological symport cycle, and gray arrows 
represent other transitions (Doki, et al. 2013). 
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Figure 2.6.  Cross-species protein sequence alignment between human, mouse 
and rat PepT1 transporters using the Cluster W 2.1 program.  The 
transmembrane domains are colored in grey, and conserved amino 
acid residues are highlighted in the blue box. 
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Figure 2.7 Key molecular structural features in compounds determining 
recognition as a substrate of PepT1. Critical structural properties 
that are essential for affinity are presented on the backbone of a 
tripeptide model (Zhang, et al. 2013).  
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Figure 2.8.  Humanized mouse model by additive transgenesis. The targeted 
human gene, either cDNA or genomic DNA, was injected into a 
fertilized mouse egg, and the egg was then transferred to a 
pseudopregnant foster mother for development. After the pups 
were delivered, genotyping PCR was applied to screen out the 
positive founders, which were then cross-mated with knockout mice 
to produce the desired humanized mice (Devoy, et al. 2012).   
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Figure 2.9.  Humanized mouse model by specific knock-in strategy. The mouse 
endogenous genome locus was replaced by a human genome BAC 
vector through homologous recombination in ESCs (Embryonic 
Stem Cells), such that the endogenous mouse locus was replaced 
by an equivalent human sequence. After positive colonies were 
screen out, the selection marker was removed by SSR (Site 
Specific Recombinase). Then transgenic ESCs were injected into 
blastocysts for producing humanized mice that can inherit the 
human gene by germline transmission (Ahn et al., 2010, Devoy, et 
al. 2012). 
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Figure 2.10. The molecular structures of GlySar (top) and cefadroxil (bottom). 
Both compounds are substrates of PepT1 and PepT2.   
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CHAPTER III 
 
DEVELOPMENT AND CHARACTERIZATION OF HUMANIZED huPEPT1 
MOUSE MODEL USING MICROINJECTION TRANSGENIC METHOLOGY 
 
 
ABSTRACT 
 
Purpose 
The proton-coupled oligopeptide transporter PepT1 is predominantly expressed 
in small intestine and mediates the uptake of protein-digested di-/tri-peptides and 
peptide-like drugs from the intestinal lumen. However, species differences in 
PepT1 protein function have been observed in yeast expressing the rat, mouse 
and human gene. The purpose of this study was to generate a novel humanized 
mouse line for hPepT1 (using the microinjection transgenic method) in order to 
examine the physiological, pharmacological and pathological roles and relevance 
of the hPepT1 protein in humanized mice as compared to wildtype mice. 
Methods 
A new humanized mouse line for hPepT1 were successfully generated using the 
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microinjection technique with a BAC construct containing the entire human 
hPepT1 genomic DNA. The gene copy number, transcripts and protein 
expression of human PepT1 were assessed using real-time quantitative PCR 
(qPCR) and immunoblotting, and location of the PepT1 protein was determined 
using histological fluorescence chemistry hybridization. Moreover, other relevant 
genes were evaluated for mRNA expression using real-time qPCR.   
Results 
No obvious behavioral abnormalities were observed in humanized mice. The 
humanized mice were viable, fertile, grew to normal size and weight, and had no 
significant differences in clinical serum chemistries as compared to wildtype and 
mPepT1 knockout mice. Real-time qPCR and immunoblot analyses 
demonstrated that humanized mice had only one copy of human PepT1 gene 
integration.  They also had abundant hPepT1 protein expression in small 
intestine, similar to that of mPepT1 in wildtype mice, and a measurable but low 
protein expression in colon. In addition, other select relevant genes were not 
aberrantly expressed in the intestine and kidney of humanized mice, although 
minor changes in gene expressions were observed in these tissues. Moreover, 
as determined by immunohistochemistry, PepT1 protein was localized at the 
apical side of epithelial cells in small intestine. 
Conclusion 
These findings demonstrated that the hPepT1 gene had only one copy of 
integration in the mouse chromosome. Consequently, the hPepT1 transporter 
had a comparable expression profile in humanized mice as compared to that of 
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mPepT1 in wildtype mice. Still, there was a significant, but small, upregulation of 
mRNA and protein expression in the colon of humanized mice. The human 
hPepT1 protein was localized at the apical side of epithelial cells in small 
intestine. These humanized huPepT1 mice might provide a valuable research 
tool to study the physiological, pharmacological and pathological characteristics 
of the human hPepT1 transporter, and to compare differences in the 
pharmacokinetics and pharmacodynamics of PepT1 transporters across species.  
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INTRODUCTION 
 
Membrane protein PepT1 (SLC15A1), along with PepT2 (SLC15A2), 
PhT1 (SLC15A4) and PhT2 (SLC15A3), are members of the solute carrier 
subfamily 15 that mediate the cellular uptake of dipeptides and tripeptides, in 
addition to a variety of peptide-like drugs. Following the cloning of rabbit PepT1 
(Fei et al., 1994), the human hPepT1 and mouse mPepT1 were cloned, where 
they shared 85% homology to each other (Fei et al., 2000, Liang et al., 1995). 
The human hPepT1 transporter had 708 amino acid residues whereas the 
mouse mPepT1 transporter had 709 amino acid residues. All peptide 
transporters were reported to have 12 transmembrane domains, the C-terminal 
and N-terminal facing inside the cytoplasm, and important residues including 
Tyr12, His57, Tyr64, Trp294, Phe297 and Glu595 being located within the highly 
conserved transmembrane domains H1, H2, H5, H7 and H10 (Smith et al., 
2013). 
In contrast to PepT2 (SLC15A2), which has a high-affinity low-capacity 
role in renal drug reabsorption (Ocheltree et al., 2005), the PepT1 transporter is a 
low-affinity high-capacity transporter responsible for nutritional intake. In this role, 
PepT1 absorbs digested proteins in the diet, available as di-/tri-peptides, from the 
intestinal lumen. PepT1 protein also has an important role in absorbing peptide-
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like drugs, including β-lactam antibiotics and antiviral nucleoside prodrugs such 
as valacyclovir (Yang et al., 2013a). Previous PCR and immunoblot results 
demonstrated that the PepT1 (SLC15A1) protein was predominantly expressed 
at the apical membrane of enterocytes, especially along the small intestine (Shen 
et al., 2001). The expression of PepT1 protein in colon is controversial.  
Notwithstanding this uncertainty, it is unlikely that colonic PepT1 has much of an 
effect on nutrient absorption, which would be completed in the small intestine. 
Species differences in the expression pattern and functional activity of 
PepT1 have been observed between rodents and humans (Jappar et al., 2010, 
Wuensch et al., 2013). Our laboratory was the first to evaluate the role and 
relevance of PepT1 in peptide/mimetic drug absorption and disposition using a 
mPepT1-/- KO mouse model (Posada et al., 2013a, Yang, et al. 2013a). In 
particular, we demonstrated that both cefadroxil and valacyclovir exhibited dose-
proportional absorption in mice after in vivo oral dose escalation, results that 
were contrary to the nonlinear intestinal absorption kinetics reported in rats and 
humans for cefadroxil (Garrigues et al., 1991, Sanchez-Pico et al., 1989) and 
valacyclovir (Weller et al., 1993). More recently, species difference in the 
substrate affinity of human, rat and mouse PepT1 was confirmed by the uptake 
of GlySar using a yeast expressing system (Hu et al., 2012). These findings 
supported the tenet that a species difference existed between human, mouse 
and rat in the pharmacokinetics of PepT1 for drug absorption and possible 
disposition. However, these results in animal and yeast expression studies may 
not truly reflect what happens in humans when physiological conditions are 
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altered. To resolve potential species differences in transporter protein 
functionality during drug discovery, a potential solution is to develop a humanized 
mouse model.  
Humanized mice have been proposed as useful animal model to address 
the issue of species differences in gene functional activities and subsequent 
relevant events during the past decades. Typically, a humanized mouse model 
can be generated by pronuclear injection or by gene targeting in embryonic stem 
cells to insert or replace the entire human genomic loci into the mouse genome, 
in which YAC or BAC construction was a useful vector to manipulate human 
genomic targeted DNA (Devoy et al., 2012). 
In the present study, the development of an hPepT1 humanized mouse 
model was achieved by hPepT1 genomic DNA injection into mPepT1-/- knockout 
mouse. Our findings demonstrated that humanized hPepT1+/- mice (huPepT1) 
have a different protein expression level and tissue distribution of hPepT1 
protein, compared to mPepT1 expression patterns in wildtype mice.  
 
MATERIALS AND METHODS 
 
Chemicals 
Rabbit anti-human hPepT1 antiserum was a generous gift of Dr. 
Hannelore Daniel (Technische Univeristy Muchen, Germany). Alex Fluor488 and 
Prolong Diamond Antifade Mounting reagent with DAPI was purchased from 
Thermo Fisher Scientific Inc. (Walthan, MA). Proteinase inhibitor cocktail was 
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purchased from Roche (Seattle, WA).  Power SYBR-green PCR Matrix was 
purchased from Applied Biosystems (Foster City, CA). All other chemicals were 
acquired from standard sources.   
Animals   
In-house breeding of gender- and weight-matched mice, 8 to 10 weeks 
old, included mPepT1+/+ (wildtype; WT), mPepT1-/- (mPepT1 knockout; KO) and 
humanized mPepT1-/-/hPepT1+/- mice (hPepT1 humanized; huPepT1; HU).  All 
mouse strains were congenic on a C57BL/6 background, in which KO and HU 
mice were identified by genotyping and culled from the same breeding litters. The 
mice were housed in a temperature-controlled environment with 12-hour light and 
12-hour dark cycles, and received a standard diet and water ad libitum (Unit for 
Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI). All mouse 
studies were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted and promulgated by the U.S. National Institutes 
of Health (Institute of Laboratory Animal Sources, 1996).   
The Sensitivity of Genotyping PCR  
The specificity and sensitivity of PCR genotyping for one copy of the 
human PepT1 gene within the mouse genome was necessary for achieving 
success in the development of humanized huPepT1 mice, as well as for avoiding 
interference from the mouse mPepT1 gene.  Two pairs of primers were designed 
to test the sensitivity of PCR genotyping using a series of human hPepT1 genes 
from 0.001, 0.01, 0.1, 1 to 10 copies in 200 ng of mouse genomic DNA. The first 
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pair of primers were forward 5’-ATCTTCTTCATCGTGGTCAATG-3’ and reverse 
5’-CCCAGCTGATGAAATTTGTGAA-3’ (product size of 200 bp). The second pair 
of primers were forward 5’-CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3’ 
and reverse 5’-CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3’ (product 
size of 524 bp). The PCR conditions were:  94oC initiated for 2 min, followed by 
94oC x 30 sec, 60oC x 45 sec, 72oC x 60 sec for 35 cycles, 72oC x 10 min, then 
hold at 4oC.  
Generation of hPepT1 humanized mouse line and initial characterization   
The approach used to generate a humanized mouse line for hPepT1 was 
described previously (Van Keuren et al., 2009), with help from the Transgenic 
Core at the University of Michigan. In brief, fertilized eggs donated by female 
mPepT1 KO mice (Hu et al., 2008), 20-24 days old, which were mated with 
mPepT1 KO males, were injected with purified BAC DNA, RP11-782G13 
(~179kb[chr13: 98,091,462 - 98,270,723], Empire Genomics, Buffalo, New York).  
The BAC clone contained the entire human hPepT1 genomic DNA (~70kb), 
including the 5’-terminal regulatory elements, coding area, and 3’-terminal 
regulatory elements. Only intact microinjected eggs were transferred to 
pseudopregnant recipients for generating transgenic founder offspring.   
The transgenic hPepT1 alleles were detected in offspring by PCR using 
the genomic DNA isolated from tail biopsies. The lack of an endogenous 
mPepT1 gene was also confirmed by PCR, as described previously (Hu, et al. 
2008). After genotyping, the humanized huPepT1 mice were maintained and 
subsequently bred to hemizygosity by mating with mPepT1-/- mice (Figure 3.1). 
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The humanized mice were evaluated for viability and serum chemistry, as 
described previously for mPepT1 KO mice (Hu, et al. 2008).   
Gene Copy Measurement of Human hPepT1 in Humanized Mice  
The integration copy number of human hPepT1 gene in the mouse 
genome was measured using real-time PCR. The procedure was reported before 
but slightly modified (Huang et al., 2013, Mancini et al., 2011). Briefly, the 
absolute quantitation of human hPepT1 gene in humanized mice was performed 
using the 7300 real-time PCR system (Applied Biosystems, Foster City, CA). 
Mouse endogenous gene β-globin was set as the control amount of mouse 
genomic DNA because it was identified as a single copy gene (Konkel et al., 
1978). Primers and standards for the DNA of mouse β-globin and the human 
hPepT1 gene (Table 3.3) was designed with Primer 3.0 (Applied Biosystems, 
Foster City, CA) and synthesized by IDT (Coraville, IA). The real-time qPCR 
conditions were 1 cycle at 50oC for 2 min, 1 cycle at 95oC for 10 min, 40 cycles at 
95oC for 15 sec and 60oC for 60 sec. Relative amounts of the β -globin and 
human hPepT1 genes were calculated based on the standard curve, and the 
absolute copy number of human hPepT1 gene was calculated by the ratio of 
human hPepT1 to β -globin.   
Real-time PCR and Immunoblot Analyses  
Quantitation of hPepT1, mPepT1, mPepT2, mPhT1, mPhT2 and select 
relevant genes in the small intestine, colon and kidney from wildtype, mPepT1 
knockout and humanized huPepT1 mice was performed using the 7300 Real-
time PCR system (Applied Biosystems, Foster City, CA) as described previously 
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(Hu et al., 2014). In brief, 2.0 µg of total RNA, which was isolated using the 
RNeasy Plus mini Kit (Qiagen, Valencia, CA), was reversely transcribed into 
cDNA using Omniscript RT kit (Qiagen, Valencia, CA) with 16-mer random 
primers. The mouse mGapdh gene was used as an internal standard for cDNA 
quality and quantity. The primers in Table 3.2 were designed with Primer 3.0 
(Applied Biosystems, Foster City, CA) and synthesized by Integrated DNA 
Technologies (Coraville, IA). The real-time PCR thermal conditions were 1 cycle 
at 50oC for 2 min, 1 cycle at 95oC for 10 min, 40 cycles at 95oC for 15 sec and 
60oC for 60 sec. The ∆CT method was used to calculate the relative gene 
transcript levels in mice, where the ratio of target gene to mGapdh gene was 
equal to 2-∆CT, ∆CT=CT(gene)-CT(GAPDH) 
Immunoblot analyses were performed using a standard, as described 
previously (Jappar, et al. 2010), Protein samples were prepared from different 
segments of the small intestine, colon and kidney of wildtype, mPepT1 knockout 
and humanized huPepT1 mice using 2.0 ml of Nonidet P40-lysis buffer (50 mM 
Tris-HCl, 150mM NaCl, 1% Nonidet P40, proteinase inhibitor cocktail, pH 8.0). 
The homogenates then were sonicated for 10 pulses, on ice at half strength of 
power, and then centrifuged for 15 min at 15,000g, 4oC. The final concentration 
of proteins was measured using the BCA Protein Assay Kit (Pierce, Rockford, 
IL). Proteins were denatured at 40oC for 45 min and resolved by 10% SDS-
PAGE gel electrophoresis, transferred to a PVDF membrane (Millipore, Billerica, 
MA), and then blotted with specific polyclonal anti-hPepT1 antiserum (raised 
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against the COOH-terminal region, NRLEKSNPYFMSGANSQKQM, amino acids 
689-708) (1:3000 diluted).  
Cryosectioning and In Situ Fluorescence Immunoblot Analyses 
 
After being euthanized with CO2, the small intestine and colon were 
removed from the animals, trimmed of contaminating tissue, and then cut into 
fragments no more than 5 mm thick. The tissues were then placed into Optimal 
Cutting Temperature (O.C.T)-prefilled base molds, without air bubbles, and set at 
the bottom of the mold. The base molds containing tissues were quickly placed 
into a beaker of cold 2-methylbutane, precooled in liquid nitrogen, until the tissue 
matrix completely solidified, at which time it was stored at -80oC until ready for 
sectioning.   
 
Before sectioning, the tissue matrix block was equilibrated to that of the 
cryostat temperature of -25oC, mounted on a cryostat specimen disk with O.C.T 
(Optimal Cutting Temperature) (Sakura Finetek USA, Torrance, CA), and then 
adjusted to align with the knife blade. The desired section thickness was set at 5 
to 10 µM (usually 7 µM). The cut section was adhered to a Superfrost Plus slide 
(Thermo Fisher Scientific Inc. Walthan, MA), the slide fixed by immersion in cold 
fresh acetone (-20oC or ice-cold) for 2 x 10 minutes, and then air dried and 
processed for staining.   
The fixed slides were washed three times with PBS, 2 min each, and then 
aspirated around the tissue until the slide was dry. The slides were then placed in 
a humid chamber, prepared by putting one wet paper towel on the bottom of 
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chamber with a couple of sticks over it. After blocking with 5% goat serum in PBS 
containing 0.05% Triton X-100 for one hour at room temperature, the slides were 
then incubated with 150 µL of 2% goat PBS, containing 0.2 µL of anti-human 
hPepT1 antiserum, for one hour at room temperature in a humidified chamber, 
then followed by rinsing the slides with PBS five times, 2 min each time. The 
secondary antibody (Alex Fluor488), diluted 1:300 with 2% goat PBS containing 
0.05% Triton X-100, was added to the slides and then incubated in the humidified 
chamber for one hour at room temperature. After that, the slides were washed 
twice with PBS/tritonx-100 buffer, 2 min each, followed by three washes with 
PBS, 2 min each. After the slides were dry, 2 drops of Prolong Diamond Antifade 
Mounting reagent was added with DAPI to each section, a cover slip placed over 
the section, and the slides then remaining overnight, at room temperature, 
protected from the light. Once the slides were completely dry, the edges of the 
cover slip were sealed with clear nail polish. Fluorescence staining of the slides 
was checked by microscopy.  
H&E Staining for Frozen Tissue Sections  
After being air-dried for several minutes to remove moisture, tissue 
sections were stained with filtered 0.1% Mayers Hematoxylin (Sigma; MHS-16) 
for 10 min in a 50 mL conical tube. The sections were then placed in a Coplin jar 
and rinsed with cool running ddH2O for 5 min.  After being dipped in 0.5% Eosin 
(1.5g dissolved in 300mL of 95% ethanol) 12 times, the sections were washed in 
distilled water until the eosin stopped streaking.  They were then dipped in 50% 
and then 70% ethanol, 10 times each, and equilibrated in 95% and 100% ethanol 
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for 30 and 60 sec, respectively. Finally, the sections were dipped in Xylene 
several times, the excess liquid aspirated away, the slides cleaned with a paper 
tower, and then mounted by a coverslip with Cytoseal XYL (Thermo Fisher 
Scientific Inc. Waltham, MA).  
Data analysis  
Data were reported as mean ± SE, unless otherwise noted. Statistical 
differences between two groups were determined using an unpaired t-test. 
Multiple treatment groups were compared using one-way analysis of variance 
(ANOVA), followed by either a Tukey’s or Dunnett’s post hoc test (GraphPad 
Prism 5.0; GraphPad software, Inc., La Jolla, CA). A p value ≤ 0.05 was 
considered significant.    
RESULTS 
 
The Sensitivity of Genotyping PCR  
In order to screen founder mice for positive colonies of human hPepT1 
genomic DNA contained in the chromosome, PCR genotyping was necessary 
because of its sensitivity to probe at least one copy of integration in the entire 
mouse genome. As shown in Figure 3.2, a serial dilution of human hPepT1 gene 
(BAC DNA: RP11-782G13) was added to the PCR reaction system using two 
different pairs of primers. Both primer pairs could be used to specifically amplify 
the target gene of human hPepT1 from samples containing even less than one 
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copy in 200 ng genomic of DNA (the estimated amount in one mouse genome), 
up to 0.01 copy per 200 ng genomic DNA for primer #1. Moreover, no band was 
found in the negative control containing only mouse genomic DNA. Therefore, 
this genotyping PCR method was sensitive enough to screen for positive 
colonies of humanized huPepT1 mice.   
 Identification of Humanized Transgenic Mice   
Humanized huPepT1mice were generated on the background of C57BL/6 
mPepT1 knockout mice using a traditional microinjection transgenic strategy with 
BAC DNA (Van Keuren, et al. 2009).  In this way, the whole genomic DNA of 
hPepT1, comprising all regulatory elements and coding regions, can be 
integrated into the mouse chromosome for inheritance. As shown in Figure 3.3, 
hPepT1 genomic DNA appeared only in humanized huPepT1 mice and the BAC 
RP11-782G13, which was set as the positive control. In contrast, hPepT1 
genomic DNA was not found in mPepT1-/-/hPepT1-/-, mPepT1+/+ and mPepT1-/-
mice, the latter being used as the negative control. In addition, mouse mPepT1 
genomic DNA was not detected in mPepT1-/-/hPepT1+/-, mPepT1-/-/hPepT1-/- and 
mPepT1-/-, but was detected in mPepT1+/+/hPepT1-/- and wildtype mice using 
wildtype primers. Since mPepT1 KO primers were targeted for the Neo gene, 
which was designed to replace endogenous mPepT1 genomic DNA when 
creating the mPepT1 knockout mouse model, the observed band during the PCR 
reaction with mPepT1 KO primers means that mouse mPepT1 genomic DNA 
was abolished in mPepT1-/-/hPepT1+/-, mPepT1-/-/hPepT1-/-and mPepT1-/- mice, 
but not mPepT1+/+/hPepT1-/- mice.   
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 Six founder mice were identified as containing the BAC RP11-782G13 
DNA. However, only five of the mice succeeded in germline transmission of this 
DNA, and only three mice showed hPepT1 mRNA expression (Figure 3.4). The 
humanized huPepT1 mouse (HU #4) showed the highest level of mRNA 
expression and, as a result, was selected for further breeding and studies.  
 The integration copy number of transferred BAC RP11-782G13 DNA was 
measured using real-time PCR. Two humanized mouse lines (HU#4 and HU#5) 
were found to have one copy of hPepT1 genomic DNA in their genome, as 
shown in Figure 3.5.   
Initial Phenotypic and Physiological-Chemical Analysis  
Hemizygous humanized huPepT1 mice appeared normal with no obvious 
behavioral phenotype. They cannot be distinguished from wildtype or mPepT1 
knockout mice based on appearance alone. The humanized huPepT1 mice had 
normal survival rates, fertility, litter size, gender distribution and body weight 
(Table 3.1) as compared to wildtype and mPepT1 KO mice. Moreover, as shown 
in Table 3.1, there were no significant differences in serum clinical chemistry 
between the three genotypes, including electrolytes, protein, glucose and 
enzymes. Histologic evaluation, by hematoxylin and eosin staining, also 
demonstrated normal morphology of the small intestine (duodenum, jejunum and 
ileum) (Figure 3.6), cecum/colon (Figure 3.7) and kidney (Figure 3.8). 
 
Stable Expression of hPepT1 Transporter in Intestine of Humanized Mice  
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 qPCR was carried out to demonstrate that human, but not mouse, PepT1 
transcripts were expressed in humanized mice.  In this regard, hPepT1 mRNA 
was abundantly found in small intestine and to a lesser extent in colon of 
huPepT1, but not wildtype and mPepT1 KO mice (Figure 3.9A).  In contrast, 
mouse mPepT1 was expressed in wildtype, but not in PepT1 KO and humanized 
huPepT1 mice (Figure 3.9B).  Of note, whereas hPepT1 expression was clearly 
observed in the proximal and distal colon of humanized mice (Figure 3.9A), 
mouse mPepT1 mRNA levels were only found in distal and not proximal colon of 
wildtype mice (Figure 3.9B).  
Immunoblot analyses of intestinal and kidney tissue were performed to 
assess whether the expression levels of hPepT1 mRNA matched that of hPepT1 
protein. Regional segments of small intestine and colon were probed using 
specific anti-human hPepT1 antiserum. hPepT1 protein was detected at high 
levels in humanized mouse duodenum, jejunum and ileum, and at low levels in 
proximal and distal colon; no hPepT1 protein was observed in kidney (Figure 
3.10A). Specificity of the antibody was confirmed by the absence of signal in 
samples taken from wildtype and mPepT1 mouse jejunum, and by the presence 
of a strong signal in Caco-2 cells (Figure 3.10A).  As expected, there was no 
mouse mPepT1 protein in the humanized mice, as determined using a specific 
anti-mouse mPepT1 antibody (Hu, et al. 2008).  In agreement with real-time 
qPCR results, mouse mPepT1 protein was expressed in the jejunum of wildtype 
mice, but not in the jejunum of mPepT1 knockout and humanized huPepT1 mice 
(Figure 3.10B).   
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Tissue Expression Profile of Selected Relevant Transporters   
Tissue expression levels of select relevant genes, as assessed by real-
time qPCR, are shown in Figures 3.11 (C-E). In these analyses, the three other 
mouse POT genes (i.e., mPepT2, mPhT1 and mPhT2) had very low expression 
levels of transcript in both the small and large intestines of wildtype, mPepT1 KO 
and humanized huPepT1 mice; mPepT2, however, had high expression levels of 
transcript in kidney for all three genotypes. Even though statistically significant 
changes were observed for some genes, given their very low expression levels, it 
highly unlikely that mPepT2 in the intestines and mPhT1/2 in the intestines and 
kidney will have meaningful protein expression. We also searched for potential 
changes in mRNA expression of genes involved in amino acid and/or drug 
transport, as shown in Figure 3.12 (A-C). Thus, mPAT1 expression was 
increased about 2-fold in the small intestine of humanized huPepT1 mice as 
compared to wildtype and mPepT1 KO mice. In kidney, mOAT1 transcripts 
increased about 2-fold in mPepT1 KO mice, however, no change was observed 
in this transcript between humanized and wildtype mice.  Other statistically 
significant differences were viewed as minor (with little impact) given their very 
low expression levels. 
 
Localization of hPepT1 Transporters in Humanized Mouse Small Intestine    
The correct localization of transport proteins is essential for their correct 
functional activity. Normally, the PepT1 transporter is localized to the apical side 
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of epithelial cells in small intestine. As shown in Figure 3.13, fluorescence 
immunoblotting demonstrated that human hPepT1 protein is also localized to the 
apical side of enterocytes in humanized mouse jejunum, which is in agreement 
with that in wildtype mice (Wuensch, et al. 2013). 
 
DISCUSSION 
 
Membrane transporters play an important role in drug absorption, 
distribution and elimination, along with drug safety and efficacy (International 
Transporter et al., 2010, Keogh 2012). For example, the peptide transporter 
PepT1 (a proton-coupled oligopeptide transporter family member), which is 
located at the apical side of epithelial enterocytes, is responsible for the 
absorption of protein-digested di-/tri-peptides and peptide-like drugs from the 
lumen of small intestine. Pharmacologically, intestinal PepT1 was used as a 
target in drug discovery for increasing the oral bioavailability of drugs/prodrugs 
(Zhang et al., 2013). For example, by adding a L-valyl ester group to acyclovir, 
the intestinal absorption of valacyclovir, mediated by PepT1, was substantially 
improved along with the systemic availability of its parent drug acyclovir (Yang, et 
al. 2013a, Yang et al., 2013b).  However, whereas a dose-proportional increase 
in the AUC of valacyclovir was observed in wildtype mice, a nonlinear increase in 
the AUC of valacyclovir, as a function of increasing dose, was observed in 
human subjects (Weller, et al. 1993, Yang, et al. 2013a).  Furthermore, our 
laboratory reported that the Km of GlySar for human hPepT1, using yeast 
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transformants, was three-fold higher than that for mouse mPepT1 (0.86mM vs. 
0.30mM) (Hu, et al. 2012). It should be appreciated that species differences in 
membrane transporters can also be defined by their tissue distribution, 
expression levels and prevailing isoforms. For example, a single P-gp protein 
(MDR1) has been observed in humans, but two isoforms (MDR1a and MDR1b) 
were observed in rodents (Shirasaka et al., 2011).  
Humanized mouse models, produced by transgenic methods, are widely 
used to investigate if differences exist in the gene activity of human transporters, 
enzymes and receptors as compared to animals. In the past several years, the 
generation and characterization of humanized mice has lead to substantial 
progress in the drug discovery arena. For instance, transgenic mouse models 
containing human CYP450, conjugation enzymes and nuclear receptors were 
developed to study drug metabolism, degradation and transport (Gonzalez et al., 
2006, Gossen et al., 1994, Jiang et al., 2011, Raybon et al., 2011, Scheer et al., 
2013, Xie et al., 2000). However, with the exception of several organic anion-
transporting polypeptide transporters (OATPS) (van de Steeg et al., 2012, van de 
Steeg et al., 2009, van de Steeg et al., 2013) and multidrug resistance-
associated protein (MRP2) humanized mouse models (Scheer et al., 2012), no 
other plasma membrane transporters have been humanized so far. Thus, the 
ability to generate a huPepT1 mouse model containing the entire human genome 
offers an unparalleled opportunity to more reliably study the in vivo performance 
of human PepT1-mediated processes such as drug transport, intestinal 
absorption, pharmacologic response, disease and regulation.   
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In the present studies, a novel mouse line was established and initially 
characterized for the humanized hPepT1 transporter. In doing so, we made the 
following observations: 1) humanized huPepT1 mice had no obvious behavioral 
or pathological phenotype; 2) only one copy of the hPepT1 gene was integrated 
into the mouse genome; 3) mRNA and protein profiles indicated that huPepT1 
mice had substantial hPepT1 expression in all regions of the small intestine (i.e. 
duodenum, jejunum and Ileum); 4) a low but measurable expression of hPepT1 
mRNA and protein was observed in both proximal and distal segments of the 
colon in humanized mice; 5) in situ fluorescence immunoblotting indicated that 
the hPepT1 protein was correctly localized to the apical side of small intestinal 
enterocytes.   
Previous transgenic mouse models of human hPepT1 were reported, 
where human hPepT1 cDNA was introduced into wildtype mice and the hPepT1 
protein ubiquitously expressed under the control of the β-actin or villin promoter, 
for investigating hPepT1’s potential role in inflammatory bowel disease (IBD) 
(Dalmasso et al., 2011). However, these transgenic mouse models did not rule 
out the impact of endogenous mPepT1, even though the human hPepT1 protein 
was abundantly detected in normal mouse colon and slightly up-regulated in IBD.  
In contrast, our humanized huPepT1 mouse model was generated by injection of 
purified BAC DNA, which contained the entire hPepT1 genomic DNA, into eggs 
from mPepT1 knockout mice. Thus, our humanized mouse model abolished the 
potential influence of endogenous mPepT1 protein and avoided the interruption 
of other endogenous genes by maintaining the humanized mice in a hemizygous 
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state.  Another advantage of using genomic DNA is that the transcripts of 
hPepT1 gene can be regulated by their own regulatory elements given that the 
mammalian translation mechanism should be conserved among species.   
It was difficult to directly compare the protein expression of PepT1 
between wildtype and humanized mice because of species-specific antibodies. 
However, the mRNA levels of hPepT1 in the small intestine of our humanized 
mice (Colony HU#4 in Figure 3.4) were comparable to that of PepT1 in humans 
(Ziegler et al., 2002) and wildtype mice (Jappar, et al. 2010). Since the 
humanized mice have only one copy of hPepT1 genomic DNA, the expression of 
hPepT1 transcripts in select tissues of humanized mice are somewhat lower than 
wildtype mice, as are the relatively lower levels of hPepT1 protein (Figure 3.9). 
Still, there is general agreement among species (e.g., rat, mouse, human) 
regarding the abundant protein expression of PepT1 in duodenal, jejunal and 
ileal segments of small intestine, and its apical localization (Ford et al., 2003, 
Groneberg et al., 2001, Jappar, et al. 2010, Merlin et al., 2001, Ogihara et al., 
1996, Shen, et al. 2001, Walker et al., 1998, Wuensch, et al. 2013, Ziegler, et al. 
2002).  
The colonic expression of PepT1 is controversial and may be the result of 
species differences, the specificity of antibody being used, regionality of tissue 
expression, and the methods used by different laboratories in preparing the 
sample. Whereas some studies have reported the expression of PepT1 protein in 
normal mouse, rat and human colon (Ford, et al. 2003, Wuensch, et al. 2013, 
Ziegler, et al. 2002), other studies have been unable to detect PepT1 in normal 
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human, rat and mouse colon (Groneberg, et al. 2001, Jappar, et al. 2010, Merlin, 
et al. 2001, Ogihara, et al. 1996, Shen, et al. 2001). In particular, Wuensch et al. 
(2013) found a distinct spatial distribution of colonic PepT1 in mice, rats and 
humans, in which immunostaining was not observed in proximal colon but 
significant staining was observed in the distal colon. In our hands, we have 
consistently detected abundant expression of PepT1 protein in all regions of 
mouse and rat small intestine, but not in the colon of rodents past 7 days of age 
(Jappar, et al. 2010, Shen, et al. 2001).  In addition, the functional activity of 
mouse PepT1 was consistent with these expression levels, as determined by the 
permeability of GlySar (Jappar, et al. 2010), cefadroxil (Posada et al., 2013b) and 
valacyclovir (Yang, et al. 2013b) in wildtype compared to mPepT1 knockout 
mice.  
With respect to pathological conditions, PepT1 has been implicated by 
some investigators, but not others, as having a role in the further development of 
inflammatory bowel disease (Ayyadurai et al., 2013, Buyse et al., 2001, Buyse et 
al., 2002, Dalmasso et al., 2008, Dalmasso et al., 2010, Dalmasso, et al. 2011, 
Ingersoll et al., 2012, Kovacs-Nolan et al., 2012, Nguyen et al., 2009, Wang et 
al., 2013, Wuensch et al., 2014). Our humanized huPepT1 mice may provide 
another model to study how PepT1 impacts the development of IBD, since 
hPepT1 was expressed in the colon in a similar manner to that of PepT1 colonic 
expression in humans.  The humanized huPepT1 mice may also prove useful in 
studying hPepT1 gene expression and regulation.   
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In concluding, the present study reports, for the first time, the development 
and initial characterization of humanized huPepT1 mice.  These mice are unique 
in that they contain a copy of the entire human genome in mice previously nulled 
for mPepT1, and appear to have comparable protein expression and tissue 
distribution to that of humans.   
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Table 3.1 Serum clinical chemistry of wildtype (WT), mPepT1 knockout (KO) 
and humanized huPepT1 (HU) micea  
 
 WT KO HU 
Body Weight: 
Male (7-8 wks.)  (g) 21.5±0.6 (12) 21.3±0.6 (12) 22.1±0.5 (12) 
Female (7-8 wks.) (g) 17.9±0.3 (12) 17.7±0.4 (12) 18.0±0.3 (12) 
Serum: 
Sodium            (mmol/L)            145±0.87 (6) 147±1.31 (6) 146.±1.40 (6) 
Potassium (mmol/L) 7.28±0.48 (6) 7.35±0.29 (6) 7.72±0.53 (6) 
Chloride (mmol/L) 113±0.91 (6) 113±1.05 (6) 113±1.21 (6) 
Calcium (mg/dL) 9.68±0.47 (6) 9.47±0.14 (6) 9.77±0.20 (6) 
Albumin  (g/dL) 3.40±0.058 (6) 3.47±0.021 (6) 3.55±0.067 (6) 
Protein  (g/dL) 6.40±0.084 (6) 6.38±0.14 (5) 6.32±0.13 (4) 
Creatinine (mg/dL) 0.24±0.026 (6) 0.25±0.0030 (6) 0.28±0.05 (6) 
Bilirubin (mg/dL) 0.16±0.051 (5) 0.08±0.020 (5) 0.14±0.024 (5) 
Glucose  (mg/dL) 131±22.38 (5) 163±17.55 (6) 188±5.86 (4) 
Urea Nitrogen (mg/dL) 29.5±2.35 (6) 27.5±1.50 (6) 33.3±2.11 (6) 
Alanine Transaminase (U/L) 95.2±16.02 (6) 78.0±4.79 (6) 101±5.57 (6) 
Alkaline Phosphatase (U/L) 186±28.54 (6) 94.2±11.71 (6) 149±15.35 (6) 
Aspartate Aminotransferase (U/L) 124±17.51 (6) 124±16.20 (6) 104±9.86 (6) 
 
* WT= mPepT1+/+ wildtype mice; KO= mPepT1-/-/hPepT1-/- KO mice; HU=mPepT1-/-/hPepT1+/- humanized mice 
**No statistical significances were observed, as determined using ANOVA followed by a 
Dunnett’s post hoc test where the control group was WT.  
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Table 3.2 Primers used in quantitative real time PCR of select genes 
 
Genea Forward primer Reverse primer 
mGapdh (EC=1.2.1.12) 5’-GAGACAGCCGCATCTTCTTGT-3’ 5’-CACACCGACCTTCACCATTTT-3’ 
hPepT1 (SLC15A1) 5’-TGACCTCACAGACCACAACCA-3’ 5’-GCCAGGCCGATCAAGGA-3’ 
mPepT1 (Slc15a1) 5’-CCACGGCCATTTACCATACG-3’ 5’-TGCGATCAGAGCTCCAAGAA-3’ 
mPepT2 (Slc15a2) 5’-TGCAGAGGCACGGACTAGATAC-3’ 5’-GGGTGTGATGAACGTAGAAATCAA-3’ 
mPHT1 (Slc15a4) 5’-GCTGCCACCTGCATTACTACTTC-3’ 5’-CGTACTTCACAGACACAATGAGGAA-3’ 
mPHT2 (Slc15a3) 5’-GCTGAAGCTTGCGTTCCAA-3’ 5’-AACAGGTGGGCACTTTCAGAGT-3’ 
mBPHL (EC=3.1.-.-) 5’-GCCAAGGTGGCTGTGAATG-3’ 5’-GATCGCATGTTCCCCTTCTC-3’ 
mBo,+ (Alc6a14) 5’-TCAGGATTTGACTTGGCATTCA-3’ 5’-CAAGGCCCAATGTTAAAAGCA-3’ 
mOat1 (Sl22a6) 5’-CCACCTGCTAATGCCAACCT-3’ 5’-GATTCGGGTCGTCCTTGCT-3’ 
mOat2 (Slc22a7) 5’-TGTCGCAAAGACCCTCGTACT-3’ 5’-ACATCATCATGCAGCACAGTGA-3’ 
mOat3 (Slc22a8) 5’-GCCCCAGCCTCACTGTCTATAT-3’ 5’-ACATTCAAGATAATGGTGCTCAGAGA-3’ 
mOct1 (Slc22a1) 5’-TGGTGTTCAGGCTGATGGAA-3’ 5’-GCCCAAAACCCCAAACAAA-3’ 
mMate1 (Slc47a1) 5’-TTCTGCTTGTGACACGCTCAT-3’ 5’-AGTGTCCCCCTTTGCAGGAT-3’ 
mMate2 (Slc47a2) 5’-GACATCATTTCCCTTGTGAGTCAA-3’ 5’-GCCCGCAAGTGCATCAA-3’ 
mPat1 (Slc36a1) 5’-TCTGCTGTGTCTACTTCGTGTTTCT-3’ 5’-GGATCACGGTCACATTGTTGTT-3’ 
aShown as gene name (solute carrier group or enzyme commission number) for human (h) and mouse (m) 
transporters or enzymes  
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Table 3.3 Primers used in quantitative real time PCR of gene copy number  
 
Genea Sequence 
mbeta-globin 
Primers 
Forward: 5’- CTGAGAACTTCAGGGTGAGTCTGA -3’ 
Reverse: 5’- CCCTAGAATCGCTTCCCCTTT -3’ 
Standard 
Oligo DNA 
 
5’-CTGAGAACTTCAGGGTGAGTCTGATGGGCACCTCCTGGGTTTCCTTC 
CCCTGGCTATTCTGCTCAACCTTCCTATCAGAAAAAAAGGGGAAGCGATT
CTAGGG -3’ 
hPepT1 (SLC15a1) 
Primers 
Forward: 5’- TGACCTCACAGACCACAACCA -3’ 
Reverse: 5’- CGAAGACTTAAGGCATCAAATGC -3’ 
Standard 
Oligo DNA 
 
5’-TGACCTCACAGACCACAACCATGATGGCACCCCCGACAGCCTTCCTGT 
GCACGTGTGAGTTGGTGCTCACTGCTGCCCCCATCACCCTCCCACCTTGTG
CGCATTTGATGCCTTAAGTCTTCG -3’ 
 
aShown as gene name (solute carrier group or enzyme commission number) for human (h) and 
mouse (m) transporters or enzymes 
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Figure 3.1  Schematic of breeding strategy to maintain the colony of 
humanized mice. Humanized mice (hPepT1+/-/mPepT1-/-) were 
cross-mated with mPepT1 knockout mice (hPepT1-/-/mPepT1-/-) to 
produce hemizygous humanized mice (hPepT1+/-/mPepT1-/-), which 
were then used for subsequent experiments.  
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/mPepT1
-/-
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/mPepT1
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Cross Mate 
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Figure 3.2 Sensitivity of genotyping PCR for identifying the hPepT1 gene. Two 
pairs of primers were designed and showed similarly high 
confidence in screening the one copy of gene integrated into the 
entire mouse genome. Lane 1: 10 copies/200 ng DNA; Lane 2: 1 
copy/200 ng DNA; Lane 3: 0.1 copy/200 ng DNA; Lane 4: 0.01 
copy/200 ng DNA; Lane 5: 0.001 copy/200 ng DNA; Lane 6: 
positive control for BAC; Lane 7: Negative control for blank; Lane 8: 
100 bp ladder DNA marker.   
    
        1      2      3      4     5      6     7      8  
A: Primer #1 for hPepT1 gene  B: Primer #2 for hPepT1 gene  
        1      2      3      4     5      6     7      8  
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Figure 3.3  Genotyping results for the identification of humanized huPepT1 
mice. Genomic DNA was extracted from mouse tail biopsies and 
genotyped by PCR using specific primers, as described in the text. 
The DNA ladder, consisting of 100 bp repeats, was used to 
determine the size of PCR products. mPepT1-/-/hPepT1+/- 
represents the positive screen for humanized PepT1 (huPepT1) 
mice, mPepT1-/-/hPepT1-/- the negative screen for humanized 
PepT1 mice, mPepT1+/+ the wildtype mice, mPepT1-/- the PepT1 
knockout mice, and RP11-782G13 the purified BAC DNA (used to 
inject fertilized eggs in generating huPepT1), which served as a 
positive control.  
  
mPepT1 KO primers 
Wildtype primers 
hPepT1 primers #2 
hPepT1 primers #1  
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Figure 3.4  Expression of hPepT1 transcripts in humanized mouse founder 
lines (n=2), as determined by real-time qPCR. Total RNA was 
isolated from five mouse colonies (HU #1 to HU #6), wildtype and 
mPepT1 knockout mouse jejunum. Caco-2 cells served as a 
positive control, and wildtype and mPepT1 knockout mice served 
as negative controls. HU represents the humanized huPepT1 mice.     
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Figure 3.5  Gene copy number of transgenic BAC DNA in humanized huPepT1 
mice. Only one copy of BAC integration was detected using real-
time PCR. HU represents humanized huPepT1 mice.   
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                                     WT                                             HU                                            KO              
Figure 3.6  H & E staining of the small intestine for wildtype (WT), humanized 
huPepT1 (HU) and mouse mPepT1 knockout (KO) mice 
(magnification set at 20x).     
Duodenum 
Jejunum 
Ileum 
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                                     WT                                             HU                                            KO           
Figure 3.7 H & E staining of the colon for wildtype (WT), humanized huPepT1 
(HU) and mouse mPepT1 knockout (KO) mice (magnification set at 
20x).    
   
Proximal  Colon 
Distal Colon 
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                                     WT                                             HU                                            KO        
Figure 3.8 H & E staining of the kidney for wildtype (WT), humanized huPepT1 
(HU) and mouse mPepT1 knockout (KO) mice (magnification set at 
20x).   
  
 109 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  Real-time PCR analyses of human hPepT1 (A) and mouse 
mPepT1 (B) transcripts in the small intestine, colon and kidney of WT, KO and 
HU mice, where the gene expression levels were normalized by the mouse 
Gapdh gene. WT represents the wildtype mice, KO the mPepT1 knockout mice, 
and HU the humanized huPepT1 mice. Duo is the duodenum, Jej the jejunum, Ile 
the ileum, PC the proximal colon, DC the distal colon, and Kid the kidney. Data 
were expressed as mean ± SE (n=4-6). Statistical differences were determined 
for each tissue by ANOVA followed by a Dunnett’s post hoc test, where the 
control group was WT.  
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Figure 3.10  Immunoblots of hPepT1 protein in the small intestine, large 
intestine, and kidney of wildtype (WT), mPepT1 knockout (KO), and 
humanized huPepT1 (HU) mice (A), and mouse mPepT1 protein in 
the jejunum of the same genotypes (B). Protein samples were 
separated by 10% SDS-PAGE, transferred onto PVDF membranes, 
and incubated for 1.5 hr. with rabbit anti-human hPepT1 antiserum 
(1:3000) (A) or anti-mouse mPepT1 antiserum (1:5000) (B), and a 
mouse monoclonal antibody for β-actin (1:1000). The membranes 
were washed three times with TBST and then incubated for 1 hr 
with an appropriate secondary antibody of IgG conjugated to HRP 
(1:3000). Caco-2 cells served as positive and negative controls, 
respectively, for hPepT1 and mPepT1. Duo represents the 
duodenum, Jej the jejunum, Ile the ileum, PC the proximal colon, 
DC the distal colon, and Kid the kidney.    
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Figure 3.11  Real-time PCR analyses of mouse mPepT2 (C), mouse mPhT1 (D) 
and mouse mPhT2 (E) transcripts in the small intestine, colon and 
kidney of WT, KO and HU mice, where the gene expression levels 
were normalized by the mouse Gapdh gene. WT represents the 
wildtype mice, KO the mPepT1 knockout mice, and HU the 
humanized huPepT1 mice. Duo is the duodenum, Jej the jejunum, 
Ile the ileum, PC the proximal colon, DC the distal colon, and Kid 
the kidney. Data were expressed as mean ± SE (n=4-6). Statistical 
differences were determined for each tissue by ANOVA followed by 
a Dunnett’s post hoc test, where the control group was WT. *P < 
0.05 and **p < 0.01.   
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Figure 3.12   Real-time PCR analyses of select non-POT genes (other 
transporters and enzymes) in the small intestine (A), large intestine 
(B) and kidney (C), where the gene expression levels were 
normalized by the mouse Gapdh gene. WT represents the wildtype 
mice, KO the mPepT1 knockout mice, and HU the humanized 
huPepT1 mice. Refer to Table 3.2 for gene identification. Data were 
expressed as mean ± SE (n=4-6). Statistical differences were 
determined for each gene by ANOVA followed by a Dunnett’s post 
hoc test, where the control group was WT. *P < 0.05 and **p < 
0.01.   
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Figure 3.13 Immunofluorescence localization of hPepT1 protein in the jejunum 
of humanized huPepT1 mice. The hPepT1 protein is clearly 
observed at the apical side of epithelial cells (highlighted square 
box was magnified 10x).     
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CHAPTER IV 
 
FUNCTIONAL VALIDATION OF hPEPT1 PROTEIN IN HUMANIZED huPEPT1 
MICE USING THE MODEL DIPEPTIDE GLYCYLSARCOSINE 
 
 
ABSTRACT  
 
Purpose 
PepT1, a member of the proton-coupled oligopeptide transporter family, is 
abundantly expressed in the small intestine and mediates the uptake of protein-
digested di-/tri-peptides and peptide-like drugs from the intestinal lumen. 
However, species differences in PepT1 protein function has been observed in 
yeast transformants expressing the rat, mouse and human gene. To address 
such cross-species difference for PepT1, we generated and initially characterized 
a novel humanized mouse line for hPepT1 using transgenic methodology. In the 
present study, we evaluated the functional activity of PepT1 in humanized 
huPepT1, mPepT1 knockout and wildtype mice using the model dipeptide 
glycylsarcosine (GlySar).   
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Methods 
A humanized mouse line for hPepT1 was successfully generated using a 
microinjection technique with BAC construction containing the entire human 
hPepT1 genomic DNA. The transport kinetics of GlySar were evaluated in 
humanized huPepT1, mPepT1 knockout and wildtype mice by in situ single-pass 
intestinal perfusion studies, and by in vivo oral pharmacokinetic studies.   
Results 
In agreement with previous results regarding the mRNA, protein expression, and 
tissue distribution of PepT1, in situ perfusion studies with GlySar indicated that 
the small intestinal permeability of dipeptide in humanized huPepT1 mice was 
~70% of that observed in wildtype animals. In comparison, the jejunal 
permeability of GlySar in mPepT1 knockout mice was only ~2.0% of the value 
observed in wildtype mice. These results were confirmed by in vivo studies in 
which the area under plasma concentration-time curves (AUC) of GlySar were 
virtually superimposable in humanized and wildtype mice, but ~2-fold lower in 
mPepT1 knockout mice after oral dosing.   
Conclusion 
These findings demonstrated that PepT1 had a comparable functional activity in 
humanized mice as compared to that of mPepT1 knockout and wildtype mice, 
especially, the transport kinetics of GlySar in colon gave an agreement with 
colonic occupancy profile of mRNA and protein in humanized mice and wildtype 
mice, while as of a significant increment of mRNA and protein expression in 
colon of humanized mice. Such indicated that humanized mice might provide a 
 125 
value model to investigate the relevant role of hPepT1 protein in the tissue of 
colon, such as its functional role in colonic inflammatory bowel diseases, and to 
clarify the species discrepancy of PepT1 in drug development.  
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INTRODUCTION 
 
The peptide transporter family consists of four mammalian members: 
PepT1 (SLC15A1), PepT2 (SLC15A2), PhT1 (SLC15A4) and PhT2 (SLC15A3). 
Among them, PepT1 has received the most attention because of its apical 
location in the small intestine, and ability to mediate the uptake of nutrients 
digested from dietary proteins and the intestinal absorption of drugs such as 
cefadroxil (Posada et al., 2013b) and valacyclovir (Yang et al., 2013b). Currently, 
PepT1 is being used as a drug target, during the drug discovery and design 
process, for enhancing the absorption of low-bioavailability drugs (e.g., BCS III 
and BCS IV categories) (Zhang et al., 2013).  
In general, PepT1 can transport dipeptides, tripeptides and peptide-like 
drugs with low affinity and high capacity. However, PepT1 has shown species 
differences between rodents and humans in its tissue distribution and functional 
activity (Garcia-Carbonell et al., 1993, Garrigues et al., 1991, Jappar et al., 2010, 
Posada et al., 2013a, Wuensch et al., 2013, Yang et al., 2013a). More recently, 
species differences were observed in the affinity of PepT1 for transporting GlySar 
in yeast transformants expressing the human, rat and mouse gene (Hu et al., 
2012). These findings clearly demonstrated that a species difference existed 
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between the human, mouse and rat PepT1 transporter, a difference that might 
affect the absorption and disposition of PepT1 substrates.   
In Chapter III, we described the development of a humanized huPepT1 
mouse line using transgenic methodology. These humanized mice were initially 
characterized with respect to the expression levels of PepT1 transcripts and 
protein, as well as the tissue distribution of PepT1 protein. A cross-species 
difference was observed between humanized huPepT1 and wildtype mice, as 
demonstrated by lower mRNA and protein expression levels of hPepT1 in 
humanized small intestine, but by higher levels of hPepT1 protein in colon (Hu et 
al., 2014). These findings suggested that physiological and pharmacological 
differences might occur in the handling of di-/tri-peptides and peptide-like drugs 
by PepT1-mediated processes. GlySar, a model dipeptide substrate of PepT1 
(Hu, et al. 2012, Hu et al., 2008, Jappar et al., 2009, Jappar et al., 2011, Jappar, 
et al. 2010), was selected to initially characterize the functional activity of PepT1 
in humanized mice as compared to wildtype and/or mPepT1 knockout animals.  
In the present study, we evaluated the functional activity of PepT1 protein 
in humanized huPepT1 and wildtype mice with GlySar using in situ intestinal 
perfusion and in vivo pharmacokinetic studies after oral administration. Our 
findings demonstrated that the small intestinal permeability of GlySar was lower 
in humanized huPepT1 than wildtype mice, but higher in the colon of humanized 
mice. During the concentration-dependent perfusion studies, the Km of GlySar in 
humanized mice was two-fold lower than that in wildtype mice. However, the oral 
pharmacokinetic studies did not show differences in the systemic exposure of 
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dipeptide between the two genotypes. Collectively, the findings indicated that the 
functional activity of PepT1 protein, as judged by oral drug absorption of GlySar, 
was fully recovered in the humanized huPepT1 mice.   
 
 
MATERIALS AND METHODS 
 
Chemicals  
[3H]GlySar (29.4 Ci/mmol), [14C]GlySar (113 mCi/mmol) and [14C]inulin 
5000 (1.1 mCi/g) were purchased from Moravek Biochemicals and 
Radiochemicals (Brea, CA). Unlabeled GlySar and inulin-5000 were purchased 
from Sigma-Aldrich (St. Louis, MO). All other chemicals were acquired from 
standard sources.   
Animals   
In-house breeding of gender- and weight-matched, 8-10 week, mPepT1+/+ 
(wildtype, WT), mPepT1-/-/hPepT1-/- (mPepT1 knockout, KO) and humanized 
mPepT1-/-/hPepT1+/- (humanized huPepT1, HU] mice, on a C57BL/6 background, 
were used for all experiments unless otherwise noted. The KO and HU mice 
were identified by genotyping and culled from the same litter. The mice were 
housed in a temperature-controlled environment with 12-hr light and 12-hr dark 
cycles, and received a standard diet and water ad libitum (Unit for Laboratory 
Animal Medicine, University of Michigan, Ann Arbor, MI). All mouse studies were 
 129 
performed in accordance with the Guide for the Care and Use of Laboratory 
Animals as adopted and promulgated by the U.S. National Institutes of Health 
(Institute of Laboratory Animal Sources, 1996).   
In Situ Single-Pass Intestinal Perfusion Studies   
Humanized huPepT1, mPepT1 knockout and wildtype mice were fasted 
overnight (~12 hrs.) with free access to water and then anesthetized with sodium 
pentobarbital (40-60mg/kg ip). Perfusion studies of jejunum or other regional 
segments were carried out according to methods described previously (Adachi et 
al., 2003, Jappar, et al. 2010).  In brief, after sterilizing the abdominal area with 
70% ethanol, and keeping the mice on top of a heating pad to maintain body 
temperature, the intestines were exposed by a mid-line incision of the abdomen. 
A 4-cm segment of duodenum, 8-cm segment of proximal jejunum (i.e. ~2 cm 
distal to the ligament of Treitz), 6-cm segment of ileum (i.e. ~1 cm proximal to the 
cecum), and 4-cm segment of colon (i.e. ~0.5 cm distal to the cecum) was 
isolated and incisions then made at both the proximal and distal ends. The 
segments were rinsed with 0.9% isotonic saline solution and a glass cannula (2.0 
mm outer diameter) inserted at each end of the intestinal segment, and secured 
in place with silk sutures. The isolated intestinal segment(s) were covered with 
saline-wetted gauze and parafilm to prevent dehydration. After cannulation, the 
animals were transferred to a temperature-controlled chamber, at 31oC, to 
maintain body temperature during the entire perfusion procedure. The cannulas 
were then connected to inlet tubing, which was attached to a 10-mL syringe (BD, 
Franklin Lakes, NJ USA) placed on a perfusion pump (Model 22: Harvard 
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Apparatus, South Natick, MA), and to outlet tubing which was placed in a 
collection vial.   
The perfusate buffer contained 135 mM NaCl, 5 mM KCl and 10 mM 
MES/Tris (pH6.5), plus 10 µM of [3H]GlySar (0.5 µCi) and 0.01% (w/v) [14C]inulin-
5000 (0.25 µCi) (which served as a nonabsorbable marker to correct for water 
flux), during the intestinal perfusion studies. The buffer was perfused through the 
intestinal segments at a flow rate of 0.1 mL/min, and the exiting perfusate was 
collected every 10 min for 90 min. A 100-µL aliquot of each perfusate collection 
was added to a vial containing 6.0 mL of scintillation cocktail (Cytosine, Ecolite 
MP Biochemicals, Solon, OH), and the samples were measured for radioactivity 
by a dual-channel liquid scintillation counter (Beckman LS 6000 SC, Beckman 
Coulter Inc., Fullerton, CA). At the end of experimentation, the actual length of 
intestinal segments was measured.  
For the concentration-dependent jejunal perfusion studies, in wildtype and 
humanized huPepT1 mice, GlySar varied from 0.01-50 mM in perfusate buffer 
containing 0.5 µCi [3H]GlySar and 0.01% (w/v) [14C]inulin-5000 (0.25 µCi). 
In Vivo Oral Pharmacokinetic Studies    
Following an overnight fast (~12 hr), humanized huPepT1, mPepT1 
knockout and wildtype mice were anesthetized briefly with isoflurane prior to oral 
administration of [14C]GlySar (5.0 nmol/g, 5.0 µCi/mouse) by gastric lavage in 
200 µL of saline.  After oral dosing, serial blood samples were collected at 5, 7.5, 
15, 30, 45, 60, 90, 120, 180, 240 and 360 min via tail transections. Blood 
samples (15-20 µL) were harvested into a tube containing 1.0 µL of EDTA-K3 
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and centrifuged for 3 min at 3000 g to obtain plasma (10 µL).  Animals were 
returned to their cages in between blood sampling where they had free access to 
water and, 2 hr later, to food. Radioactivity in the plasma samples was measured 
by a dual-channel liquid scintillation counter (Beckman LS 6000 SC, Beckman 
Coulter Inc., Fullerton, CA).  
Data Analysis  
Steady-state loss of drug from perfusate in the intestinal segment was 
achieved approximately 30 min after the start of perfusion. The effective 
permeability (Peff) of drug was calculated according to a complete radial mixing 
(parallel tube) model (Komiya et al., 1980, Kou et al., 1991) as:  
 
Peff =
−Q • ln(Cout / Cin )
2π RL      (1)
 
where Q was the perfusion flow rate (0.1 mL/min), Cout the outlet drug 
concentration after correction for changes in water flux, Cin the inlet drug 
concentration, R the internal radius (0.1 cm for small intestine and 0.2 cm for 
colon), and L the length of intestinal segment. Water flux across the epithelium 
was calculated as (Amidon et al., 1988, Johnson et al., 1988):  
      (2) 
where Cout,uncorr was the original (uncorrected) outlet drug concentration, Iin the 
inulin-5000 inlet concentration, and Iout the inulin-5000 outlet concentration.  
The intrinsic or wall permeability (Pw) is referenced to intestinal wall 
concentrations and determined by factoring out the aqueous layer permeability 
(Paq) using the formula:  
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Pw =
Peff
1− Peff /Paq
     (3) 
The boundary layer approach can be used to estimate the aqueous permeability 
according to:  
 
Paq = (A
R
D
Gz1/ 3)−1
    (4) 
 
Gz =
πDL
2Q      (5) 
where A is a unitless constant (see below for calculation), R the radius, D the 
diffusion coefficient in water (6.60 x 10-4 cm2/min), and Gz the Graetz number 
(0.0829). Once the Graetz number was calculated, A was estimated as: 
A = 2.50 Gz + 1.125  (when Gz ≥ 0.030) 
A = 4.50 Gz + 1.065  (when 0.030 > Gz ≥ 0.010) 
A = 10.0 Gz + 1.010  (when 0.010 > Gz ≥ 0.004) 
Given these relationships, the concentration of drug at the membrane surface 
(Cw) was calculated as: 
 
Cw = Cin (1 −
Peff
Paq
)      (6) 
The intrinsic parameters Jmax (maximum transport rate) and Km (Michaelis 
constant) were determined using the following equation: 
 
 
Pw =
Jmax
Km + Cw
+ Pm       (7) 
where Pm is the passive (nonsaturable) permeability. The carrier permeability (Pc) 
was calculated as: 
 
Pc =
Jmax
Km
      (8) 
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 The steady-state flux (J) can also be referenced to intestinal wall concentrations 
(Cw) and the intrinsic kinetic parameters expressed as: 
 
J =
Jmax • Cw
Km + Cw
+ PmCw = Peff • Cin     (9) 
The apparent kinetic parameters can also be determined by the following: 
     (10) 
and the flux calculated as: 
     (11)  
The concentration-dependent flux (J) of GlySar in jejunum was best fit to a 
single Michaelis-Menten term as: 
    (12)
 
where the parameters J*max and K*m were referenced to inlet drug concentrations 
(Cin), and the parameters Jmax and Km were referenced to intestinal wall drug 
concentrations ( ), once corrected for the unstirred aqueous layer permeability.   
Data were reported as mean ± SE, unless otherwise noted. Statistical 
differences between two groups were determined using an unpaired t-test.  
Multiple treatment groups were compared using one-way analysis of variance 
(ANOVA) followed by either a Tukey’s test or Dunnett’s test, with wildtype serving 
as the control group (GraphPad Prism 5.0; GraphPad software, Inc., La Jolla, 
CA). P ≤ 0.05 was considered significant. Pharmacokinetics analyses were 
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carried out using a non-compartmental model (NCA) in Phoenix WinNonlin 6.3 
(Certara, St. Louis, MO USA).  
 
RESULTS  
In Situ Regional Perfusion Studies of GlySar in Humanized huPepT1 Mice 
Compared to Wildtype and mPepT1 Knockout Mice  
Given the advantage of an intact blood supply, in situ perfusion studies 
were performed to evaluate the function of PepT1 in regional segments of the 
small and large intestines for humanized, wildtype and mPepT1 KO mice. As 
shown in Figure 4.1 and Table 4.1, and in agreement with real-time PCR and 
immunoblot results, the permeability of GlySar was negligible in mPepT1 KO 
mice. In comparing PepT1-competent animals, permeability values in the small 
intestine of humanized mice were about 54-70% of values observed in wildtype 
mice.  In addition, the permeability in colon was 11-fold greater in humanized 
huPepT1 mice. Thus, it appears that the permeability of GlySar was comparable 
in the duodenum, jejunum and Ileum of wildtype and humanized mice.  However, 
whereas colonic permeability was < 1% of that in wildtype jejunum, colonic 
permeability was ~12% of that in humanized jejunum. 
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Concentration-Dependent Transport Kinetics of GlySar in Humanized and 
Wildtype mice 
To assess if there were species-dependent difference in the PepT1-
mediated transport kinetics of GlySar, concentration-dependent perfusion studies 
were performed in the jejunum of wildtype and humanized huPepT1 mice. As 
shown in Figure 4.2, the maximal flux J*max = 3.75 ± 0.11 nmol/cm2/sec and the 
Michaelis constant K*m = 13.2 ± 1.0 mM for WT mice (r2 = 0.988). In contrast, the 
J*max = 0.50 ± 0.04 nmol/cm2/sec and the K*m = 3.3 ± 0.9 mM for humanized 
huPepT1 mice (r2 = 0.838) (Figure 4.2A). As observed, the maximal flux and 
Michaelis constant of GlySar were substantially lower in humanized huPepT1 
mice. Furthermore, when referenced to intestinal wall concentrations, the 
maximal flux Jmax = 3.24 ± 0.13 nmol/cm2/sec and Michaelis constant Km = 5.5 ± 
0.7 mM for WT mice (r2 = 0.993); the Jmax = 0.49 ± 0.03 nmol/ cm2/sec and Km = 
2.7 ± 0.6 mM for humanized huPepT1 mice (r2 = 0.973) (Figure 4.2B).  Thus, the 
Km value was also two-fold lower in humanized huPepT1 mice than in wildtype 
animals. These results demonstrated that a species differences existed in the 
transport kinetics of intestinal PepT1, and that human hPepT1 is more likely to be 
saturated than mouse mPepT1.   
In Vivo Oral Pharmacokinetic Studies of GlySar in Humanized Mice 
Compared to Wildtype and mPepT1 Knockout Mice  
To assess the in vivo functional activity of hPepT1 in humanized mice, 
pharmacokinetic studies were performed with the model dipeptide GlySar after a 
single oral dose. As shown in Figure 4.3, plasma concentrations of GlySar 
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increased rapidly within the absorption phase of wildtype and humanized 
huPepT1 mice, and then declined over time with virtually superimposable curves. 
In contrast, mPepT1 knockout mice had substantially reduced plasma 
concentrations than PepT1-competent mice (Figure 4.3). In fact, the AUC and 
Cmax of wildtype and humanized huPepT1 mice were not significantly different, 
but mPepT1 knockout mice had AUC values that were ~2-fold lower (Table 4.2). 
Values for mean residence time (MRT) were similar between the three genotypes 
although a statistically significant difference was observed between wildtype and 
mPepT1 knockout mice.  These findings were consistent with our previous 
results from in situ perfusions of GlySar, where substantial expression of PepT1 
in all regions of small intestine accounted for an apparent fully restored hPepT1 
function in the oral absorption of GlySar in humanized mice.   
 
DISCUSSION 
 
In Chapter III, a humanized huPepT1 mouse line was successfully 
established and its biological properties initially defined. Indeed, species 
differences were observed between wildtype and humanized huPepT1 mice in 
PepT1 tissue distribution and protein expression levels, consistent with the 
literature (Jappar, et al. 2010, Merlin et al., 2001, Shen et al., 2001, Wuensch, et 
al. 2013, Ziegler et al., 2002). However, the functional activity of PepT1 protein in 
humanized huPepT1 mice needed further evaluation as compared to wildtype 
mice because: 1) we previously reported a species difference in the affinity of 
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GlySar for PepT1, in which the Km values varied over a 5.4-fold range in yeast 
Pichia pastoris expressing the human (0.86 mM), mouse (0.30 mM) and rat (0.16 
mM) transformants (Hu, et al. 2012); 2) appropriate mRNA and protein 
expression does not guarantee that the transporter will maintain correct 
functional activity; and 3) oral absorption studies were lacking and, as a result, it 
was important to validate the in vivo functionality of hPepT1 in humanized mice 
as compared to other genotypes.   
In this study, we examined the in situ intestinal permeability and in vivo 
oral absorption kinetics of GlySar in humanized mice as compared to wildtype 
animals. Our results clearly showed that: 1) the in situ permeability of GlySar in 
huPepT1 mice was similar to but lower than wildtype animals in small intestine, 
and greater than wildtype mice in colon; 2) the functional activity of intestinal 
PepT1 appeared fully restored (compared to mPepT1 knockout mice) as 
indicated by the nearly identical pharmacokinetics and plasma concentration-time 
profiles of orally administered GlySar in huPepT1 and wildtype mice; and 3) no 
difference was observed between wildtype and humanized mice in the in vivo 
pharmacokinetics after a 5 nmol/g oral dose.  This dose corresponds to an initial 
mouse stomach concentration of ~250 µM, which is much lower than the K*m 
values for both genotypes (i.e., 13.2 mM for WT and 3.3 mM for huPepT1 mice).   
As compared to wildtype and mPepT1 knockout mice, our humanized 
huPepT1 mice showed an apparent full restoration of PepT1 functional activity 
(Figures 4.1-4.3), although humanized huPepT1 mice were maintained as 
hemizygotes in order to avoid interrupting other endogenous genes.  The in situ 
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single-pass perfusion studies showed that the permeability of GlySar in 
humanized huPepT1 mice was ~71% (duodenum), ~62% (jejunum), and ~54% 
(ileum) of that in wildtype mice. The absolute values of GlySar permeability in 
wildtype mouse jejunum were comparable to previous reports (e.g., 2.1x10-4 
cm/sec in this study vs. 1.6x10-4 cm/sec by Hu et al. 2008; Jappar et al. 2010).  
Of note, the colonic permeability of GlySar increased by ~11-fold in humanized 
mice as compared to wildtype and mPepT1 knockout mice.  A minor permeability 
of GlySar in colon was also observed in other mouse studies (Dalmasso et al., 
2008, Hu et al., 2008, Jappar, et al. 2010, Nguyen et al., 2009). Only the study by 
Wuensch et al. (2013) reported a physiological function of PepT1 in the healthy 
distal colon of mouse, where it contributed to electrolyte and water handling. 
Taken as a whole, the permeability of GlySar in various intestinal segments was 
consistent the pattern of PepT1 mRNA and protein expression (Figures 3.6-3.9 in 
Chapter III). The hPepT1 functional activity in humanized mice also was 
evaluated further by in vivo oral pharmacokinetic studies with GlySar (Figure 
4.3).  At a dose of 5 nmol/g, the Cmax, Tmax and AUC of GlySar was comparable 
between wildtype and humanized mice, whereas substantial differences were 
observed between mPepT1 knockout mice and PepT1-competent animals (Table 
4.2).  
A discrepancy was observed in affinity of GlySar for PepT1 transporter 
between in yeast expressing system (Hu, et al. 2012)  and in mouse model, 
where the Km values varied over a 5.4-fold range in yeast Pichia pastoris 
expressing the human (0.86 mM), mouse (0.30 mM) and rat (0.16 mM) 
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transformants, as while the Km values in humanized  mouse is 2.7 mM and in 
wildtype mouse 5.5 mM. This opposite of Km value for PepT1 transporter 
probably accounts on that yeast Pichia pastoris and mouse models belong two 
different biological systems, which have different post-translational modifications, 
such as glycosylation and phosphorylation for PepT1 transporters, such results in 
affinity of GlySar varied.     
Overall, the present study demonstrated that the function of PepT1 was 
fully restored from previously mPepT1 null mice. There is excellent agreement 
between hPepT1 expression in the intestines, and the in situ permeability and in 
vivo oral absorption of the model dipeptide GlySar.  These humanized huPepT1 
mice should prove a valuable tool in future studies investigating the role, 
relevance and regulation of Pep T1 in diet and disease, and in the drug discovery 
process.  
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Table 4.1  The effective permeability of GlySar in mouse intestinal segments 
during in situ perfusions (pH 6.5) 
 
 
 
 
  
 WT KO HU 
 
Mean 
(x10-4cm/s) 
SE N 
Mean 
(x10-4cm/s) 
SE N 
Mean 
(x10-4cm/s) 
SE N 
Duodenum 1.59 0.060 4 0.0088 0.0030 4 1.12 0.079 4 
Jejunum 2.13 0.10 4 0.043 0.017 4 1.33 0.065 6 
Ileum 1.20 0.15 4 0.0030 0.0019 4 0.65 0.055 4 
Colon 0.015 0.0079 5 0.0012 0.00024 4 0.17 0.028 5 
* WT, represents wildtype mice; KO, mPepT1 knockout mice; and HU, humanized huPepT1 mice 
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Table 4.2  Non-compartmental analysis of the pharmacokinetics of [14C]GlySar 
following a 5.0 nmol/g oral dose 
 
 WT KO HU 
Cmax  (µM) 2.71±0.09 (3) 1.27±0.05 (3) 
*** 2.86±0.09 (3) 
Tmax (hr) 0.33±0.08 (3) 1.83±0.17 (3)
 *** 0.33±0.08 (3) 
AUC0-0.5 (hr*µM) 1.12±0.02 (3) 0.34±0.01 (3) 
*** 1.04±0.04 (3) 
AUC0-1 (hr*µM) 2.42±0.07 (3) 0.87±0.02 (3) 
*** 2.29±0.07 (3) 
AUC0-2 (hr*µM) 4.76±0.12 (3) 2.04±0.04 (3) 
*** 4.61±0.04 (3) 
AUC0-3 (hr*µM) 6.75±0.26 (3) 3.27±0.10 (3)
 *** 6.72±0.03 (3) 
AUC0-4 (hr*µM) 8.47±0.40 (3) 4.44±0.15 (3) 
*** 8.61±0.11 (3) 
AUC0-6 (hr*µM) 11.60±0.59 (3) 6.66±0.25 (3) 
*** 12.11±0.27 (3) 
MRT (hr) 2.68±0.04 (3) 3.07±0.02 (3) 
*** 2.79±0.04 (3) 
Cmax: Highest plasma GlySar concentration observed after oral administration 
Tmax: Time at which the highest GlySar concentration occurs after oral administration 
AUC0-t: Area under the plasma concentration-time curve from time 0 to t after dosing 
MRT: Mean residence time of a molecule within the body 
Data are expressed as mean±SE  
***P<0.001 level against WT as determined by ANOVA/Dunnett’s post doc test.  
WT, represents wildtype mice; KO, mPepT1 knockout mice; and HU, humanized huPepT1 mice. 
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Figure 4.1. In situ perfusion studies of 10 µM GlySar in intestinal segments of 
wildtype (WT), mPepT1 knockout (KO) and humanized huPepT1 
(HU) mice. Data are expressed as mean ± SE (n=4-6). ***P<0.001 as 
compared to WT.   
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Figure 4.2 Concentration-dependent flux of [3H]GlySar (0.01-50 mM) during 
jejunal perfusions of wildtype (WT) and humanized huPepT1 (HU) 
mice. Cin is the inlet concentration of GlySar in perfusate in which 
J*max = 3.75 ± 0.11 nmol/cm2/sec and K*m = 13.2 ± 1.0 mM for WT 
mice (r2 = 0.988); J*max = 0.50 ± 0.04 nmol/cm2/sec and K*m = 3.3 ± 
0.9 mM for HU mice (r2 = 0.838) (top panel). Cw is the estimated 
concentration of GlySar at the membrane wall in which Jmax = 3.24 ± 
0.13 nmol/cm2/sec and Km = 5.5 ± 0.7 mM for WT mice (r2 = 0.993); 
Jmax = 0.49 ± 0.03 nmol/ cm2/sec and Km = 2.7 ± 0.6 mM for HU 
mice (r2 = 0.973) (bottom panel). All studies were performed in pH 
6.5 buffer. Data are expressed as mean ± SE (n = 4−6).    
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Figure 4.3. In vivo pharmacokinetics of 5.0 nmol/g [14C]GlySar after oral gavage 
in wildtype (WT), mPepT1 knockout (KO) and humanized huPepT1 
(HU) mice. Data are expressed as mean ± SE (n=3).   
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CHAPTER V 
 
APPLICATION OF HUMANIZED huPEPT1 MOUSE MODEL TO EVALUATE 
THE ABSORPTION AND DISPOSITION KINETICS OF CEFADROXIL  
 
ABSTRACT 
 
 
Purpose 
Cefadroxil, a first generation β-lactam antibiotic, has high oral bioavailability, 
good stability in the gastrointestinal tract, and > 90% recovery in urine over 24 
hours after oral administration. However, the absorption kinetics of cefadroxil was 
shown to be saturable with escalating oral doses in humans, a finding that 
conflicted with other studies in mice. This cross-species discrepancy was 
attributed to the intestinal transporter PepT1, which is responsible for uptake of 
cefadroxil from the intestinal lumen. In this study, the in situ intestinal 
permeability and in vivo absorption and disposition kinetics of cefadroxil were 
evaluated in humanized huPepT1 mice as compared to wildtype animals. 
Methods 
The transport kinetics of cefadroxil was evaluated in humanized huPepT1, 
 150 
mPepT1 knockout and wildtype mice by in situ single-pass intestinal perfusion 
studies, and by in vivo intravenous and oral pharmacokinetic studies in 
humanized and wildtype mice. Non-compartmental analyses were used to 
determine the absorption and disposition pharmacokinetic parameters of 
cefadroxil in mice. 
Results 
During in situ regional perfusion studies, the permeability of cefadroxil was 
substantial but lower in the duodenum, jejunum and ileum of humanized 
huPepT1 than in wildtype mice. In contrast, the permeability of cefadroxil was 
reduced by 95% (or more) in mPepT1 knockout mice as compared to wildtype 
mice.  It was also observed that colonic permeability of cefadroxil in humanized 
huPepT1 mice was 14-fold higher than in wildtype mice, where permeability was 
quite low. Specificity studies in wildtype jejunum, using excess concentrations of 
potential inhibitors, demonstrated that the transport of cefadroxil was highly, if not 
solely, dependent on the functional activity of PepT1. Moreover, concentration-
dependent studies in jejunum indicated that human hPepT1 had a greater affinity 
for cefadroxil (Km = 2.7 mM) than did mouse mPepT1 (Km = 6.0 mM). The 
disposition kinetics of cefadroxil was evaluated after intravenous bolus doses. 
The plasma concentration-time profiles of cefadroxil were found to be virtually 
superimposable between humanized huPpeT1 and wildtype mice at both low and 
high doses. Pharmacokinetic analyses indicated that the humanized and wildtype 
mice had similar disposition parameters with no significant differences in CL, Vss 
and T1/2. However, several differences were observed after oral dose escalation 
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of cefadroxil such that: 1) the plasma concentration-time profiles of cefadroxil 
were lower in humanized huPepT1 mice than in wildtype animals, 2) the Tmax and 
Cmax values of cefadroxil were 2-fold lower in humanized than in wildtype mice, 
but no difference was observed in T1/2, 3) the partial accumulative AUC or Cmax 
vs. Dose relationship of cefadroxil was less than proportional (nonlinear) for 
humanized mice, but proportional (linear) for wildtype mice, 4) the absorption rate 
of cefadroxil was slower in humanized mice as compared to wildtype mice, and 
5) the AUC0-120  or Cmax vs. Dose curve was more similar for humanized huPepT1 
mice and humans than for wildtype mice and humans.   
Conclusion 
In this present study, the in situ jejunal perfusions revealed a clear species 
difference between wildtype and humanized huPepT1 mice in the maximal flux 
and affinity of cefadroxil.  Oral dose escalations confirmed that species 
differences existed in vivo in the absorption rate and PepT1-mediated saturable 
uptake of cefadroxil from the intestinal lumen. Moreover, the AUC or Cmax vs. 
Dose relationships were more similar for humanized huPepT1 mice and humans 
than for wildtype mice and humans.  As a result, it appears that humanized 
huPepT1 mice might provide a valuable animal model in the drug discovery 
process, as well as to predict the pharmacokinetic profiles of PepT1 substrates in 
humans.       
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INTRODUCTION 
 
Cefadroxil, (6R, 7R)-7-[[D-2-amino-2-(4-hydroxyphenyl) acetyl]amino]-3-
methyl-8-oxo-5-thia-l-anabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, is a first 
generation aminocephalosporin with a molecular formula of C16H17N3O5S and a 
molecular weight of 363.39. Because of good patient compliance (Pfeffer et al., 
1977), a long-acting effect, high solubility and relatively broad spectrum of anti-
bacterial activity, including most gram-positive and negative bacteria (Tanrisever 
et al., 1986, Yu et al., 1995), cefadroxil is used to treat urinary tract infections 
(Hausman 1980), skin and soft tissue infections (Ballantyne 1982, Cordero 
1976), pharyngitis (Beisel 1980, Randolph 1988) and tonsillitis (Kaminszczik 
1986). By binding to trans-peptidase enzymes, penicillin binding proteins (PBPs) 
(Williamson et al., 1980), cefadroxil can inhibit the cross-linking of peptidoglycan 
in the synthesis of the bacterial wall, which leads to bacterial autolysis (Goodman 
et al., 2011).  
Compared to cephalexin, cefadroxil has higher serum concentrations after 
oral administration of an equivalent dose (Buck et al., 1977, Hartstein et al., 
1977, Pfeffer, et al. 1977).  Cefadroxil also has low plasma protein binding (about 
20%) and good oral bioavailability of 90% or more (Garcia-Carbonell et al., 1993, 
Santella et al., 1982). Cefadroxil is more likely to exhibit saturable secretion by 
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the kidney and, as a result, has a longer serum half-life (~90 min) than 
cephalexin (~60 min). Normally, renal excretion is the primary route for the 
elimination of orally administered cefadroxil, with more than 90% of drug being 
excreted unchanged in the over 24 hours (Garrigues et al., 1991, Santella, et al. 
1982).  
As mentioned previously, cefadroxil exhibited a non-proportional increase 
in area under the plasma concentration-time curve (AUC) with increasing oral 
doses in humans and rats (Garcia-Carbonell, et al. 1993, Garrigues, et al. 1991, 
Sanchez-Pico et al., 1989). This finding suggested that membrane transporters 
might affect dose-dependent changes in the intestinal absorption and systemic 
disposition of cefadroxil. In particular, influx transporters located in the small 
intestine may contribute to the high oral bioavailability of cefadroxil (Ries et al., 
1994, Wang et al., 1992). Further studies demonstrated that cefadroxil is a 
substrate of the intestinal peptide transporter PepT1, which is responsibility for 
the drug’s uptake across the apical membrane of small intestine (Ganapathy et 
al., 1995, Naruhashi et al., 2002, Posada et al., 2013b); in kidney, PepT2 is 
primarily if not solely responsible for the tubular reabsorption of cefadroxil 
(Ocheltree et al., 2004); and in brain, PepT2 removes cefadroxil from 
cerebrospinal fluid (CSF) and into the choroid plexus (Chen et al., 2014, Shen et 
al., 2005, Shen et al., 2007). Cefadroxil has also been shown to be a substrate of 
SLC22 family transporters, including SLC22A6 (OAT1), SLC22A7 (OAT2) and 
SLC22A8 (OAT3), which are localized on the basolateral side of intestinal 
epithelia cells or renal proximal tubule (Khamdang et al., 2003, Khamdang et al., 
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2002, Takeda et al., 2002).  More recently, cefadroxil was shown to be 
transported by rat intestinal ABCC3 (MRP3) and ABCC4 (MRP4) transporters for 
efflux across the basolateral membrane into the systemic circulation (de Waart et 
al., 2012), which may partially contribute to its high oral bioavailability.  
Our laboratory first evaluated the difference in dipeptide affinity across 
species by studying the PepT1-mediated uptake of GlySar in yeast cells 
expressing human, rat and mouse PepT1 cDNA (Hu et al., 2012). Our laboratory 
also reported the impact of PepT1 ablation on the absorption kinetics after oral 
dose escalation of cefadroxil (Posada et al., 2013a) and valacyclovir (Yang et al., 
2013) in wildtype and mPepT1 knockout mice, and how these results differed 
from oral pharmacokinetic studies in humans (Garrigues, et al. 1991; Weller et 
al., 1993). Moreover, species differences in PepT1 transporter permeability was 
evaluated with GlySar using mouse jejunal perfusion studies in humanized mice 
as compared to wildtype animals (see Chapter IV and Hu et al., 2014). These 
findings clearly demonstrated that a species difference exists in the absorption 
and disposition of drugs by human, mouse and rat PepT1.    
In the present study, the permeability of cefadroxil was assessed, for the 
first time, in humanized huPepT1 and wildtype mice using in situ perfusion 
studies, along with the specificity of PepT1 transporter-mediated transport of 
drug. Furthermore, the in vivo pharmacokinetics of cefadroxil was evaluated by 
intravenous injection at low (11.01 nmol/g) and high doses (528.40 nmol/g), and 
after oral dose escalation (11.01, 33.03, 66.06, 132.10, 264.20 and 528.40 
nmol/g).   
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MATERIALS AND METHODS 
 
Chemicals  
[3H]cefadroxil (98 mCi/mmol) and [14C]inulin 5000 (1.1 mCi/g) were 
purchased from Moravek Biochemicals and Radiochemicals (Brea, CA). 
Unlabeled cefadroxil, inulin, glycylproline (GlyPro), glycylsarcosine (GlySar), 
glycine, L-histidine, para-aminohippuric acid (PAH), tetraethylammonium (TEA), 
quinidine, N1-methylnicotinamide (NMN), carnosine, cephalexin, cephalothin, and 
dimethylamiloride (DMA) were purchased from Sigma-Aldrich (St. Louis, MO). 
Cytosine Ecolite and hyamine hydroxide were purchased from MP Biochemicals, 
(Solon, OH). All other chemicals were acquired from standard sources.   
Animals 
In-house breeding of gender- and weight-matched, 8-10 week, mPepT1+/+ 
(wildtype, WT), mPepT1-/-/hPepT1-/- (mPepT1 knockout, KO) and humanized 
mPepT1-/-/hPepT1+/- (humanized hPepT1, HU] mice, on a C57BL/6 background, 
were used for all experiments unless otherwise noted. The KO and HU mice 
were identified by genotyping and culled from the same litter. The mice were 
housed in a temperature-controlled environment with 12 hr light and 12 hr dark 
cycles, and received a standard diet and water ad libitum (Unit for Laboratory 
Animal Medicine, University of Michigan, Ann Arbor, MI). All mouse studies were 
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performed in accordance with the Guide for the Care and Use of Laboratory 
Animals as adopted and promulgated by the U.S. National Institutes of Health 
(Institute of Laboratory Animal Sources, 1996).   
 
In Situ Single-Pass Intestinal Perfusion Studies 
Humanized huPepT1, mPepT1 knockout and wildtype mice were fasted 
overnight (~12 hr) with free access to water and then anesthetized with sodium 
pentobarbital (40-60mg/kg ip). Perfusion studies of jejunum or other regional 
segments were carried out according to methods described previously (Adachi et 
al., 2003, Jappar et al., 2010).  In brief, after sterilizing the abdominal area with 
70% ethanol, and keeping the mice on top of a heating pad to maintain body 
temperature, the intestines were exposed by a mid-line incision of the abdomen. 
A 4-cm segment of duodenum, 8-cm segment of proximal jejunum (i.e. ~2 cm 
distal to the ligament of Treitz), 6-cm segment of ileum (i.e. ~1 cm proximal to the 
cecum), and 4-cm segment of colon (i.e. ~0.5 cm distal to the cecum) was 
isolated and incisions then made at both the proximal and distal ends. The 
segments were rinsed with 0.9% isotonic saline solution and a glass cannula (2.0 
mm outer diameter) inserted at each end of the intestinal segment, and secured 
in place with silk sutures. The isolated intestinal segment(s) were covered with 
saline-wetted gauze and parafilm to prevent dehydration. After cannulation, the 
animals were transferred to a temperature-controlled chamber, at 31oC, to 
maintain body temperature during the entire perfusion procedure. The cannulas 
were then connected to inlet tubing, which was attached to a 10-mL syringe (BD, 
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Franklin Lakes, NJ USA) placed on a perfusion pump (Model 22: Harvard 
Apparatus, South Natick, MA), and to outlet tubing, which was placed in a 
collection vial.   
The perfusate buffer contained 135 mM NaCl, 5 mM KCl and 10 mM 
MES/Tris (pH6.5) plus 10 µM of [3H]cefadroxil (0.5 µCi) and 0.01% (w/v) [14C]-
inulin (0.25 µCi) (which served as a nonabsorbable marker to correct for water 
flux) during the intestinal perfusion studies. The buffer was perfused through the 
intestinal segments at a flow rate of 0.1 mL/min, and the exiting perfusate was 
collected every 10 min for 90 min. A 100-µL aliquot of each perfusate collection 
was added to a vial containing 6.0 mL of scintillation cocktail (Cytosine, Ecolite 
MP Biochemicals, Solon, OH), and the samples were measured for radioactivity 
by a dual-channel liquid scintillation counter (Beckman LS 6000 SC, Beckman 
Coulter Inc., Fullerton, CA). At the end of experimentation, the actual length of 
intestinal segments was measured.  
For the inhibition studies in jejunum, 10 mM of potential inhibitors were 
added to the perfusate, except for DMA (0.1 mM). For the concentration-
dependent studies in jejunum, cefadroxil varied from 0.01-25 mM in perfusate 
buffer containing [3H]cefadroxil (0.5 µCi) and 0.01% (w/v) [14C]inulin (0.25 µCi).  
In Vivo Intravenous Pharmacokinetic Studies 
Humanized huPepT1, mPepT1 knockout and wildtype mice were 
anesthetized with (40-60 mg/kg ip) sodium pentobarbital before intravenous 
bolus injection of [3H]cefadroxil (11.01 and 528.40 nmol/g body weight, 5.0 
µCi/each) in 100 µL of saline.  After dosing, serial blood samples were collected 
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at 1, 2.5, 5, 10, 20, 30, 45, 60, 90 and 120 min via tail transections. Blood 
samples (15-20 µL) were harvested into a tube containing 1.0 µL of EDTA-K3 
and centrifuged for 3 min x 3000 g to obtain the plasma (10 µL). A 30-µL aliquot 
of 30% H2O2 was then added, followed by 6.0 mL of Cytosine scintillation cocktail 
and 20 µL of 0.5 M acetic acid. Animals were returned to their cages in between 
blood samplings, where they had free access to water and food. Radioactivity in 
the plasma samples was measured by a dual-channel liquid scintillation counter 
(Beckman LS 6000 SC, Beckman Coulter Inc., Fullerton, CA).  
For the biodistribution studies, 0.2 µCi of [14C]inulin in 100 µL of  saline 
was injected intravenously 2.0 min prior to 120 min, the time at which tissue 
samples was harvested.  The tissues, including a blood sample, were weighed 
and 300 µL of hyamine hydroxide was then added and incubated at 37oC until 
the entire tissue was dissolved. After the samples cooled down to room 
temperature, 30 µL of 30% H2O2 was added, followed by 6.0 mL of Cytosine 
scintillation cocktail and 20 µL of 0.5 M acetic acid. Radioactivity in these 
samples was measured by a dual-channel liquid scintillation counter (Beckman 
LS 6000 SC, Beckman Coulter Inc., Fullerton, CA).  The cefadroxil tissue-to-
plasma concentration ratios were also calculated at 120 min.  
In Vivo Oral Pharmacokinetic Studies 
 Following an overnight fast (~12 hr), humanized huPepT1, mPepT1 
knockout and wildtype mice were anesthetized briefly with isoflurane prior to oral 
administration of [3H]cefadroxil (11.01, 33.03, 66.06, 132.10, 264.20, 528.40 
nmol/g, 10 µCi/each) by gastric lavage (oral) in 200 µL of saline. After oral 
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dosing, serial blood samples were collected at 2.5, 5, 10, 20, 30, 45, 60, 90 and 
120 min via tail transections. Animals were returned to their cages in between 
blood sampling where they had free access to water and, 2 hr later, to food. 
Blood samples (15-20 µL) were harvested into a tube containing 1.0 µL of EDTA-
K3 and centrifuged for 3 min x 3000 g to obtain plasma (10 µL). A 30-µL aliquot 
of 30% H2O2 was then added, followed by 6.0 mL of Cytosine scintillation cocktail 
and 20 µL of 0.5 M acetic acid. Radioactivity in the plasma samples was 
measured by a dual-channel liquid scintillation counter (Beckman LS 6000 SC, 
Beckman Coulter Inc., Fullerton, CA).  
Urinary Recovery of Cefadroxil 
Following an overnight fast, humanized huPepT1 and wildtype mice were 
briefly anesthetized with isoflurane, and then administered 200 µL [3H]cefadroxil 
(5.0 µCi) by oral gavage at doses of 11.01 nmol/g and 528.40 nmol/g. A 100-µL 
aliquot of [14C]inulin-5000 (0.5 µCi) was also administered by tail vein injection to 
evaluate the accuracy of urine collections. Each animal was placed in a 
metabolic cage containing a diuresis adapter (Nalge Nunc International, 
Naperville, IL), and the urine and feces collected 24 hours after dosing. After the 
feces were removed, the metabolic cage was washed with water three times and 
then added to the urine collection. A 100-µL aliquot of the diluted fecal and urine 
samples were added into scintillation vials containing 6 mL of Cytoscint cocktail, 
and the radioactivity measured by a dual-channel liquid scintillation counter 
(Beckman LS 6000 SC, Beckman Coulter Inc., Fullerton, CA).  
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Data Analysis 
Steady-state loss of drug from perfusate in the intestinal segment was 
achieved approximately 30 min after the start of perfusion. The effective 
permeability (Peff) of drug was calculated according to a complete radial mixing 
(parallel tube) model (Komiya et al., 1980, Kou et al., 1991) as:  
 
Peff =
−Q • ln(Cout / Cin )
2π RL     (1)
 
where Q was the perfusion flow rate (0.1 mL/min), Cout the outlet drug 
concentration after correction for changes in water flux, Cin the inlet drug 
concentration, R the internal radius (0.1 cm for small intestine and 0.2 cm for 
colon), and L the length of intestinal segment. Water flux across the epithelium 
was calculated as (Amidon et al., 1988, Johnson et al., 1988):  
      (2) 
where Cout,uncorr was the original (uncorrected) outlet drug concentration, Iin the 
inulin-5000 inlet concentration, and Iout the inulin-5000 outlet concentration.  
The intrinsic or wall permeability (Pw) is referenced to intestinal wall 
concentrations and determined by factoring out the aqueous layer permeability 
(Paq) using the formula:  
 
Pw =
Peff
1 − Peff /Paq
     (3) 
The boundary layer approach can be used to estimate the aqueous permeability 
according to:  
 
Paq = (A
R
D
Gz1/ 3)−1
     (4) 
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Gz =
πDL
2Q      (5) 
where A is a unitless constant (see below for calculation), R the radius, D the 
diffusion coefficient in water (3.82 x 10-4 cm2/min), and Gz the Graetz number 
(0.0829). Once the Graetz number was calculated, A was estimated as: 
A = 2.50 Gz + 1.125  (when Gz ≥ 0.030) 
A = 4.50 Gz + 1.065  (when 0.030 > Gz ≥ 0.010) 
A = 10.0 Gz + 1.010  (when 0.010 > Gz ≥ 0.004) 
Given these relationships, the concentration of drug at the membrane surface 
(Cw) was calculated as: 
 
Cw = Cin (1 −
Peff
Paq
)     (6) 
The intrinsic parameters Jmax (maximum transport rate) and Km (Michaelis 
constant) were determined using the following equation: 
 
 
Pw =
Jmax
Km + Cw
+ Pm       (7) 
where Pm is the passive (nonsaturable) permeability. The carrier permeability (Pc) 
was calculated as: 
 
Pc =
Jmax
Km
      (8) 
 The steady-state flux (J) can also be referenced to intestinal wall concentrations 
(Cw) and the intrinsic kinetic parameters expressed as: 
 
J =
Jmax • Cw
Km + Cw
+ PmCw = Peff • Cin    (9) 
The apparent kinetic parameters can also be determined by the following: 
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      (10) 
and the flux calculated as: 
     (11)  
The concentration-dependent flux (J) of cefadroxil in jejunum was best fit 
to a single Michaelis-Menten term as: 
    (12)
 
where the parameters J*max and K*m were referenced to inlet drug concentrations 
(Cin), and the parameters Jmax and Km were referenced to intestinal wall drug 
concentrations ( ), once corrected for the unstirred aqueous layer permeability.   
The body surface area (BSA) of mice was calculated by: 
  
where the body weight of humans was 70 kg, the BSAhumans was 1.8 m2.   
Data were reported as mean ± SE, unless otherwise noted. Statistical 
differences between two groups were determined using an unpaired t-test.  
Multiple treatment groups were compared using one-way analysis of variance 
(ANOVA) followed by either a Tukey’s test or Dunnett’s test, with wildtype serving 
as the control group (GraphPad Prism 5.0; GraphPad software, Inc., La Jolla, 
CA). P ≤ 0.05 was considered significant. Pharmacokinetics analyses were 
carried out using a non-compartmental model (NCA) in Phoenix WinNonlin 6.3 
(Certara, St. Louis, MO USA).  
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RESULTS 
Concentration-Dependent In Situ Transport Kinetics of Cefadroxil in 
Jejunum of Humanized huPepT1 and Wildtype Mice 
The Jmax and Km of GlySar for the PepT1 transporter were previously 
shown to be much lower in humanized mice than in wildtype animals during in 
situ jejunal perfusions (Figure 4.2, Chapter IV).  Therefore, we believed that the 
transport kinetics of cefadroxil would also be significantly lower in humanized 
huPepT1 mice than in wildtype mice during these single-pass perfusion studies. 
As shown in Figure 5.1, both genotypes demonstrated a saturable transport of 
cefadroxil. When referenced to cefadroxil inlet concentrations (Cin), the maximal 
flux J*max=0.380 nmol/cm2/sec for wildtype vs. 0.057 nmol/cm2/sec for humanized 
mice, and the Michaelis constant K*m =6.01 mM for wildtype vs. 2.69 mM for 
humanized mice (Figure 5.1A). When referenced to cefadroxil wall 
concentrations (Cw), the maximal flux Jmax=0.392 nmol/cm2/sec for wildtype vs. 
0.056 nmol/cm2/sec for humanized mice, and the Michaelis constant Km=4.80 
mM for wildtype vs. 2.37 mM for humanized mice (Figure 5.1B).  Thus, the 
affinity of cefadroxil for PepT1 in humanized mice was higher (i.e., lower Km) than 
that of wildtype mice.   
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In Situ Transport Kinetics of Cefadroxil in Regional Intestinal Segments of 
Humanized huPepT1 and Wildtype Mice 
Given a Km for cefadroxil on the order of 2.4-6.0 mM, subsequent studies 
were performed at 10 µM cefadroxil to maintain conditions of transport linearity. 
Based on the GlySar results (Chapter IV), we hypothesized that the permeability 
of cefadroxil would be significantly lower in all regions of small intestine, and 
significantly higher in the colon, of humanized huPepT1 mice as compared to 
wildtype animals during the intestinal perfusions. As shown in Figure 5.2, the 
permeability of cefadroxil was considerable in duodenum, jejunum and ileum of 
wildtype and humanized mice, although it was 50-60% lower in humanized mice. 
In contrast, the permeability of cefadroxil in mPepT1 knockout mice was minimal, 
with a residual permeability of 5% or less as compared to wildtype animals. Still, 
the permeability of cefadroxil in the colon of humanized mice was measurable 
and 14-fold higher than that of wildtype mice.   
Substrate Specificity of hPepT1 in Humanized Mouse Jejunum by In Situ 
Perfusion Studies  
In the presence of excess concentrations of potential inhibitors, the 
permeability of cefadroxil was reduced 90% by GlyPro, 80% by GlyGlyHis and 
about 60% by carnosine or cephalexin during jejunal perfusion studies in 
humanized huPepT1 mice (Figure 5.3).  In contrast, amino acid inhibitors (glycine 
and L-histidine), OAT inhibitors (probenecid and PAH), OCT inhibitors (TEA, 
quinidine and NMN), and cephalosporins lacking a α-amino group (cephalothin) 
had no effect on the jejunal permeability of cefadroxil in humanized huPepT1 
 165 
mice.  However, DMA, an inhibitor of the sodium-proton exchanger, was able to 
reduce the permeability of cefadroxil by 50% as compared to the control group.  
 
In Vivo Pharmacokinetic Studies Following Intravenous Bolus Doses of 
Cefadroxil 
Humanized huPepT1 mice were evaluated following single intravenous 
doses of [3H]cefadroxil at 11.01 nmol/g and 528.40 nmol/g (5 µCi). As shown in 
Figure 5.4, the plasma concentration-time profiles of cefadroxil were virtually 
superimposable between genotypes for each dose. Non-compartmental analyses 
indicated that both wildtype and humanized mice had similar pharmacokinetic 
parameters, including CL, Vss and T1/2 (Table 5.1). In fact, no significant 
differences in pharmacokinetics were observed between humanized huPepT1 
mice and wildtype animals for either dose. Furthermore, two-way ANOVA 
showed no significant differences with respect to dose or genotype. As shown in 
Figure 5.5, no significant differences were found between humanized huPepT1 
and wildtype mice in any of the tissues studied.   
In Vivo Pharmacokinetic Studies Following Oral Dose Escalation Dose of 
Cefadroxil   
The in vivo functional activity of PepT1 was evaluated in humanized and 
wildtype mice after increasing oral doses of cefadroxil. Mouse dose were scaled 
from human doses (250-2000 mg for adults) by body surface area, and produced 
similar concentrations of cefadroxil in the stomach as well as systemic 
circulation. As shown in Figure 5.6, the plasma concentrations of cefadroxil were 
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much lower in humanized mice than in wildtype animals for all doses (11.01, 
33.03, 66.06, 132.10, 264.20, 528.40 nmol/g). According to non-compartmental 
analyses (Table 5.2), area under the plasma concentration-time curve (AUC) and 
peak plasma concentrations (Cmax) of cefadroxil were about 2-fold lower in 
humanized mice than in wildtype mice, and the time to reach peak 
concentrations (Tmax) about 2-fold longer in humanized mice. However, the 
terminal half-life (T1/2) was not significantly different between humanized and 
wildtype mice, which agreed with the results following single intravenous doses.  
Bioavailability of Cefadroxil in Humanized and Wildtype Mice  
Mass balance studies of [3H]cefadroxil were performed in wildtype and  
humanized huPepT1 mice using a metabolic cage studies. As shown in Table 
5.7, the bioavailability (F) of radiolabelled cefadroxil was 83.8 % and 82.4% in 
wildtype mice, and 82.1% and 81.7% in humanized huPepT1 mice, respectively, 
after the 11.01 nmol/g and 528.40 nmol/g oral doses of drug. However, the 
bioavailability (F) of cefadroxil, calculated from plasma data, was 82.6% and 
105.0% for wildtype mice, but only 47.1% and 52.7% for humanized huPepT1 
mice, after these same oral doses of 11.01 nmol/g and 528.40 nmol/g (Table 
5.8). 
Evaluation of Partial AUC versus Time or Dose for Comparison of 
Cefadroxil Absorption Kinetics between Humanized and Wildtype Mice   
The rate of drug absorption was evaluated by comparing the partial AUC-
time curves of cefadroxil from 5 to 30 min.  As shown in Figure 5.7 and Table 5.3, 
the slopes of cefadroxil for all 6 oral doses were about 2-fold steeper in wildtype 
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mice than in humanized mice, indicating a greater absorption rate of cefadroxil in 
these animals. Because of the higher affinity of cefadroxil for human over mouse 
PepT1, as determined by in situ perfusion studies, the oral absorption of 
cefadroxil was more likely to be saturated in humanized mice than in wildtype 
animals. As shown in Figure 5.8 and Table 5.4, a nonlinear relationship was 
observed for the partial cumulative AUC vs. dose profiles of cefadroxil in 
humanized huPepT1 but not wildtype mice during oral dose escalation studies. In 
fact, values of AUC0-120 vs. Dose (body surface area-normalized) for cefadroxil 
were strikingly similar between the humanized huPepT1 mice and human values 
obtained from the literature (Garrigues et al, 1991) (Figure 5.9 and Table 5.5). A 
similar relationship for cefadroxil’s Cmax was also observed in Figure 5.10 and 
Table 5.6, where the Cmax vs. Dose (body surface area-normalized) curves were 
linear for wildtype, but nonlinear and strikingly close for humanized huPepT1 
mice and human values obtained from the literature (Garrigues et al, 1991). 
Taken as a whole, it appears that humanized huPepT1 mice are a good model to 
predict the oral absorption and disposition of cefadroxil in humans.   
 
DISCUSSION  
In the present study, the effective permeability of cefadroxil during in situ 
single-pass intestinal perfusions, and pharmacokinetics of cefadroxil following 
intravenous and oral dosing were examined in humanized huPepT1 and wildtype 
mice. From these experiments, we made the following observations: 
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1) the in situ permeability pattern of cefadroxil in small intestine was 
comparable, but smaller, in huPepT1 mice as compared wildtype mice. However, 
the colonic permeability of cefadroxil was measurable and higher in humanized 
huPepT1 animals.  
2) a species difference was found in the in situ PepT1-mediated kinetics of 
cefadroxil in jejunum, in which the Jmax and Km of drug were significantly lower in 
humanized huPepT1 mice as compared to wildtype animals.   
3) inhibition studies showed that cefadroxil uptake from the intestinal lumen 
depended primarily upon PepT1 functional activity, which was influenced by the 
proton gradient.   
4) After intravenous dosing of cefadroxil (11.01 and 528.40 nmol/g), the 
plasma concentration-time profiles were virtually superimposable between 
humanized hPepT1 and wildtype mice. No significant differences were observed 
between genotypes in the disposition parameters (e.g., CL and Vss) of cefadroxil, 
or pattern of tissue distribution.   
5) after oral dose escalation of cefadroxil (11.01, 33.03, 66.06, 132.10, 264.20 
and 528.40 nmol/g), non-compartmental analyses demonstrated that the Cmax, 
Tmax and AUC of drug were lower in humanized huPepT1 mice (Hemizygotes) 
than that in wildtype animals. Moreover, the partial AUC-Dose and Cmax-Dose 
profiles of cefadroxil indicated a nonlinear relationship for humanized huPepT1 
mice but not for wildtype mice.  
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6) the slope of partial AUC-Time curves indicated that the rate and extent of 
absorption for cefadroxil were significantly lower in humanized huPepT1 mice 
than in wildtype animals.  
7) the Cmax-Dose and AUC120-Dose profiles of cefadroxil were similar between 
human subjects and humanized huPepT1, as compared to human subjects and 
wildtype mice, indicating that the humanized huPepT1 mouse model might be 
preferred for translating the intestinal absorption and systemic exposure of orally 
administered drugs to humans.   
The interpretation of our observations depends upon the faithful 
expression and functional activity of PepT1 in the small and large intestines, and 
the initial stomach concentrations of cefadroxil after the escalating oral doses. 
PepT1 is considered a high-capacity, low-affinity transporter with Km values 
ranging from 0.2 to 10 mM (Brandsch et al., 2008, Rubio-Aliaga et al., 2002, 
Rubio-Aliaga et al., 2008). During our in situ jejunal perfusion studies, the affinity 
of cefadroxil was two-fold higher in humanized mice (Km=2.7 mM) than in 
wildtype animals (Km=6.0 mM).  These values are similar to the Km of 2-4 mM 
during jejunal perfusions in wildtype mice (Posada, et al. 2013b), and to the Km 
of 5.9 mM (Sinko et al., 1988) and 6.6 mM (Sanchez-Pico, et al. 1989) during 
small intestinal perfusions of cefadroxil in rat.  
The cefadroxil permeability of 0.80x10-4 cm/s, as reported by Posada et al 
(2013b), was similar to our permeability estimate of 0.62x10-4 cm/s in wildtype 
mice, but larger than the 0.17x10-4 cm/s estimate in humanized mice during in 
situ jejunal perfusions. The intestinal permeability of cefadroxil in humans, 
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however, is currently not available. Still, the permeability of cephalexin (another 
PepT1 substrate) was 1.56x10-4 cm/s in human jejunum (Cao et al., 2006, 
Lennernas 2007, Zakeri-Milani et al., 2007). Even though both compounds are 
from the same class of orally administered aminocephalosporin drugs, they do 
have different chemical structures that could impart different affinities between 
species and, as a result, have different permeability in the small intestine.  
Different substrate affinities for a particular transporter, along with different 
expression patterns of transporters (and enzymes), can account for differences in 
drug absorption and bioavailability between rodents and humans (Cao, et al. 
2006).  
During our in situ perfusion studies, the permeability of cefadroxil was two-
fold larger in the small intestine (duodenal, jejunal and ileal segments) of wildtype 
vs. humanized mice, but lower in the colon of wildtype vs. humanized huPepT1 
animals (Figure 5.2). These results are in agreement with the protein expression 
pattern of PepT1 in the small and large intestines of these two genotypes.  
Similar differences in intestinal permeability were reported previously by our 
group for GlySar in humanized huPepT1 and wildtype mice (Hu et al., 2014) and 
for cefadroxil in wildtype and mPepT1 knockout mice during in situ perfusion 
studies (Posada, et al. 2013b).  Given these species differences, it was 
hypothesized that the in vivo oral absorption and systemic availability of 
cefadroxil would differ between humanized huPepT1 and wildtype mice. 
 Our laboratory has previously performed a number of substrate specificity 
studies for PepT1, using a wide range of potential inhibitors, during in situ 
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perfusion studies (Jappar, et al. 2010, Ma et al., 2011, Posada, et al. 2013b). 
Cefadroxil can be transported by both SLC and ABC family members. Using 
excess concentrations of potential inhibitors, the jejunal permeability of cefadroxil 
was significantly reduced by GlyPro, GlyGlyHis, carnosine and cephalexin, 
indicating that the uptake of cefadroxil from intestinal lumen was mainly mediated 
by PepT1 transporters.  This observation was supported by a study 
demonstrating that PepT1 protein accounted for about 50% of all relevant 
transporters in human small intestine (Drozdzik et al., 2014), and that ABCC3 
protein, which is responsible for cellular efflux of cefadroxil across the basolateral 
membrane, accounted for only 7% of all relevant transporters in this region. Even 
though PhT1, another POT transporter, was reported in chicken intestine 
(Zwarycz et al., 2013) and mouse intestine (Hu et al., 2008), it has an 
intracellular localization in which its function is unrelated to the uptake of 
cefadroxil from the intestinal lumen (Nakamura et al., 2014, Sasawatari et al., 
2011).  The lack of a PhT1 effect was confirmed in our studies such that the 
jejunal permeability of cefadroxil was unchanged when perfused with high 
concentrations of L-histidine (Figure 5.3).   
Studies have shown that the impact of pH is limited during in situ perfusion 
studies of cefadroxil when the buffer was changed from 5.0 to 7.4 (Jappar, et al. 
2010). This finding probably reflects the fact that the acidic microclimate layer, 
formed by mucus and sodium/proton exchange at the brush border membrane, is 
highly resistant to changes by bulk fluid pH in the intestine (Hogerle et al., 1983, 
Lucas 1983, McKie et al., 1988). Therefore, DMA (dimethyl-amiloride), an 
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inhibitor of the sodium/proton exchanger (NHE), was used to diminish exchange 
of Na+ and H+ across the brush border membrane within this thin layer. As a 
result, the permeability of cefadroxil was reduced by 50% in humanized mouse 
jejunum during co-perfusion with DMA. To rule out other potential transporters, 
the jejunal permeability of cefadroxil was evaluated by co-perfusing the drug with 
high concentrations (10 mM) of known OAT (i.e., probenecid and PAH) and OCT 
transport inhibitors (TEA, quinidine and NMN), as well as the non-
aminocephalosporin drug cephalothin. In doing so, no significant difference was 
observed in the permeability of cefadroxil (Figure 5.3), thereby, ruling out the 
importance of transporters other than PepT1 in its intestinal uptake. The 
negligible permeability of cefadroxil in all segments of the small intestine of 
mPepT1 knockout mice also demonstrated that other transporters have little to 
no influence on the uptake of cefadroxil from intestinal lumen (Figure 5.2).  
After oral administration of cefadroxil, less than proportional increases in 
AUC and Cmax were observed in humans (Garrigues, et al. 1991) and rats 
(Garcia-Carbonell, et al. 1993, Sanchez-Pico, et al. 1989, Wang, et al. 1992) with 
increasing doses of drug.  In contrast, linear oral absorption kinetics were 
observed in wildtype mice under similar dosing conditions (Posada, et al. 2013a). 
We also observed a dose-proportional increase of AUC and Cmax in our oral 
wildtype mouse studies; however, in our humanized mice a less than proportional 
increase of AUC and Cmax was observed after oral escalation dose. Potential 
reasons for this inter-species discrepancy in the oral pharmacokinetics of 
cefadroxil might include: 1) a saturable PepT1-mediated intestinal absorption of 
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drug in humans (or humanized huPepT1 mice) but not in mice, and 2) a 
saturable OAT-mediated secretion and/or PepT2-mediated reabsorption in the 
renal tubules of one species and not the other. Regarding the second point, a 
previous study by our group reported the concentration-dependent saturation of 
renal tubular secretion by OATs and renal tubular reabsorption by PepT2 for 
cefadroxil following a range of intravenous doses (Shen, et al. 2007). However, in 
the present study, the plasma concentration-time profiles of cefadroxil were 
virtually superimposable in humanized huPepT1 and wildtype mice after either 
low (11.01 nmol/g) or high (528.40 nmol/g) intravenous doses of drug (Figure 
5.4). Thus, no differences were observed in the disposition parameters of 
cefadroxil between both genotypes and as a function of dose (Table 5.2). 
Although one cannot totally rule out dose-dependent alterations in the renal 
tubular secretion and reabsorption of cefadroxil, since equal and opposite 
changes would result in an “apparent” linear relationship between AUC and dose, 
this outcome is unlikely. Moreover, the lack of significant changes in transcript 
levels of PepT2, Oat1/3 and others in kidney (Figure 3.3, Chapter III), and the 
lack of significant differences between wildtype and humanized huPepT1 mice in 
cefadroxil tissue distribution (Figure 5.4), would argue against dispositional 
changes occurring with intravenous dose. Therefore, we concluded that the non-
linear relationship between AUC or Cmax with cefadroxil dose in humanized mice 
was not caused by changes in disposition, but by saturable intestinal absorption 
of hPepT1 after oral escalation dose.    
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 A saturable intestinal absorption rate was also considered for cefadroxil by 
evaluating the partial AUC vs. time profiles of drug after oral dose escalation. In 
this regard, the plasma concentrations of cefadroxil were about two-fold higher in 
wildtype than humanized hPepT1 mice during the first 30 min of oral dosing, and 
the time to reach peak concentration (Tmax) about two-fold lower in wildtype 
animals. This would suggest that wildtype mice absorbed drug as twice the rate 
as compared to humanized huPepT1 mice. Further analysis confirmed this 
suggestion, where the slopes of partial cumulative AUC vs. time (over 5-30 min) 
in wildtype mice were double of that in humanized huPepT1 mice (Table 5.3), a 
method which was proposed as a good way of determining absorption rate, as 
compared to other methods such as Cmax and Tmax  (Chen 1992, Chen et al., 
2001, Yang, et al. 2013).  The ratio of slopes (HU/WT) may also suggest a 
saturable PepT1 absorption rate since these values were reduced somewhat 
with increasing dose (i.e., from 0.55 to 0.37).   
 For the oral escalation dose studies, cefadroxil doses (11.01 to 528.40 
nmol/g) were chosen in mice (20 g) so that their initial stomach concentrations 
would mimic that observed after clinical oral doses of 250 to 2000 mg in humans 
(70 kg). Thus, given a stomach fluid volume of 0.4 ml for mice (McConnell et al., 
2008) and 250 ml for humans (Rowland et al., 2009), the initial stomach 
concentrations of cefadroxil were similar between species, ranging from 0.55-
26.4 mM in mice and from 2.8-22.1 mM in humans.  These estimated stomach 
concentrations were higher than the Km values of cefadroxil as estimated during 
the in situ jejunal perfusions of wildtype (i.e., 6.0 mM) and humanized huPepT1 
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mice (i.e., 2.7 mM) (Figure 5.1). However, given the lower Km value, it is more 
likely for the humanized mice to show saturable PepT1 intestinal absorption of 
cefadroxil in vivo than wildtype animals. This contention was confirmed in Figure 
5.8, where the AUC from 0-30, 0-60, 0-90 and 0-120 min increased linearly with 
increasing dose in wildtype mice, a result consistent with our previous reports for 
cefadroxil (Posada, et al. 2013a) and valacyclovir (Yang, et al. 2013). In contrast, 
the AUC values (from 0-30, 0-60, 0-90 and 0-120 min) in humanized huPepT1 
mice increased less than proportionately with increasing dose, a result consistent 
with the systemic profiles of cefadroxil after oral dosing in humans (Garrigues, et 
al. 1991) and rats (Garcia-Carbonell, et al. 1993, Sanchez-Pico, et al. 1989). A 
similar finding was also observed in comparing the Cmax vs. oral dose relationship 
in wildtype and humanized huPepT1 mice (Figure 5.9).   
Possible reasons to explain the dose-proportional increase of AUC or Cmax 
in wildtype mice might include the following: 1) as cefadroxil travels down from 
proximal to distal regions of small intestine, the concentration of drug remains 
below its Km value, and 2) since AUC=FDose/CL, perhaps there are changes in 
cefadroxil F (bioavailability) and CL (clearance) that are of the same magnitude 
and direction, thereby, masking dose-dependent changes in AUC.  The latter 
explanation is unlikely, though, since bioavailability did not change as a function 
of dose.  This claim was based on subsequent 24-hr mass balance studies of 
orally administered cefadroxil, as shown in Table 5.7.  In this regard, the 
bioavailability of cefadroxil in wildtype mice was 83.8% after an 11.01 nmol/g oral 
dose and 82.1% after a 528.40 nmol/g oral dose. However, a discrepancy in 
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bioavailability was observed between genotypes when plasma data calculations 
were compared with mass balance calculations for this parameter (see Tables 
5.7 and 5.8).  For example, at the 11.01 nmol/g dose, the bioavailability of 
cefadroxil in humanized huPepT1 mice was only 47.1% when based on plasma 
data but 82.1% when calculated from mass balance studies.  This discrepancy 
might reflect the fact that different animals were used to determine plasma AUC 
following the oral and intravenous doses of drug (i.e., not a cross-over design).  It 
is also possible, but unlikely, that substantial cefadroxil still remains in the body 
after oral dosing in the humanized, but not wildtype, mice such that the 
extrapolated AUC (i.e., post 2-hr collection) does not account for this effect in 
calculating the bioavailability parameter.   
In concluding, the in situ jejunal studies revealed a clear species 
difference between wildtype and humanized huPepT1 mice in the maximal flux 
and affinity of cefadroxil.  The oral dose escalation studies confirmed that species 
differences existed in vivo in the absorption rate and PepT1-mediated saturable 
uptake of cefadroxil from the intestinal lumen. Moreover, the AUC or Cmax vs. 
Dose relationships were more similar for humanized huPepT1 mice and humans 
than for wildtype mice and humans.  As a result, it appears that humanized 
huPepT1 mice might provide a valuable animal model in the drug discovery 
process, as well as to predict the pharmacokinetic profiles of PepT1 substrates in 
humans.       
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Table 5.1 Non-compartmental pharmacokinetics of cefadroxil after 
intravenous bolus dosing in wildtype and humanized huPepT1 
micea 
a CL: Total clearance  of cefadroxil from plasma 
T1/2: Elimination half-life 
Vss: Volume of distribution under steady state conditions based on drug concentration in plasma 
AUC0-t: Area under the plasma concentration-time curve from time 0 to t after dosing 
MRT: Mean residence time of a molecule within the body 
Data are expressed as mean ± SE (n=3-5). No significant differences were observed between 
wildtype (WT) and humanized huPepT1 (HU) mice in the disposition parameters and as a 
function of dose, as evaluated by two-way ANOVA (except for differences in AUC between the 
low and high doses; p<0.001).   
 
  
Parameters 
11.01 
nmol/g IV 
528.40 
nmol/g IV 
WT HU WT HU 
CL (mL/hr) 21.57 ± 1.04 21.63 ± 0.84 25.48 ± 2.63 23.99 ± 1.81 
T1/2 (min) 51.66 ± 3.41 56.15 ± 1.25 44.13 ± 12.65 72.37 ± 26.80 
Vss (mL) 11.99 ± 1.25 11.90 ± 0.70 17.25 ± 5.26 13.37 ± 2.30 
MRT (min) 19.55 ± 0.77 18.46 ± 1.30 19.12 ± 0.40 16.91 ± 0.57 
AUC0-120 (µM•min) 569 ± 31 564 ± 21 23614 ± 2638 23826 ± 2219 
AUC0-∞ (µM•min) 616 ± 30 613 ± 23 25482 ± 2926 26744 ± 2086 
% Extrapolation 7.6 8.0 7.3 10.9 
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Table 5.2 Non-compartmental analysis of disposition parameters of 
[3H]cefadroxil following oral dose escalation in wildtype and 
humanized micea  
 
Dose Cmax Tmax T1/2 
(nmol/g) (µM) (min) (min) 
 WT HU WT HU WT HU 
11.01 14.20±1.12 6.86±1.00*** 9.28±1.89 20.71±4.42*** 32.13±8.68 32.45±4.03 
33.03 36.99±1.34 17.76±3.59*** 13.33±2.11 27.5±4.03*** 36.31±5.25 38.45±6.56 
66.06 96.26±4.27 41.33±7.71*** 7.50±1.18 30.00±5.00*** 28.00±1.08 33.62±3.07 
132.10 185.38±4.40 84.40±11.84*** 9.17±0.83 21.67±1.67*** 26.06±1.29 28.94±1.10 
264.20 382.04±15.93 173.78±15.40*** 10.00±0.00 18.33±1.67*** 23.98±1.94 27.19±2.36 
528.40 636.77±34.59 263.47±34.90*** 13.33±2.11 24.28±2.02*** 29.82±3.12 31.49±2.71 
 
 
aData are expressed as mean ± SE (n=6-7). *** P<0.001, as evaluated by unpaired t-test between wildtype (WT) and 
humanized huPept1 (HU) mice.  
 
 
  
Dose AUC0-120 AUC0-∞ Extrapolation 
(nmol/g) (µM•min) (µM•min) % 
 WT huPepT1 WT huPepT1 WT huPepT1 
11.01 473±28 263±20*** 509±31 289±15*** 7.6 9.8 
33.03 1605±86 793±116*** 1785±133 887±110*** 11.2 11.8 
66.06 2823±299 2223±197*** 2979±337 2468±185*** 5.5 11.0 
132.10 6067±235 3948±244*** 6365±252 4270±248*** 4.9 7.1 
264.20 12149±841 7921±518*** 12616±905 8415±526*** 3.8 6.2 
528.40 25336±1342 12718±1329*** 26749±1414 14101±1425*** 5.6 10.8 
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Table 5.3 Slopes of partial cumulative area under the plasma concentration-
time curve (AUC) of [3H]cefadroxil vs. time (5-30 min) after oral 
dose escalation in wildtype and humanized huPepT1 micea 
 
aData are expressed as mean ± SE (n=6-7). *** P<0.001, as evaluated by unpaired t-test 
between wildtype (WT) and humanized huPepT1 (HU) mice (hemizygotes).  
 
 
 
 
  
Dose 
(nmol/g) 
From 5 min to 30 min Ratio 
Slope R2 Dose Normalized Slope HU/WT 
WT HU WT HU WT HU  
11.01 10.39 ± 0.73 5.27 ±0.76 0.88 0.65 10.39 ± 0.73 5.27 ±0.76*** 0.51 
33.03 30.53 ± 1.18 16.69 ± 2.42 0.97 0.73 10.17 ± 0.39 5.56 ± 0.81*** 0.55 
66.06 62.34 ± 4.11 33.08 ± 5.19 0.91 0.65 10.39 ± 0.68 5.51 ± 0.87*** 0.53 
132.10 138.4 ± 6.28 69.33 ± 7.06 0.96 0.81 11.53 ± 0.52 5.77 ± 0.59*** 0.50 
264.20 290.0 ± 11.39 140.9 ± 10.16 0.97 0.90 12.08 ± 0.47 5.87 ± 0.42*** 0.49 
528.40 544.6 ± 18.71 200.8 ± 23.16 0.97 0.74 11.35 ± 0.39 4.18 ± 0.48*** 0.37 
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Table 5.4 Regression parameters of partial cumulative area under the plasma 
concentration-time curve (AUC) of [3H]cefadroxil vs. dose after oral 
dose escalation in wildtype and humanized huPepT1 micea  
aAUC0-t: Area under plasma cefadroxil concentration-time profile from time 0 to time t after 
administration 
Data are expressed as mean ± SE (n=6-7), where WT is wildtype and HU is humanized. 
Nonlinear regression equation:    
  
 WT HU 
Partial AUC Linear Nonlinear 
(min*µM) Slope R2 
AUCmax 
(µM•min) 
Km  
(nmol/g) 
R2 
AUC0-30 27.53±0.65 0.98 12313±4775 724.9±431.4 0.78 
AUC0-60 40.92±1.20 0.97 28688±11397 1023±568 0.86 
AUC0-90 45.69±1.44 0.97 35898±13610 1082±565 0.89 
AUC0-120 47.95±1.39 0.97 40789±15263 1156±587 0.90 
 181 
 
 
 
 
Table 5.5 Regression parameters of area under the plasma concentration-
time curve from 0-120 min (AUC0-120) of [3H]cefadroxil vs. dose after 
oral dose escalation in wildtype and humanized huPepT1 mice, and 
in human subjectsa 
 
aData are expressed as mean ± SE (n=6-7), where WT is wildtype and HU is humanized mice.     
Nonlinear regression equation:    
  
WT HU Humans 
Linear Nonlinear Nonlinear 
Slope 
(min*m2/L) 
R2 
 
AUCmax 
(min*µM) 
Km 
(µmol/m2) 
R2 
 
AUCmax 
(min*µM) 
Km 
(µmol/m2) 
R2 
 
24.78±0.72 0.971 40794±15267 5838±2965 0.899 38494±8410 6177±1910 0.989 
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Table 5.6 Regression parameters of Cmax of [3H]cefadroxil vs. dose after oral 
dose escalation in wildtype and humanized huPepT1 mice, and in 
human subjectsa  
aData are expressed as mean ± SE (n=6-7), where WT is wildtype and HU is humanized mice.   
Nonlinear regression equation:    
 
  
WT HU Humans 
Linear Nonlinear Nonlinear 
Slope 
(m2/L) 
R2 
 
Cmax 
(µM) 
Km 
(µmol/m2) 
R2 
 
Cmax 
(µM) 
Km 
(µmol/m2) 
R2 
 
0.59 ± 0.013 0.998 554±187 4002±2030 0.843 322±42 3762±818 0.962 
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Table 5.7  Bioavailability of cefadroxil, as assessed by mass balance, in 
wildtype and humanized huPepT1 mice after oral dosesa   
 
aData are expressed as the mean of n=4 animals for each treatment group.  Mass balance 
studies were performed in wildtype (WT) and humanized (HU) mice in which the urine and feces 
were collected for 24 hours after dosing.  The bioavailability (F) of cefadroxil was calculated 
as: %Cef recovered in the urine divided by %Inu recovered in the urine; the bioavailability (F) of 
inulin was calculated as: %Inu recovered in the urine plus feces, where inulin was given as a 
[14C]-labeled intravenous bolus injection at the same time as the oral dosing of cefadroxil. Cef 
represents cefadroxil and Inu represents inulin.   
   
 [3H]Cefadroxil Oral Dose – 11.01 nmol/g [3H]Cefadroxil Oral Dose – 528.40 nmol/g 
 WT  HU WT  HU  
 Urine Feces F Urine Feces F Urine Feces BA Urine Feces F 
%Cef 81.6 8.3 83.8 78.2 12.2 82.1 76.3 6.6 82.4 75.6 9.4 81.7 
%Inu 97.4 3.7 101.1 95.2 3.5 98.5 92.6 4.0 96.6 92.5 2.9 95.4 
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Table 5.8 Bioavailability of cefadroxil, as assessed by plasma, in wildtype and 
humanized huPepT1 mice after oral dosesa  
 11.01 nmol/g of cefadroxil 528.40 nmol/g of cefadroxil 
 WT HU WT HU 
AUCoral(min*µM) 509 289 26749 14101 
AUCiv(min*µM) 616 613 25482 26744 
F (%) 82.6 47.1 105.0 52.7 
 
aData are expressed as mean (n=3-5), for wildtype (WT) and humanized (HU) mice. The 
%bioavailability (F) of cefadroxil was calculated as: AUCoral (min*µM) divided by AUCiv(min*µM) in 
which AUC was the area under the plasma concentration-time profile from time zero to infinity. 
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Figure 5.1 Concentration-dependent flux of [3H]cefadroxil (0.01 to 25.0 mM) 
during jejunal perfusion studies in wildtype (WT) and humanized 
huPepT1 (HU) mice (n=4). Cin is the inlet concentration of drug, 
where J*max=0.380±0.001 nmol/cm2/sec and K*m=6.01±0.46 mM for 
WT (r2=0.982); J*max=0.057±0.006 nmol/cm2/sec and 
K*m=2.69±0.928 mM for HU mice (r2=0.658) (A). Cw is the estimated 
concentration of drug at the membrane wall where Jmax 
=0.392±0.010 nmol/cm2/sec and Km=4.80±1.0 mM for WT 
(r2=0.996); Jmax=0.0557±0.009 nmol/cm2/sec and Km=2.37±1.21 
mM for HU (r2=0.728) (B). 
  
 186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Effective permeability of 10 µM [3H]cefadroxil in different regions of 
small and large intestines in wildtype (WT), humanized huPepT1 
(HU) and mPepT1 knockout (KO) mice (n=4). Different letters 
represent significant differences between the treatment groups, as 
evaluated by ANOVA/Tukey’s test.   
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Figure 5.3 Specificity studies on the jejunal permeability of 10 µM 
[3H]cefadroxil, +/- 10 mM of potential inhibitors (0.1 mM for DMA) in 
humanized huPept1 mice (n=3). ***P<0.001, as evaluated by 
ANOVA/Dunnett’s test in which HU without inhibitor was set as the 
control group. PAH, p-aminohippuric acid, TEA, 
tetraethylammonium; NMN, N1-methylnicotinamide; DMA, dimethy-
lamiloride. 
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Figure 5.4 Plasma concentration-time profiles of [3H]cefadroxil in wildtype 
(WT) and humanized huPepT1 (HU) mice following intravenous 
bolus injections (n=4-5) in which the y-axis is displayed on a linear 
scale (left panel) and on a logarithmic scale (right panel).  
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Figure 5.5 Tissue distribution and plasma-normalized tissue distribution 
profiles of [3H]cefadroxil in wildtype (WT) and humanized huPepT1 
(HU) mice following intravenous bolus dosing. Tissues were 
collected 120 min after dosing (n=4-5). No significant differences 
were observed between the two genotypes, as evaluated by 
unpaired t-test.  
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Figure 5.6 Plasma concentration-time profiles of [3H]cefadroxil in wildtype 
(WT) and humanized huPepT1 (HU) mice following oral dose 
escalation (n=6-7) in which the y-axis is displayed on a linear scale 
(left panel) and on a logarithmic scale (right panel).  
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Figure 5.6 Continued (see previous page for description) 
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Figure 5.7 Partial cumulative area under the plasma concentration-time curve 
(AUC) of [3H]cefadroxil as a function of time in wildtype (WT) and 
humanized huPepT1 (HU) mice. Data are expressed as mean ± SE 
(n=6-7).  
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Figure 5.8 Partial cumulative area under the plasma concentration-time curve 
(AUC) of [3H]cefadroxil vs. dose in wildtype (WT) and humanized 
huPepT1 (HU) mice following oral dose escalation. A proportional 
increase of AUC vs. dose was observed in WT mice, whereas this 
relationship was nonlinear in HU mice.  Data are expressed as 
mean ± SE (n=6-7). 
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Figure 5.9 Area under the plasma concentration-time curve from 0-120 min 
(AUC0-120) of [3H]cefadroxil vs. Dose in wildtype (WT), humanized 
huPepT1 (HU) and clinical data (Humans, n=3) obtained from 
Garrigues et al.(Garrigues, et al. 1991) 
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Figure 5.10 Cmax vs. Dose of [3H]cefadroxil in wildtype (WT) mice, humanized 
huPepT1 (HU) mice, and clinical data (Humans, n=3) obtained from 
Garrigues et al. (Garrigues, et al. 1991)    
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APPENDICES 
Appendix A: Individual data from Chapter III 
 
Table A.3.3 mRNA transcripts of hPepT1 in funder of humanized huPepT1 mice 
Mouse Mean value SEM N 
Caco-2 565.3489 16.1015 2 
HU#1 3.992029 0.2168624 2 
HU#3 29.41921 3.315452 2 
HU#4 1530.387 403.6676 2 
HU#5 7.692222 1.770403 2 
HU#6 64.327 10.28008 2 
Wildtype 0.05577244 0.0007595922 2 
mPepT1 KO 0.07403623 0.02631376 2 
 
 
Table A.3.4 Gene copy number of BAC DNA in huPepT1 mice 
Mouse wildtype HU#4 HU#5 
1 0.00000303 1.090869 0.791723 
2 0.0000654 0.960634 0.982002 
3 0.0000498 0.922837  
4 0.000044 1.235112  
5 0.0000569 1.186792  
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Table A.3.6 Real-time PCR analysis of PepT1 gene in WT, KO and huPepT1 
hPepT1 in huPepT1 
Tissue #1 #2 #3 #4 #5 #6 
Duo 430.81 494.39 493.43 445.42 552.41 514.89 
Jej 916.01 1133.30 715.35 1170.58 1086.30 1196.34 
Ile 1053.68 1115.71 1301.21 1045.89 1703.89 1500.04 
PC 257.52 187.04 226.62 297.31 390.35 368.98 
DC 230.80 121.98 207.02 263.66 293.40 267.39 
Kid 4.76 4.48 4.75 42.89 14.13 14.31 
 
 
 
 
 
hPepT1 in Wildtype 
Tissue #1 #2 #3 #4 #5 #6 
Duo 3.44 1.99 1.77 1.70 2.95 4.03 
Jej 2.52 2.29 2.07 2.43 3.58 3.11 
Ile 1.13 2.19 4.79 2.58 1.94 2.69 
PC 0.53 0.39 0.28 0.30 0.48 0.62 
DC 0.28 0.48 0.77 0.43 0.48 0.89 
Kid 0.42 0.26 0.51 0.32 0.20 0.07 
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hPepT1 in mPepT1 KO 
Tissue #1 #2 #3 #4 #5 #6 
Duo 0.57 0.78 1.49 0.48 0.54 5.53 
Jej 7.84 0.25 2.74 2.74 1.77 3.01 
Ile 0.84 5.11 3.16 0.34 0.34 0.33 
PC 7.91 1.09 1.30 6.73 0.69 3.93 
DC 0.87 1.70 7.73 0.61 0.43 9.84 
Kid 1.26 0.80 0.40 0.85 0.45 0.60 
 
 
 
 
 
mPepT1 in huPepT1 
Tissue #1 #2 #3 #4 #5 #6 
Duo 13.47 13.95 15.21 21.55 18.05 21.53 
Jej 34.67 55.63 26.00 54.43 38.36 50.17 
Ile 49.57 53.61 38.66 54.45 42.91 64.08 
PC 1.56 1.62 1.19 4.98 5.25 5.17 
DC 2.41 2.42 2.25 3.72 3.07 3.68 
Kid 1.37 1.04 1.02 1.64 0.43 1.94 
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mPepT1 in Wildtype 
Tissue #1 #2 #3 #4 #5 #6 
Duo 1353.81 898.34 1027.85 709.77 805.54 1626.68 
Jej 2580.85 2094.82 2958.01 2967.34 2008.34 1929.59 
Ile 1594.45 1244.70 1904.47 1798.29 1273.88 1542.56 
PC 27.41 31.68 34.52 16.44 27.08 34.13 
DC 169.66 286.96 514.92 274.60 206.72 596.76 
Kid 6.26 7.60 7.10 7.44 5.69 4.89 
 
 
 
 
 
hPepT1 in mPepT1 KO 
Tissue #1 #2 #3 #4 #5 #6 
Duo 4.62 0.79 1.02 0.52 0.56 3.48 
Jej 5.88 22.56 39.80 10.79 4.41 3.72 
Ile 6.50 19.20 18.50 4.00 2.49 0.85 
PC 12.63 14.80 1.33 17.70 14.23 14.79 
DC 12.34 14.80 17.52 18.21 5.09 5.43 
Kid 2.38 0.98 1.00 2.85 0.96 0.43 
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Table A.3.7 Real-time PCR analysis of POT gene in WT, KO and huPepT1 
PepT2 in huPepT1 
Tissue #1 #2 #3 #4 #5 #6 
Duo 0.91 0.79 1.09 14.82 7.74 9.97 
Jej 4.10 4.94 4.09 0.56 0.58 0.56 
Ile 1.12 0.94 0.95 2.34 2.66 2.96 
PC 6.22 3.81 4.18 2.33 4.58 2.88 
DC 5.00 6.66 5.43 0.82 0.75 0.55 
Kid 575.76 376.19 231.73 655.44 394.62 471.86 
 
 
 
 
mPePT2 in Wildtype 
Tissue #1 #2 #3 #4 #5 #6 
Duo 5.90 1.37 0.93 4.88 4.44 4.58 
Jej 3.09 8.12 1.93 2.64 3.34 4.45 
Ile 0.52 0.23 0.79 1.67 0.61 0.36 
PC 2.13 2.68 0.88 2.81 4.47 4.19 
DC 0.28 0.46 0.48 0.00 0.38 0.64 
Kid 446.84 531.57 544.36 520.48 259.25 383.85 
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mPepT2 in mPepT1 KO 
Tissue #1 #2 #3 #4 #5 #6 
Duo 0.68 0.03 0.33 0.16 0.32 0.17 
Jej 1.67 1.12 0.95 0.39 1.03 0.44 
Ile 0.26 0.49 1.59 0.09 0.08 0.18 
PC 2.71 0.20 0.14 0.73 0.21 0.44 
DC 0.03 1.93 0.06 0.05 0.03 0.90 
Kid 302.04 664.96 545.39 434.00 376.84 790.39 
 
 
 
 
mPhT1 in huPepT1 
Tissue #1 #2 #3 #4 #5 #6 
Duo 11.95 13.45 10.27 23.91 20.80 19.97 
Jej 24.99 22.08 21.79 15.23 17.24 43.14 
Ile 54.77 52.66 67.90 29.10 11.42 0.39 
PC 110.13 46.36 62.22 31.77 68.61 18.28 
DC 47.75 49.44 42.59 52.35 54.14 46.16 
Kid 34.53 25.22 28.97 20.36 21.29 22.62 
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mPhT1 in Wildtype 
Tissue #1 #2 #3 #4 #5 #6 
Duo 17.96 19.57 33.22 10.38 26.36 10.37 
Jej 96.68 54.37 37.11 78.21 33.14 52.18 
Ile 16.33 43.46 55.22 51.06 60.24 56.63 
PC 108.26 115.55 99.35 96.60 86.39 110.84 
DC 42.30 28.53 0.00 26.88 30.96 38.11 
Kid 49.25 75.64 65.13 72.75 46.10 30.71 
 
 
 
mPhT1 in mPepT1 KO 
Tissue #1 #2 #3 #4 #5 #6 
Duo 14.21 33.87 17.86 22.49 6.71 30.68 
Jej 31.82 25.47 96.05 30.88 28.67 103.05 
Ile 63.61 66.41 42.45 26.51 10.84 16.14 
PC 125.98 23.51 10.50 65.72 49.34 49.79 
DC 36.66 56.33 10.25 18.72 19.30 16.81 
Kid 39.38 40.71 8.15 43.30 16.96 9.69 
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mPhT2 in huPepT1 
Tissue #1 #2 #3 #4 #5 #6 
Duo 12.37 8.72 8.31 47.28 25.09 30.15 
Jej 11.71 11.08 9.32 12.68 8.12 11.57 
Ile 42.86 42.74 31.12 21.46 22.20 18.67 
PC 24.48 16.33 21.22 39.47 59.94 38.90 
DC 8.17 10.80 7.00 47.15 46.99 25.32 
Kid 6.66 5.54 5.35 12.49 11.89 7.50 
 
 
 
 
mPhT2 in Wildtype 
Tissue #1 #2 #3 #4 #5 #6 
Duo 21.12 21.47 20.68 16.47 16.27 22.93 
Jej 25.20 17.94 16.02 33.77 5.74 11.86 
Ile 10.07 25.07 16.94 19.33 14.13 18.38 
PC 19.17 13.98 16.03 10.97 8.26 12.81 
DC 3.78 6.32 4.14 3.72 4.28 4.35 
Kid 5.80 7.58 7.83 12.07 6.66 9.06 
 
 
 
 
 
 213 
mPhT2 in mPepT1 KO 
Tissue #1 #2 #3 #4 #5 #6 
Duo 12.00 19.26 21.06 3.71 18.59 20.35 
Jej 53.92 12.82 23.41 14.08 39.46 80.43 
Ile 18.03 38.91 106.70 5.13 6.38 5.99 
PC 25.35 18.48 19.06 14.06 3.54 9.28 
DC 22.37 7.21 5.23 19.03 12.32 26.29 
Kid 4.96 5.25 6.13 15.32 4.61 13.33 
 
 
 
 
 
Table A.3.8 Real-time PCR analysis of relevant gene in WT, KO and HU 
Genes in huPepT1 small intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 47.02 55.28 69.78 46.82   
Bo,+ 124.53 121.43 214.82 82.68   
OAT1 0.94 0.84 14.43 12.37   
OAT2 0.04 0.04 2.72 2.63   
OAT3 0.19 0.10 8.74 8.47   
PAT1 92.14 63.13 79.33 71.08   
OCT1 50.88 41.79 85.40 51.70   
MATE1 0.08 0.07 2.52 2.09   
MATE2 47.02 55.28 69.78 46.82   
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Genes in mPepT1 KO small intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 51.19 34.96 39.61 46.78 37.73 46.45 
Bo,+ 174.58 52.26 129.58 136.02 114.38 200.54 
OAT1 1.38 1.55 2.05 0.88 1.89 2.04 
OAT2 0.23 0.23 0.31 0.15 0.27 0.19 
OAT3 0.92 0.89 1.01 0.29 1.12 1.02 
PAT1 84.90 136.02 153.03 250.33 136.02 222.51 
OCT1 73.40 98.20 147.82 158.43 115.18 157.34 
MATE1 0.83 1.48 1.34 0.62 0.98 1.15 
MATE2 51.19 34.96 39.61 46.78 37.73 46.45 
Gene in huPepT1 Large Intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 194.17 153.86 135.81 75.34   
Genes in wildtype small intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 55.63 61.72 50.83 52.63 54.86 47.10 
Bo,+ 216.42 214.93 213.44 164.02 429.86 180.73 
OAT1 1.93 2.04 5.85 2.51 3.62 0.97 
OAT2 0.44 0.53 3.70 0.99 0.99 0.39 
OAT3 0.76 1.14 5.13 2.01 4.25 0.64 
PAT1 96.18 180.73 0.00 117.60 184.53 68.96 
OCT1 99.58 134.15 123.44 148.85 157.34 172.17 
MATE1 1.02 0.92 4.52 1.98 3.97 0.79 
MATE2 55.63 61.72 50.83 52.63 54.86 47.10 
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Bo,+ 2762.03 2701.44 2906.79 1320.72   
OAT1 0.56 0.77 3.60 3.40   
OAT2 0.36 0.07 0.58 0.60   
OAT3 0.53 0.32 8.55 8.25   
PAT1 97.07 135.28 27.81 38.59   
OCT1 22.00 18.16 4.91 4.59   
MATE1 0.30 0.03 2.61 2.04   
MATE2 194.17 153.86 135.81 75.34   
 
Genes in WT Large Intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 89.74 65.24 81.44 66.61 43.95 54.11 
Bo,+ 2300.47 1549.63 2973.02 1008.30 1174.40 1367.87 
OAT1 1.19 1.43 1.14 1.37 0.62 0.97 
OAT2 0.24 0.24 0.16 0.15 0.06 0.13 
OAT3 1.12 0.59 0.44 0.46 0.04 0.17 
PAT1 37.73 76.52 47.10 19.67 14.70 21.82 
OCT1 0.64 1.03 0.77 3.80 0.24 0.81 
MATE1 0.40 0.58 0.14 0.22 0.04 0.05 
MATE2 89.74 65.24 81.44 66.61 43.95 54.11 
Genes in mPepT1 KO Large Intestine 
gene #1 #2 #3 #4 #5 #6 
BPHL 78.13 77.59 90.37 37.21 75.99 44.56 
Bo,+ 1743.43 2268.80 2332.58 915.05 1615.44 1321.27 
OAT1 0.78 1.23 1.14 0.55 0.65 0.72 
OAT2 0.14 0.17 0.14 0.04 0.13 0.02 
OAT3 0.15 1.49 0.37 0.11 0.18 0.14 
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PAT1 36.70 29.20 47.43 16.77 29.20 9.97 
OCT1 2.13 1.41 0.79 0.67 2.51 0.88 
MATE1 0.25 0.66 0.24 0.07 0.04 0.02 
MATE2 78.13 77.59 90.37 37.21 75.99 44.56 
 
Genes in huPepT1 Kidney 
gene #1 #2 #3 #4 #5 #6 
BPHL 831.35 719.83 1432.00 879.85   
Bo,+ 164.68 88.24 751.18 336.86   
OAT1 929.18 803.59 1806.66 1340.09   
OAT2 260.03 159.42 592.64 479.84   
OAT3 2853.10 2630.30 2438.39 1750.82   
PAT1 501.92 584.52 1930.30 1118.47   
OCT1 644.58 649.87 2513.55 2112.47   
MATE1 831.35 719.83 1432.00 879.85   
MATE2 164.68 88.24 751.18 336.86   
Genes in wildtype Kidney 
gene #1 #2 #3 #4 #5 #6 
BPHL 717.94 774.82 633.72 486.98 467.14 555.53 
Bo,+ 138.88 128.69 143.78 137.92 84.31 102.37 
OAT1 1182.57 1029.49 1339.72 953.91 1166.29 1830.11 
OAT2 328.04 129.58 72.39 37.73 236.83 124.30 
OAT3 2891.72 3142.53 4292.83 3208.56 1111.05 1250.00 
PAT1 1051.12 733.02 708.05 651.54 451.23 268.30 
OCT1 2030.63 1036.65 1158.24 1150.23 1199.08 1051.12 
MATE1 0.71 0.09 0.35 0.48 0.31 0.10 
MATE2 717.94 774.82 633.72 486.98 467.14 555.53 
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Genes in mPepT1 KO Kidney 
gene #1 #2 #3 #4 #5 #6 
BPHL 1073.21 807.72 529.22 642.57 651.54 1073.21 
Bo,+ 48.09 89.12 32.40 78.67 93.55 48.09 
OAT1 2431.64 2348.81 3035.49 2222.11 2316.47 2431.64 
OAT2 127.80 105.25 89.74 166.31 275.84 127.80 
OAT3 1649.38 1707.55 2517.39 1894.65 1731.39 1649.38 
PAT1 780.21 764.15 1051.12 339.60 387.41 780.21 
OCT1 1907.82 1842.84 2087.72 973.96 1294.08 1907.82 
MATE1 0.17 0.11 0.14 0.01 0.23 0.17 
MATE2 1073.21 807.72 529.22 642.57 651.54 1073.21        
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Appendix B: Individual data from Chapter IV 
 
Table B.4.1 In Situ Perfusion studies with GlySar in intestinal segments 
Permeability in huPepT1 (10-4, cm/sec) 
Tissue #1 #2 #3 #4 #5 #6 
Duo 1.209 1.305 1.016 0.969   
Jej 1.487 1.478 1.314 1.351 1.052 1.299 
Ile 0.602 0.728 0.523 0.757   
Colon 0.188 0.113 0.120 0.266 0.170  
 
Permeability in Wildtype (10-4, cm/sec) 
Tissue #1 #2 #3 #4 #5 #6 
Duo 1.512 1.557 1.512 1.763   
Jej 2.283 2.261 1.827 2.144   
Ile 1.630 1.224 0.968 0.994   
Colon 0.008 0.005 0.003 0.046 0.015  
 
Permeability in mPepT1 KO (10-4, cm/sec) 
Tissue #1 #2 #3 #4 #5 #6 
Duo 0.0100 0.0170 0.0042 0.0042   
Jej 0.0144 0.0616 0.0811 0.0155   
Ile 0.0012 0.0010 0.0012 0.0087   
Colon 0.0008 0.0011 0.0009 0.0018   
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Table B.4.2 Concentration-dependent flux of GlySar by in situ jejunal Perfusion 
studies in huPepT1 and Wildtype mice 
 
Flux of GlySar in huPEPT1 Jejunum (nmol/cm2/sec) 
Conc. 
(mM, Cin) 
#1 #2 #3 #4 #5 #6 
0.010 0.00149 0.00148 0.00131 0.00135 0.00105 0.00130 
0.100 0.00900 0.00740 0.00851 0.00632   
0.250 0.03220 0.01680 0.00729 0.02223   
0.500 0.04360 0.05300 0.02177 0.04080   
1.000 0.06240 0.10800 0.09685 0.08607   
2.500 0.15640 0.16760 0.24178 0.14849   
5.000 0.43440 0.43420 0.26197 0.21715   
10.000 0.35960 0.44220 0.50230 0.45306   
25.000 0.32340 0.25640 0.51148 0.56380   
 
Flux of GlySar in Wildtype Jejunum (nmol/cm2/sec) 
Concentration 
(mM, Cin) 
#1 #2 #3 #4 #5 #6 
0.010 0.00228 0.00226 0.00183 0.00214   
0.100 0.01820 0.01840 0.02090 0.01130   
0.250 0.07120 0.06340 0.05720 0.04030   
0.500 0.12660 0.11580 0.13218 0.06072   
1.000 0.22920 0.18740 0.23420 0.22230   
2.500 0.54300 0.70520 0.36100 0.34690   
5.000 1.10380 1.15360 1.17630 0.95370   
10.000 1.68710 1.63220 1.47870 1.54200   
25.000 2.43900 2.62960 2.39560 2.75710   
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Table B.4.3 Plasma concentration of GlySar after oral administration (µM) 
 huPepT1 Wildtype mPepT1 KO 
Time(hour) #1 #2 #3 #1 #2 #3 #1 #2 #3 
0.08 1.392 1.432 0.929 0.965 0.904 0.947 0.153 0.134 0.181 
0.13 2.204 2.340 1.505 2.151 1.780 1.605 0.580 0.339 0.684 
0.25 2.820 2.680 2.950 2.881 2.577 2.609 0.832 0.808 0.927 
0.50 2.947 2.545 2.870 2.682 2.424 2.666 0.993 1.160 0.909 
0.75 2.732 2.433 2.541 2.623 2.405 2.441 1.010 1.114 1.022 
1.00 2.600 2.306 2.360 2.487 2.306 2.482 1.054 1.191 1.104 
1.50 2.452 2.475 2.302 2.192 2.321 2.377 1.159 1.176 1.115 
2.00 2.317 2.252 1.889 2.066 2.394 2.311 1.133 1.321 1.327 
3.00 2.113 1.787 1.544 1.968 2.128 1.816 1.082 1.303 1.207 
4.00 1.755 1.790 1.355 1.791 1.967 1.660 1.108 1.237 1.089 
6.00 1.528 1.624 1.206 1.648 1.827 1.599 0.986 1.187 1.041 
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Appendix C: Individual data from Chapter V 
Table C.5.1 Concentration dependent flux of cefadroxil in jejunal perfusions (nmol/cm2/sec) 
 huPepT1 Wildtype 
Conc. (mM, Cin) #1 #2 #3 #4 #1 #2 #3 #4 
0.010 0.10116 0.00021 0.00023 0.00014 0.00066 0.00052 0.00052 0.00076 
0.100 0.00126 0.00103 0.00192 0.00137 0.00605 0.00596 0.00695 0.00616 
0.250 0.00144 0.00131 0.00697 0.00504 0.01476 0.02145 0.01929 0.01464 
0.500 0.00587 0.00721 0.00735 0.00599 0.03573 0.02826 0.04949 0.03001 
1.000 0.02341 0.01904 0.01445 0.02310 0.05942 0.04297 0.04927 0.08165 
1.750 0.01524 0.03328 0.02317 0.02028 0.12942 0.07031 0.09029 0.07369 
2.500 0.01584 0.02809 0.01830 0.02071 0.11955 0.12015 0.08802 0.12839 
3.750 0.04411 0.05078 0.05502 0.02954 0.11331 0.13552 0.21789 0.13559 
5.000 0.03115 0.00751 0.04362 0.02182 0.15881 0.12823 0.24983 0.18129 
7.500 0.01223 0.04102 0.03822 0.06740 0.20729 0.22210 0.27674 0.20685 
10.000 0.04894 0.04433 0.07574 0.03469 0.17313 0.24420 0.24660 0.28832 
17.500 0.01223 0.04102 0.06726 0.07080 0.29207 0.26860 0.29124 0.37721 
25.000 0.03146 0.06318 0.05079 0.05749 0.29071 0.25861 0.32014 0.43816 
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Table C.5.2 Effective permeability of cefadroxil in intestinal perfusions ( x10-4,cm/sec) 
 huPepT1 Wildtype mPepT1 KO 
 #1 #2 #3 #4 #1 #2 #3 #4 #1 #2 #3 #4 
Duodenum 0.148 0.338 0.216 0.251 0.447 0.622 0.759 0.385 0.004 0.001 0.002 0.002 
Jejunum 0.101 0.208 0.233 0.141 0.658 0.518 0.523 0.762 0.005 0.028 0.001 0.008 
Ileum 0.118 0.096 0.141 0.126 0.196 0.320 0.369 0.278 0.002 0.001 0.002 0.004 
Colon 0.067 0.079 0.027 0.046 0.000 0.007 0.009 0.001 0.001 0.003 0.005 0.002 
 
Table C.5.3 Substrate specificity of cefadroxil in jejunal perfusions ( x10-4,cm/sec) 
 Control GlyPro GlyGlyHis Glycine L-Histidine Probenecid Quinidine 
#1 0.204664 0.002628807 0.04567644 0.1860432 0.1908105 0.1730913 0.191484 
#2 0.176511 0.003623258 0.05791553 0.1737148 0.2080944 0.2430571 0.128626 
#3 0.217475 0.01525932 0.0122279 0.183770 0.164126 0.1767742 0.260177 
 NMN Cephalexin Cephalothin Carnosine TEA PAH DMA 
#1 0.1810611 0.05597154 0.1865378 0.04168647 0.1568414 0.157590 0.07851509 
#2 0.1647314 0.09567235 0.1799209 0.07425112 0.2349168 0.192994 0.08304737 
#3 0.1761521 0.05596873 0.1951328 0.0608801 0.1333012 0.178770 0.09818064 
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Table C.5.4 Plasma concentration of cefadroxil after IV single dose (µM) 
 IV single dose at 11.01 nmol/g BW 
 huPepT1 Wildtype 
Time (min) #1 #2 #3 #4 #5 #1 #2 #3 #4 #5 
1.0 55.50 61.43 64.90 81.27 48.26 57.75 101.87 62.39 52.24  
2.5 120.72 128.23 133.58 157.33 104.31 122.12 175.94 130.47 113.59  
5.0 199.98 202.15 209.07 234.96 169.54 193.23 236.44 207.72 185.70  
10.0 300.79 297.52 307.02 344.30 254.41 276.39 321.64 309.19 270.89  
20.0 397.15 408.73 414.05 459.58 347.80 360.65 424.60 422.93 353.61  
30.0 435.10 463.07 465.31 500.39 392.02 401.46 484.11 481.67 398.05  
45.0 460.84 505.48 513.49 531.25 433.10 436.44 536.58 533.48 438.31  
60.0 476.35 534.85 544.68 547.58 458.35 459.05 563.31 565.49 463.72  
90.0 497.80 576.76 580.98 569.03 490.69 487.10 593.67 606.08 501.01  
120.0 513.64 605.14 606.72 585.20 512.14 506.57 611.82 632.48 525.76  
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 IV single dose at 528.40 nmol/g BW 
 huPepT1 Wildtype 
Time (min) #1 #2 #3 #4 #5 #1 #2 #3 #4 #5 
1.0 2139.75 2473.47 1970.97   1757.08 2350.22 1914.96   
2.5 1426.19 2160.88 1659.34   1347.07 1962.90 1504.01   
5.0 897.66 1380.95 1519.09   995.24 1228.59 827.24   
10.0 456.73 731.85 625.90   622.28 702.65 481.90   
20.0 169.79 265.95 279.88   259.04 346.35 209.66   
30.0 101.01 133.77 136.36   133.32 189.87 126.75   
45.0 46.35 57.01 56.63   59.11 106.20 67.87   
60.0 38.28 41.26 46.64   44.10 69.02 45.58   
90.0 28.39 30.79 30.50   26.99 43.37 31.08   
120.0 27.91 26.95 29.33   27.89 32.04 27.33   
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Table C.5.6 Plasma concentration of cefadroxil after oral escalation doses (µM) 
 
 Cefadroxil Oral Dose at 11.01 nmol/g BW 
 huPepT1 Wildtype 
Time 
(min) 
#1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 #7 
2.5 0.28 0.63 1.30 2.12 0.23 0.21 0.24 7.29 5.16 9.97 0.62 2.59 0.65 2.49 
5.0 0.59 1.91 5.93 7.46 2.13 1.61 1.50 15.93 11.9 15.26 7.28 11.61 4.24 10.3 
10.0 0.76 3.24 10.95 8.43 5.29 3.93 4.35 18.58 15.99 13.49 10.08 14.94 10.76 13.8 
20.0 1.00 7.68 8.29 8.33 6.53 5.60 6.58 12.33 8.74 7.23 9.38 9.83 9.8 9.06 
30.0 1.14 5.55 4.69 3.94 4.34 3.45 3.99 7.28 7.41 4.49 6 4.64 7.85 6.11 
45.0 2.31 1.98 1.87 1.85 2.57 2.91 3.29 4.68 2.64 1.8 3.84 2.82 4.98 3.16 
60.0 1.69 0.91 0.90 0.98 1.84 1.74 1.83 3.47 1.4 1.35 2.42 2.53 2.95 1.66 
90.0 1.23 0.41 0.48 0.52 0.71 1.00 1.18 1.08 0.7 0.64 1.31 0.87 1.73 1.03 
120.0 0.79 0.44 0.46 0.44 0.40 0.54 0.60 0.96 0.57 0.65 0.73 0.53 1.21 0.59 
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 Cefadroxil Oral Dose at 33.03 nmol/g BW 
 huPepT1 Wildtype 
Time (min) #1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 #7 
2.5 2.78 2.89 0.74 4.15 0.79   10.82 17.78 6.31 3.28 5.41 3.36  
5.0 9.09 11.59 2.59 16.48 3.14   26.90 29.54 22.78 23.23 25.78 19.69  
10.0 21.11 20.22 4.74 24.82 6.63   39.00 41.83 34.85 29.69 35.63 30.53  
20.0 23.84 23.24 13.53 27.48 10.99   27.55 36.26 27.46 37.97 30.62 32.66  
30.0 12.76 15.87 16.70 18.18 11.02   12.87 24.99 17.18 28.06 19.92 25.59  
45.0 5.72 8.26 15.02 10.74 8.88   10.97 14.44 12.70 20.26 13.63 13.88  
60.0 3.50 5.22 5.17 5.41 5.94   7.65 9.28 8.46 10.44 9.48 10.22  
90.0 2.12 3.09 1.67 1.88 2.95   3.76 7.06 7.11 7.86 4.75 3.73  
120.0 1.80 2.18 1.40 1.06 1.67   2.51 2.74 2.24 5.27 3.83 1.92  
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 Cefadroxil Oral Dose at 66.06 nmol/g BW 
 huPepT1 Wildtype 
Time 
(min) 
#1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 #7 
2.5 1.99 6.44 7.21 2.24 1.76 2.13  71.48 47.77 45.21 11.05 16.05 37.55  
5.0 5.72 26.49 23.59 10.52 6.90 8.770001  100.82 95.76 109.07 64.63 50.55 99.09  
10.0 8.32 51.47 50.39 25.65 18.22 25.74  102.98 91.21 103.44 92.06 78.63 85.73  
20.0 14.27 64.22 62.95 30.12 23.50 38.30  52.49 46.55 54.88 45.95 54.90 40.54  
30.0 16.42 46.72 39.40 36.07 28.31 31.33  34.22 27.86 41.32 30.40 33.47 23.38  
45.0 14.85 23.88 21.54 36.50 29.57 29.41  14.35 23.77 38.22 11.90 17.03 11.01  
60.0 13.79 13.18 12.58 23.92 25.39 24.24  8.02 13.10 39.07 7.02 11.58 6.34  
90.0 8.08 7.09 6.43 6.97 10.42 10.66  4.24 5.87 9.53 3.32 5.06 2.95  
120.0 5.32 4.26 4.08 4.00 5.26 7.09  3.65 5.02 7.33 1.76 2.66 2.31  
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 Cefadroxil Oral Dose at 132.10 nmol/g BW 
 huPepT1 Wildtype 
Time 
(min) 
#1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 
#
7 
2.5 6.94 11.25 5.69 6.39 8.89 10.64  107.44 42.15 97.75 29.39 41.25 35.22  
5.0 16.18 41.15 27.63 19.17 46.19 26.55  198.72 153.06 164.46 59.75 60.83 65.99  
10.0 36.42 97.45 95.62 37.44 71.05 51.11  191.32 190.62 181.12 188.82 186.24 166.79  
20.0 50.24 106.08 125.04 59.97 95.80 62.88  140.33 126.58 132.28 132.99 120.80 138.96  
30.0 41.24 57.85 70.19 66.36 69.97 62.52  74.11 65.31 86.80 87.80 88.94 86.49  
45.0 33.34 33.60 37.31 46.86 52.36 48.39  46.49 33.24 51.31 44.39 46.66 43.72  
60.0 28.81 21.04 23.42 28.00 32.00 35.66  28.68 23.51 23.42 23.66 32.50 25.22  
90.0 11.53 8.39 11.13 12.44 13.36 13.64  25.08 9.44 16.74 10.72 7.44 8.55  
120.0 6.65 7.35 9.03 9.30 7.28 6.31  9.71 8.11 8.34 5.33 5.06 10.50  
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 Cefadroxil Oral Dose at 264.20 nmol/g BW 
 huPepT1 Wildtype 
Time 
(min) 
#1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 #7 
2.5 15.34 11.89 11.21 23.48 21.36 28.01  66.67 89.70 74.51 61.73 57.97 77.12  
5.0 55.18 39.05 47.28 95.59 74.93 100.49  191.82 228.34 260.22 193.07 213.82 210.69  
10.0 172.81 68.31 107.63 158.17 116.33 195.71  320.04 363.47 408.42 366.06 414.50 419.74  
20.0 221.16 116.24 144.01 187.00 178.59 122.16  210.02 329.09 242.13 317.16 273.55 340.82  
30.0 156.58 107.96 101.47 147.69 139.57 132.87  141.77 262.12 122.41 180.71 181.11 165.00  
45.0 72.66 80.08 58.93 81.20 96.44 119.98  59.13 143.47 48.62 86.85 116.16 80.95  
60.0 41.77 75.19 36.40 35.78 67.26 74.49  54.58 73.14 21.87 46.25 59.38 42.48  
90.0 20.35 23.39 12.07 10.30 31.72 30.72  21.12 36.14 11.74 16.59 19.72 14.59  
120.0 13.35 12.90 13.14 6.83 15.00 12.24  15.16 20.35 11.32 10.94 9.75 9.41  
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 Cefadroxil Oral Dose at 528.40 nmol/g BW 
 huPepT1 Wildtype 
Time 
(min) 
#1 #2 #3 #4 #5 #6 #7 #1 #2 #3 #4 #5 #6 #7 
2.5 16.11 53.02 34.63 26.13 10.81 18.53 23.41 292.35 192.34 176.41 110.70 177.36 152.43  
5.0 28.88 123.39 112.02 99.77 53.67 56.57 69.76 438.53 427.63 449.07 361.31 492.51 353.00  
10.0 48.16 269.09 179.98 227.67 120.26 89.93 151.51 743.71 556.41 714.83 521.72 670.00 579.34  
20.0 65.97 344.38 208.34 356.91 295.77 142.41 300.85 479.36 579.20 647.22 533.52 625.30 563.91  
30.0 93.27 266.16 143.42 303.31 240.58 236.37 309.29 305.65 337.99 515.51 409.96 377.53 387.88  
45.0 92.28 135.86 99.72 192.75 170.43 168.79 146.96 148.99 136.80 282.16 229.97 252.52 241.05  
60.0 75.11 64.68 61.52 104.58 113.53 112.88 127.18 108.27 64.45 143.83 130.35 136.87 137.14  
90.0 27.07 25.54 21.03 38.73 36.33 62.96 66.85 48.51 39.20 71.07 50.31 54.86 46.68  
120.0 24.20 21.91 17.63 24.31 31.58 41.08 41.93 26.13 24.96 40.02 31.05 39.10 40.88  
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Appendix D: Species-dependent uptake of glycylsarcosine but not 
oseltamivir in Pichia Pastoris expressing rat, mouse, and human intestinal 
peptide transporter PEPT1                                   
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Appendix E: Divergent developmental expression and function of the 
proton-coupled oligopeptide transporters PepT2 and PhT1 in regional brain 
slices of mouse and rat.            
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Appendix F: Development and characterization of a novel mouse line 
humanized for the intestinal peptide transporter PEPT1              
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Appendix G: Impact of peptide transporter 1 on the intestinal absorption 
and pharmacokinetics of valacyclovir after oral dose escalation in wild-type 
and PepT1 knockout mice 
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Appendix H: Corticosterone mediates stress-related increased intestinal 
permeability in a region-specific manner                                       
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Appendix I: Functional and Molecular Expression of the Proton-Coupled 
Oligopeptide Transporters in Spleen and Macrophages from Mouse and 
Human
 237 
Appendix J: Expression and regulation of the proton-coupled oligopeptide 
transporter PhT2 by LPS in macrophages and mouse spleen 
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Appendix K: Abbreviations   
ABC transporters:  ATP-binding cassette transporters 
AUC:   Area Under Plasma Concentration-Time 
BAC:     Bacterial Artificial Chromosome;  
BSA:    Body Surface Area 
hPepT1:   human source peptide transporter 1;  
Gapdh:   Glyceraldehyde 3-phosphate dehydrogenase;  
GlySar:  Glycylsarcosine;  
IBD:    Inflammatory Bowel Diseases;  
mPepT1:   mouse source peptide transporter 1;  
NHE:   sodium proton exchanger 
PepT2:   peptide transporter 2, also called SLC15a2; 
PhT1:   peptide/histidine transporter 1, also called SLC15a4; 
PhT2:   peptide/histidine transporter 2, also called LSC15a3; 
OAT:    Organic Anion Transporter;  
OCT:   Organic Cation Transporter; 
PBS:   Phosphate Buffered Saline;  
PCR:    Polymerase Circle Reaction;  
PK/PD:   Pharmacokinetics/Pharmacodynamics;  
POT:   Proton-Coupled Oligopeptide Transporter;  
PPB:   Potassium Phosphate Buffer pH 6.5;  
SLC transporters: Solute Carrier Transporters 
